

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## BEST AVAILABLE COPY

[illegible]

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## DESCRIPTION

## NOVEL PROTEIN, ITS PRODUCTION AND USE

Technical Field

5           The present invention relates to a novel protein showing a physiological activity on the central nervous system such as nerve-extending activity, neuroregenerative activity, gliocyte (glial cells) stimulating activity and so on.

10

Background Art

          The engram or trace of memory in the brain can be divided into two phases, namely acquisition of a short-term memory and fixation of a long-term memory. It is known that electroshocks and anesthesia may destroy the short-term memory but have no effect on the long-term memory once established. On the other hand, it is known that the biochemical reactions and structural changes leading to formation of a long-term memory as the antithesis of a short-term memory can be blocked by means of protein synthesis inhibitors such as puromycin and cycloheximide (Flexner, J. B. et al., Science, 141, 57-59 (1963); Agranoff, B. W. and Klinger, P. D., Science, 146, 952-953 (1964); Agranoff, B. W. et al., Brain Research 1, 300-309 (1966)). Therefore, it has been suspected over the past twenty years that certain protein metabolisms including de novo synthesis of proteins are involved in the formation of long-term memories in the brain. However, few proteins have been identified to this day which show an increased metabolic turnover following acquisition of a new behavior (Hyden, H and Lange, P. W., Proceedings of the National Academy of Sciences of the U.S.A., 65, 898-904 (1970); Shashoua, V. E., Science, 193, 1264-1266 (1976)).

35

          Ependymin, among such proteins, was first reported

as an entity comprising two kinds of proteins whose expression was increased after learning in the brain of goldfish as assayed by a double-labeling technique using [<sup>3</sup>H]valine and [<sup>14</sup>C]valine (Shashoua, V. E.,  
5 Science, 193, 1264-1266 (1976)). Early immunohistological distribution studies (Shashoua, V. E., Brain Research, 122, 113-124 (1977), Benowitz, L. I. and Shashoua, V. E., Brain Research, 136, 227-242 (1977)) revealed that those proteins occurred in high  
10 concentrations in the ependymal zone (the cellular membrane lining the brain ventricles) and accordingly they were named ependymin  $\beta$  and ependymin  $\gamma$ , respectively. However, it was subsequently suggested that those proteins were secretory proteins which were  
15 secreted into the cerebrospinal fluid (Shashoua, V. E. Brain Research, 166, 349-358 (1979); Shashoua, V. E. Neurochem. Res., 6, 1129-1147 (1981)) and more detailed immunohistological investigation endorsed the suggestion by the detection of ependymin in high  
20 concentrations in the mesencephalic structures and cerebrospinal fluid (Schmidt, R. and Lapp, H., Neurochem. Int., 10, 383-390 (1987)).

Ependymin  $\beta$  and ependymin  $\gamma$  were initially considered to be mutually distinct proteins because  
25 they gave molecular masses of 35kDa and 30kDa, respectively, on SDS-PAGE but it was later discovered that they are proteins identical in amino acid sequence and only dissimilar in sugar chain content (Schmidt, R. and Shashoua, V. E., Journal of Neurochemistry, 40,  
30 652-660, (1983)). Moreover, it was reported that those proteins formed dimers and has a sugar chain content of at least 5% (Shashoua, V. E., Cell. Mol. Neurobiol., 5, 183-207 (1985)).

Based on the above series of research findings,  
35 ependymin had come to be considered to be associated with the learning and memory processes. For example,



when an anti-ependymin antibody was injected into the cerebral ventricles, the integration of memories was blocked (Shashoua, V. E., Proceedings of the National Academy of Sciences of the U.S.A., 74, 1743-1747 (1977); Shashoua, V. E. and Moore, M. E. Brain Research, 148, 441-449 (1978); Schmidt, R. Adv. Biosci., 59, 213-222 (1986); Piront, M. L. and Schmidt, R., Brain Research, 442, 53-62 (1988)) and also in conditional experiments, the amount of expression of ependymin and its concentration had significant influences on the test results (Schmidt, R., Journal of Neurochemistry, 48, 1870-1878, (1987); Shashoua, V. E. and Hesse, G. W. Brain Research, 484, 333-339 (1989); Schmidt, R. et al., Progress in Brain Research, 91, 7-12 (1992)). Recently it has been discovered that ependymin is involved in the regeneration of the optic nerve of goldfish (Thormodsson, F. R. et al., Society Neuroscience Abstract, 14, 805 (1988)). It has also been found that ependymin is synthesized in the process of optic nerve regeneration (Schmidt, J. T. and Shashoua, V. E., Brain Research, 446, 269-284 (1988); Thormodsson, F. R. et al., Experimental Neurology, 118, 275-283 (1992)). This protein has, therefore, come to be a focus of attention. In the most recent researches using immunoelectron microscopic and in situ hybridization techniques, it was found that the mRNAs were expressed to synthesize the proteins, in reticulofibroblast cells of the inner endomeningeal cell layer but are not expressed in neurons and glial cells. However, after learning, the proteins are found in nerve cells and glial cells where the mRNAs are not detected, suggesting that the takeup of those proteins from the meninx by the neurons and glial cells has a functional importance in the plastic adaptations of the central nervous system (Rother, S. et al. Journal of Neurochemistry, 65, 1456-1464 (1995); Schmidt, R. et

al., Journal of Neurochemistry, 65, 1465-1471 (1995)).

However, those studies were invariably undertaken in fish such as goldfish and the cDNA of ependymin has been found only in fish such as zebrafish, salmon, rainbow trout, herring, and carp in addition to goldfish (Koenigstorfer, A. et al., Journal of Neurochemistry, 52, 310-312 (1989); Koenigstorfer, A., Journal of Biological Chemistry, 264, 13689-13692 (1989); Sterrer, S. et al., Neuroscience, 37, 277-284 (1990); Muller-Schmid, A. et al., Gene, 118, 189-196 (1992); Muller-Schmid, A. et al., Journal of Molecular Evolution, 36, 578-585 (1993)). Meanwhile, it has been suspected that some protein corresponding to this ependymin exists in mammals as well, and including the report that an ependymins-like immune reaction is found in rat hippocampal neurons (Schmidt, R. et al., Brain Research, 386, 245-257 (1986)), and a large number of immunohistological studies have been reported (Fazei, M. S. et al., European Journal of Neuroscience, Suppl. 1, 90 (1988); Shashoua, V. E. et al., Brain Research, 522, 181-190 (1990); Shashoua, V. E. et al., Journal of Neuroscience Research, 32, 239-244 (1992)). However, it remains to be established, biochemically or molecular biologically, whether there actually exists a mammalian counterpart of ependymin.

As the result of intensive research, the inventors of the present invention succeeded in cloning a cDNA having a novel nucleotide sequence from human placenta-, rat brain- or mouse spinal cord derived cDNA library and found that the protein encoded thereby is an ependymin-like protein having a physiological activity such as nerve-extending activity or neuroregenerative activity on the central nervous system, or gliocyte stimulating activity. As a result of continued investigations based on such findings, the present inventors have now completed the present

invention.

Disclosure of Invention

The present invention provides:

- 5 (1) An ependymin-like protein derived from a mammal, or a salt thereof;
- (2) A protein comprising an amino acid sequence represented by SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3, or a substantially equivalent thereto, or a salt
- 10 thereof;
- (3) The protein according to (2), wherein the substantially equivalent amino acid sequence to the amino acid sequence represented by SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3 is an amino acid sequence
- 15 comprising an amino acid sequence represented by SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 or SEQ ID NO:7;
- (4) The protein according to (2), wherein the substantially equivalent amino acid sequence to the amino acid sequence represented by SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3 is an amino acid sequence having an
- 20 identity of not less than about 95% to the amino acid sequence represented by SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3;
- (5) The protein according to (2), wherein the substantially equivalent amino acid sequence to the amino acid sequence represented by SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3 is (i) an amino acid sequence wherein one or more amino acid residues are deleted
- 25 from the amino acid sequence represented by SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3, (ii) an amino acid sequence wherein one or more amino acid residues are added to the amino acid sequence represented by SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3, (iii) an amino acid sequence wherein one or more amino acid residues in the
- 30 amino acid sequence represented by SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3 are substituted with one or more
- 35

- amino acid residues, or (iv) a combination thereof;
- (6) The protein according to (2), which has a nerve-extending activity;
- (7) A partial peptide of the protein according to (1) or (2), or a salt thereof;
- (8) The partial peptide according to (7), which has an amino acid sequence represented by any one of SEQ ID NO:4 to SEQ ID NO:9;
- (9) A precursor protein of the protein according to (2) or a salt thereof, which comprising an amino acid sequence represented by SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12 or SEQ ID NO:13, or a substantially equivalent thereto;
- (10) A signal peptide comprising an amino acid sequence represented by SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16 or SEQ ID NO:17, or a substantially equivalent thereto;
- (11) A DNA which comprises a DNA having a nucleotide sequence coding for the protein according to (1) or (2);
- (12) The DNA according to (11), which comprises a nucleotide sequence represented by SEQ ID NO:18, SEQ ID NO:19 or SEQ ID NO:20;
- (13) A DNA which comprises a DNA having a nucleotide sequence coding for the precursor protein according to (9);
- (14) The DNA according to (13), which comprises a nucleotide sequence represented by SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29 or SEQ ID NO:30;
- (15) A DNA which comprises a DNA having a nucleotide sequence coding for the signal peptide according to (10);
- (16) The DNA according to (15), which comprises a nucleotide sequence represented by SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33 or SEQ ID NO:34;
- (17) A recombinant vector comprising the DNA according to (11);

- (18) A transformant which is transformed with the recombinant vector according to (17);
- (19) A method for producing the protein according to (1) or (2) or a salt thereof, which comprises
- 5 cultivating the transformant according to (18) under conditions suitable to express and accumulate the protein according to (1) or (2) or a salt thereof, and collecting the same;
- (20) A pharmaceutical composition which comprises the
- 10 protein according to (1) or (2), the partial peptide according to (7), or a salt thereof;
- (21) The pharmaceutical composition according to (20), which is a therapeutic or prophylactic agent for
- 15 Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, dementia or cerebellar degeneration;
- (22) A pharmaceutical composition which comprises the DNA according to (11);
- (23) The pharmaceutical composition according to (22),
- 20 which is a therapeutic or prophylactic agent for Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, dementia or cerebellar degeneration;
- (24) An antibody against the protein according to (1)
- 25 or (2), the partial peptide according to (7), the precursor protein according to (9), or a salt thereof;
- (25) A method for quantitative determination of the protein according to (1) or (2), the partial peptide
- 30 according to (7), the precursor protein according to (9), or a salt thereof, which comprises contacting the antibody according to (24) with the protein according to (1) or (2), the partial peptide according to (7), the precursor protein according to (9), or a salt thereof;
- 35 (26) A method for quantitative determination of the protein according to (1) or (2), the partial peptide

according to (7), the precursor protein according to (9), or a salt thereof in a test liquid sample, which comprises

5 (a) competitively reacting the test liquid sample and a labeled protein according to (1) or (2), the partial peptide according to (7), the precursor protein according to (9), or a salt thereof with the antibody according to (24), and

10 (b) measuring the ratio of the labeled protein according to (1) or (2), the partial peptide according to (7), the precursor protein according to (9), or a salt thereof which binds to the antibody;

(27) A method for quantitative determination of the protein according to (1) or (2), the partial peptide according to (7), the precursor protein according to (9), or a salt thereof in a test liquid sample, which comprises

15 (a) reacting the test liquid sample with the antibody according to (24) immobilized on an insoluble carrier and another labeled antibody according to (24) simultaneously or continuously, and

20 (b) measuring the activity of labeling agent on the insoluble carrier;

(28) A method for screening for a compound which promotes a function of the protein according to (1) or (2), the partial protein according to (7), or a salt thereof, which comprises measuring and comparing the function of the protein according to (1) or (2), the partial protein according to (7) or a salt thereof, in cases that (i) the protein according to (1) or (2), the partial protein according to (7) or a salt thereof is contacted with a nerve cell or a nerve tissue and (ii) the protein according to (1) or (2), the partial protein according to (7) or a salt thereof and a test compound are contacted with a nerve cell or a nerve tissue;

(29) The method according to (28), wherein the function is (i) a nerve-extending activity in the central nerve system or glia cell stimulating activity or (ii) an activity of forming memories in brain;

5 (30) The method according to (28), wherein the function is a nerve-extending activity;

(31) A kit for screening for a compound which promotes a function of the protein according to (1) or (2), the partial protein according to (7) or a salt thereof, which comprises the protein according to (1) or (2),  
10 the partial peptide according to (7) or a salt thereof;

(32) A compound, or a salt thereof, which promotes a function of the protein according to (1) or (2), the partial peptide according to (7) or a salt thereof, and  
15 which is obtained by the method for screening according to (28) or the kit for screening according to (31);

(33) A pharmaceutical composition which comprises the compound, or a salt thereof, which promotes a function of the protein according to (1) or (2), the partial  
20 peptide according to (7) or a salt thereof, and which is obtained by the method for screening according to (28) or the kit for screening according to (31);

(34) The pharmaceutical composition according to (33), which is a therapeutic or prophylactic agent for  
25 Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, dementia or cerebellar degeneration;

(35) A method for treating or preventing Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, dementia or cerebellar  
30 degeneration in a mammal which comprises administering an effective amount of the protein according to (1) or (2), the partial peptide according to (7) or a salt thereof to said mammal;

35 (36) A method for treating or preventing Alzheimer's disease, Parkinson's disease, Huntington's disease,

amyotrophic lateral sclerosis, dementia or cerebellar degeneration in a mammal which comprises administering an effective amount of the DNA according to (11) or a salt thereof to said mammal;

5 (37) Use of the protein according to (1) or (2), the partial peptide according to (7) or a salt thereof for production of a therapeutic or prophylactic agent for Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, dementia or  
10 cerebellar degeneration; and

(38) Use of the DNA according to (11) for production of a therapeutic or prophylactic agent for Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, dementia or cerebellar  
15 degeneration.

The present invention, furthermore, provides:

(39) A DNA comprising a DNA having a nucleotide sequence capable of hybridizing under a high stringent condition with the nucleotide sequence of SEQ ID NO:18,  
20 SEQ ID NO:19 or SEQ ID NO:20;

(40) A recombinant vector comprising the DNA according to (39);

(41) A transformant which is transformed with the recombinant vector according to (40);

25 (42) A method for producing the protein encoding by the DNA according to (39) or a salt thereof, which comprises cultivating the transformant according to (41) under conditions suitable to express and accumulate the protein, and collecting the same;

30 (43) A protein encoded by the DNA according to (42), or a salt thereof, which is produced by the method according to (42);

(44) A DNA comprising a DNA having a nucleotide sequence coding for the partial peptide according to  
35 (7);

(45) The DNA according to (44), which comprises a



nucleotide sequence represented by any one of SEQ ID NO:21 to SEQ ID NO:26;

(46) A recombinant vector comprising the DNA according to (45);

5 (47) A transformant which is transformed with the recombinant vector according to (46);

(48) A method for producing the partial peptide or a salt thereof according to (7), which comprises cultivating the transformant according to (47) under  
10 conditions suitable to express and accumulate the partial peptide, and collecting the same;

(49) An oligonucleotide or a derivative thereof which has a nucleotide sequence complementary or substantially complementary to the DNA according to  
15 (11) or (39) and capable of promoting an expression of the DNA;

(50) The oligonucleotide or derivative according to (49), wherein the nucleotide sequence substantially complementary to the DNA according to (11) or (39) is a  
20 nucleotide sequence having an identity of not less than about 60% (preferably not less than about 70%, more preferably not less than about 80%, still more preferably not less than about 90%, most preferable not less than about 95%) to the total nucleotide sequence  
25 or a part of the nucleotide sequence of the nucleotide sequence complementary to the DNA according to (11) or (39);

(51) A pharmaceutical composition which comprises the oligonucleotide or derivative according to (49);

30 (52) The pharmaceutical composition according to (51), which is a therapeutic or prophylactic agent for Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, dementia or cerebellar degeneration;

35 (53) The protein according to (1) or (2), which has (i) an amino acid sequence represented by SEQ ID NO:1, (ii)

- an amino acid sequence represented by SEQ ID NO:2,  
(iii) an amino acid sequence wherein Gly is added to  
the N-terminus of the amino acid sequence represented  
by SEQ ID NO:2, (iv) an amino acid sequence represented  
5 by SEQ ID NO:3 or (v) an amino acid sequence wherein 7  
amino acid residues of the C-terminus of the amino acid  
sequence represented by SEQ ID NO:17 are added to the  
N-terminus of the amino acid sequence represented by  
SEQ ID NO:3;
- 10 (54) The signal peptide according to (9), which has (i)  
an amino acid sequence represented by SEQ ID NO:14,  
(ii) an amino acid sequence represented by SEQ ID  
NO:15, (iii) an amino acid sequence represented by SEQ  
ID NO:16, (iv) an amino acid sequence wherein Gly is  
15 deleted from the C-terminus of the amino acid sequence  
represented by SEQ ID NO:16, (v) an amino acid sequence  
represented by SEQ ID NO:17 or (vi) an amino acid  
sequence wherein 7 amino acid residues are deleted from  
the C-terminus of the amino acid sequence represented  
20 by SEQ ID NO:17;
- (55) A DNA coding for the protein according to (53),  
which is (i) a DNA having a nucleotide sequence  
represented by SEQ ID NO:18, (ii) a DNA having a  
nucleotide sequence represented by SEQ ID NO:19, (iii)  
25 a DNA having a nucleotide sequence wherein GGC are  
added to 5'-terminus of the nucleotide sequence  
represented by SEQ ID NO:19, (iv) a DNA having a  
nucleotide sequence represented by SEQ ID NO:20 or (v)  
a DNA having a nucleotide sequence wherein 21 bases of  
30 the 3'-terminus of the nucleotide sequence represented  
by SEQ ID NO:34 are added to the 5'-terminus of the  
nucleotide sequence represented by SEQ ID NO:20; and  
(56) A DNA coding for the signal peptide according to  
(54), which is (i) a DNA having a nucleotide sequence  
35 represented by SEQ ID NO:31, (ii) a DNA having a  
nucleotide sequence represented by SEQ ID NO:32, (iii)

a DNA having a nucleotide sequence represented by SEQ ID NO:33, (iv) a DNA having a nucleotide sequence wherein GGC are deleted from the 3'-terminus of the nucleotide sequence represented by SEQ ID NO:33, (v) a  
5 DNA having a nucleotide sequence represented by SEQ ID NO:34 or (vi) a DNA having a nucleotide sequence wherein 21 bases are deleted from the 3'-terminus of the nucleotide sequence represented by SEQ ID NO:34.

10 The protein of the present invention includes an amino acid sequence represented by SEQ ID NO:1 (a 38th to 224th amino acid sequence of the amino acid sequence represented by SEQ ID NO:11 or Fig. 1), an amino acid sequence represented by SEQ ID NO:2 (a 35th to 224th  
15 amino acid sequence of the amino acid sequence represented by SEQ ID NO:12 or Fig. 2) or an amino acid sequence represented by SEQ ID NO:3 (a 38th to 224th amino acid sequence of the amino acid sequence represented by SEQ ID NO:13 or Fig. 3), or a  
20 substantially equivalent thereto.

The protein of the present invention may be a protein derived from any kind of cell (e.g. splenocytes, neurons, glia cells, splenic  $\beta$  cells, myelocytes, mesangial cells, Langerhan's cells,  
25 epidermal cells, epithelial cells, endothelial cells, fibroblasts, fibrous cells, muscle cells, fat cells, immune cells (e.g. macrophages, T cells, B cells, natural killer cells, mast cells, neutrophils, basophils, eosinophils, monocytes), megakaryocytes,  
30 synovial cells, chondrocytes, osteocytes, osteoblasts, osteoclasts, mammary cells, hepatocytes, interstitial cells, progenitor cells of said cells, stem cells, cancer cells, etc.) of mammals (e.g. human, guinea pig, rat, mouse, chicken, rabbit, swine, sheep, bovine,  
35 horse, monkey, etc.) or all tissues in which such cells are present, such as brain, various parts of brain

(e.g. olfactory bulb, amygdaloid nucleus, cerebral basal nucleus, hippocampus, thalamus, hypothalamus, cerebral cortex, medulla oblongata, cerebellum), spinal cord, pituitary gland, stomach, spleen, kidney, liver, gonad, thyroid, gall-bladder, bone marrow, adrenal gland, skin, muscle, lung, gastrointestinal tract (e.g. large intestine, small intestine), blood vessels, heart, thymus, spleen, submandibular gland, peripheral blood, prostate, testis, ovary, placenta, uterus, bone, joint, skeletal muscle, etc., particularly brain or various parts of brain. It may be a protein derived from fishes such as goldfish, Zebrafish, salmon, trout, herring and carp, and furthermore, may be a synthetic protein as well.

Examples of the amino acid sequence which is substantially equivalent to the amino acid sequence represented by SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3 are an amino acid sequence which is not less than about 40%, preferably not less than about 60%, more preferably not less than about 70%, still more preferably not less than about 80%, furthermore preferably not less than about 90%, most preferably not less than about 95% identity to the amino acid sequence represented by SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3, and so on.

Preferable examples of the protein of the present invention which comprises an amino acid sequence substantially equivalent to the amino acid sequence represented by SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3 are a protein having an amino acid sequence substantially equivalent to the amino acid sequence represented by SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3 and having a substantially and qualitatively equivalent activity to the protein comprising the amino acid sequence represented by SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3, and so on.

Examples of the substantially and qualitatively equivalent activity are a nerve-extending activity or neuro-regenerative activity in the central nervous system, etc., a gliocyte stimulating activity, an activity of forming memories in brain, and so on.

The term "substantially and qualitatively equivalent activity" means that the nature of these activities are physiochemically or pharmacologically equivalent. The term "substantially and qualitatively equivalent" means that the nature of these activities is physiochemically or pharmacologically equivalent. Therefore, it is preferred that the potency of activities such as a nerve-extending activity, neuro-regenerative activity and a gliocyte stimulating activity is equivalent (e.g. about 0.01 to 100 times, preferably about 0.5 to 20 times, more preferably about 0.5 to 2 times), but it is allowable that even differences in the degree of these activities and the quantity such as molecular weight of the protein are present. These activities may be measured by per se known method or an analogous method thereto.

And, other examples of the protein of the present invention are a protein having at least one amino acid sequence represented by SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 or SEQ ID NO:7 and having a substantially and qualitatively equivalent activity (e.g. nerve-extending activity or neuroregenerative activity in the central nervous system, etc., gliocyte stimulating activity, activity of formulating memories in brain) to the protein comprising the amino acid sequence represented by SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3, and so on.

The amino acid sequence represented by SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 or SEQ ID NO:7 is a common partial amino acid sequence (Fig.4) of the amino acid sequence represented by SEQ ID NO:1, the amino acid sequence represented by SEQ ID NO:2 and the amino

acid sequence represented by SEQ ID NO:3.

Furthermore, other examples of the protein of the present invention are a protein having at least one amino acid sequence represented by SEQ ID NO:4, SEQ ID NO:8, SEQ ID NO:9 or SEQ ID NO:7 and having a substantially and qualitatively equivalent activity (e.g. nerve-extending activity or neuro-regenerative activity in the central nervous system, etc., gliocyte stimulating activity, activity of forming memories in brain) to the protein comprising the amino acid sequence represented by SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3, and so on.

The amino acid sequence represented by SEQ ID NO:4, SEQ ID NO:8, SEQ ID NO:9 or SEQ ID NO:7 is a common partial amino acid sequence (Fig.5) of the amino acid sequence represented by SEQ ID NO:1 and the amino acid sequence represented by SEQ ID NO:2.

And, the protein of the present invention includes, for example, proteins comprising (1) an amino acid sequence wherein one or more amino acid residues (for example about 1 to 20, preferably about 1 to 9, and more preferably a few (1 to 5) amino acid residues) are deleted from the amino acid sequence represented by SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3, (2) an amino acid sequence wherein one or more amino acid residues (for example about 1 to 20, preferably about 1 to 9, and more preferably a few (1 to 5) amino acid residues) are added to the amino acid sequence represented by SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3, (3) an amino acid sequence wherein one or more other amino acid residues in the amino acid sequence represented by SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3 are substituted with one or more amino acid residues (for example about 1 to 20, preferably about 1 to 9, and more preferably a few (1 to 5) amino acid residues), or (4) a combination thereof.

In the above-mentioned deletion, addition or substitution in the amino acid sequence represented by SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3, examples of the positions of deletion, addition or substitution are not so critical but are preferably positions other than common amino acid sequences between the amino acid sequence represented by SEQ ID NO:1, the amino acid sequence represented by SEQ ID NO:2 and the amino acid sequence represented by SEQ ID NO:3. More specifically, preferable examples of the positions of deletion, addition or substitution are positions other than the amino acid sequence represented by SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 or SEQ ID NO:7.

In the above-mentioned deletion, addition or substitution in the amino acid sequence represented by SEQ ID NO:1 or SEQ ID NO:2, examples of the positions of deletion, addition or substitution are not so critical but are preferably positions other than common amino acid sequences between the amino acid sequence represented by SEQ ID NO:1 and the amino acid sequence represented by SEQ ID NO:2. More specifically, preferable examples of the positions of deletion, addition or substitution are positions other than the amino acid sequence represented by SEQ ID NO:4, SEQ ID NO:8, SEQ ID NO:9 or SEQ ID NO:7.

Among the above-mentioned proteins, the protein which is derived from a mammal and has an ependymin-like activity (e.g. nerve-extending activity or neuro-regenerative activity in the central nervous system, gliocyte stimulating activity, activity of forming memories in brain) is preferred.

Throughout this specification, proteins are represented in accordance with the conventions for description of peptides, that is, the N-terminus (amino terminus) at left and the C-terminus (carboxyl terminus) at right. The protein of the present

invention including the protein containing the amino acid sequence of SEQ ID NO:1 is usually in the carboxyl (-COOH) or carboxylate (-COO<sup>-</sup>) form at the C-terminus but may be in the amide (-CONH<sub>2</sub>) or ester (-COOR) form.

5        R in the ester residue includes a C<sub>1-6</sub> alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, etc., a C<sub>3-8</sub> cycloalkyl group (e.g. cyclopentyl, cyclohexyl, etc.), a C<sub>6-12</sub> aryl group (e.g. phenyl, α-naphthyl, etc.), a C<sub>7-14</sub> aralkyl group such as a phenyl-  
10       C<sub>1-2</sub> alkyl group (e.g. benzyl, phenethyl, etc.) and α-naphthyl-C<sub>1-2</sub> alkyl, (e.g. α-naphthylmethyl, etc.), as well as pivaloyloxymethyl which is commonly used for the production of esters for oral administration.

15       When the protein of the present invention has a carboxyl (or carboxylate) in any position other than the C-terminus, the corresponding amide or ester form is also included in the scope of the present invention. The ester mentioned just above may be any of the esters mentioned for the C-terminal carboxyl function.

20       Furthermore, the protein of the present invention includes (1) the protein in which the N-terminal amino acid residue is protected with a protective group (e.g. C<sub>1-6</sub> acyl such as C<sub>1-6</sub> alkanoyl such as formyl acetyl, etc.), (2) the protein in which the N-terminal side of  
25       Glu is cleaved in vivo to form pyroglutamic acid, (3) the protein in which the side chain of any relevant constituent amino acid (e.g. OH, SH, NH<sub>2</sub>, imidazole group, indole group, guanizino group, etc.) is protected by a protective group (e.g. C<sub>1-6</sub> acyl group  
30       such as C<sub>1-6</sub> alkanoyl such as formyl or acetyl, etc.), (4) the protein in which the carboxyl group on the side chain of any relevant constituent amino acid in amidated (CONH<sub>2</sub>) or esterified (-COOR), and (5) the  
35       complex protein such as glycoproteins available upon attachment of sugar chains.



More preferable examples of the protein of the present invention are (1) a human (more specifically, human placenta-derived) protein having the amino acid sequence represented by SEQ ID NO:1 (a 38th to 224th amino acid sequence of Fig. 1), (2) a rat (more specifically, rat brain-derived) protein having the amino acid sequence represented by SEQ ID NO:2 (a 35th to 224th amino acid sequence of Fig. 2), (3) a rat (more specifically, rat brain-derived) protein having the amino acid sequence wherein Gly is added to the N-terminus of the amino acid sequence represented by SEQ ID NO:2 (a 34th to 224th amino acid sequence of Fig. 2), (4) a mouse (more specifically, mouse spinal cord protein having the amino acid sequence represented by SEQ ID NO:3 (a 38th to 224th amino acid sequence of Fig. 3), (5) a mouse (more specifically, mouse spinal cord-derived) protein having the amino acid sequence (a 31st to 224th amino acid sequence of Fig. 3) wherein 7 amino acid residues of the C-terminus of the amino acid sequence represented by SEQ ID NO:17 are added to the N-terminus of the amino acid sequence represented by SEQ ID NO:3, and so on.

The partial peptide of the protein of the present invention may be any peptides of the above mentioned proteins of the present invention such as peptides comprising at least not less than about 10, preferably not less than about 50, more preferably not less than about 100 amino acid residues of the amino acid sequence of the proteins of the present invention, and preferably having activities such as a nerve-extending activity or neuro-regenerative activity in the central nervous system, etc., a gliocyte stimulating activity, an activity of forming memories and so on.

Specific examples of the partial peptide of the present invention are a peptide having (i) an amino

acid sequence represented by SEQ ID NO:4 (a 41st to 53rd amino acid sequence of the amino acid sequence represented by any one of SEQ ID NO:11 to SEQ ID NO:13 or Fig. 4), (ii) an amino acid sequence represented by  
5 SEQ ID NO:5 (a 68th to 99th amino acid sequence of the amino acid sequence represented by any one of SEQ ID NO:11 to SEQ ID NO:13 or Fig. 4), (iii) an amino acid sequence represented by SEQ ID NO:6 (a 122nd to 146th amino acid sequence of the amino acid sequence  
10 represented by any one of SEQ ID NO:11 to SEQ ID NO:13 or Fig. 4) or (iv) an amino acid sequence represented by SEQ ID NO:7 (a 195th to 211st amino acid sequence of the amino acid sequence represented by any one of SEQ ID NO:11 to SEQ ID NO:13 or Fig. 4), and so on.

15 And, other specific examples of the partial peptide of the present invention are a peptide having (i) an amino acid sequence represented by SEQ ID NO:4 (a 41st to 53rd amino acid sequence of the amino acid sequence represented by SEQ ID NO:11, SEQ ID NO:12 or  
20 Fig.5), (ii) an amino acid sequence represented by SEQ ID NO:8 (a 68th to 106th amino acid sequence of the amino acid sequence represented by SEQ ID NO:11, SEQ ID NO:12 or Fig.5), (iii) an amino acid sequence represented by SEQ ID NO:9 (a 121st to 146th amino acid  
25 sequence of the amino acid sequence represented by SEQ ID NO:11, SEQ ID NO:12 or Fig.5) or (iv) an amino acid sequence represented by SEQ ID NO:7 (a 195th to 211st amino acid sequence of the amino acid sequence represented by SEQ ID NO:11 or SEQ ID NO:12 or Fig.5),  
30 and so on.

Furthermore, other preferable examples of the partial peptide of the present invention are a peptide having (i) a 41st to 106th amino acid sequence, (ii) a 121st to 179th amino acid sequence or (iii) a 187th to  
35 211st amino acid sequence of the amino acid sequence represented by any one of SEQ ID NO:11 to SEQ ID NO:13

or Fig.5, and so on.

The partial peptide of the present invention may include peptides such as a peptide comprising (1) an amino acid sequence wherein one or more amino acid residues (for example about 1 to 10, preferably a few (1 to 5) amino acid residues) are deleted from the amino acid sequence as mentioned above, (2) an amino acid sequence wherein one or more amino acid residues (for example about 1 to 10, preferably a few (1 to 5) amino acid residues) are added to the amino acid sequence as mentioned above, (3) an amino acid sequence wherein one or more amino acid residues (for example about 1 to 10, preferably a few (1 to 5) amino acid residues) in the the amino acid sequence represented as mentioned above are substituted with other amino acid residues, or (4) a combination thereof.

The peptide of the present invention is usually in the carboxyl ( $-\text{COOH}$ ) or carboxylate ( $-\text{COO}^-$ ) form at the C-terminus, but may instead be in the amide ( $-\text{CONH}_2$ ) or ester ( $-\text{COOR}$ ) form in the same manner as the protein of the present invention as mentioned above.

Furthermore, the partial peptide of the present invention includes (1) a peptide in which the N-terminal amino acid residue (e.g. Met) is protected with a protective group, (2) a peptide in which the N-terminal side of Glu is cleaved in vivo to form pyroglutamic acid, (3) a peptide in which the side chain of any relevant constituent amino acid is protected by any protective group, (4) a peptide in which the carboxyl group of the side chain of any relevant constituent amino acid is amidated ( $-\text{CONH}_2$ ) or esterified ( $-\text{COOR}$ ), and (5) a complex peptide such as glycoproteins available upon attachment of sugar chains in the same manner as the protein of the present invention as mentioned above.

As the partial peptide of the present invention is

used as an antigen for preparation of an antibody, it does not need to have a nerve-extending activity or neuro-regenerative activity in the central nervous system, etc., a gliocyte stimulating activity or an activity of forming memories in brain.

The protein of the present invention may be a precursor protein. The precursor protein of the present invention is, for example, a protein in which one or more than 2, preferably about 1 to 200, more preferably about 1 to 100 amino acid residue bind to the N-terminus or (and) C-terminus of the protein of the present invention as mentioned above.

Specifically, the precursor protein of the present invention includes a protein having (i) an amino acid sequence represented by SEQ ID NO:10 (a 25th to 224th amino acid sequence of Fig.1), (ii) an amino acid sequence represented by SEQ ID NO:11 (a 1st to 224th amino acid sequence of Fig.1), (iii) an amino acid sequence represented by SEQ ID NO:12 (a 1st to 224th amino acid sequence of Fig.2) or (iv) an amino acid sequence represented by SEQ ID NO:13 (a 1st to 224th amino acid sequence of Fig.3) or (v) a substantial equivalent thereto, and so on.

The precursor protein of the present invention may be a protein derived from the above-mentioned cells of mammals or all tissues in which such cells are present, or may be a protein derived from fishes such as goldfish, zebrafish, salmon, trout, herring and carp, or may be a synthetic protein.

Examples of the substantially equivalent amino acid sequence to the amino acid sequence represented by SEQ ID NO:10 are an amino acid sequence having an identity of not less than about 40%, preferably not less than about 60%, more preferably not less than about 70%, furthermore preferably about 80%, still more preferably not less than about 90%, most preferably not

less than about 95% to the amino acid sequence represented by SEQ ID NO:10, and so on.

The precursor proteins comprising the substantially equivalent amino acid sequence to the amino acid sequence represented by SEQ ID NO:10 include any proteins having a substantially equivalent amino acid sequence to the amino acid sequence represented by SEQ ID NO:10 and capable of yielding the protein of the present invention as mentioned above. Therefore, it is allowable that even differences among molecular weight, etc. are present.

Examples of the substantially equivalent amino acid sequence to the amino acid sequence represented by SEQ ID NO:11 are an amino acid sequence having an identity of not less than about 40%, preferably not less than about 60%, more preferably not less than about 70%, furthermore preferably about 80%, still more preferably not less than about 90%, most preferably not less than about 95% to the amino acid sequence represented by SEQ ID NO:11, and so on.

The precursor proteins comprising the substantially equivalent amino acid sequence to the amino acid sequence represented by SEQ ID NO:11 include any proteins having a substantially equivalent amino acid sequence to the amino acid sequence represented by SEQ ID NO:11 and capable of yielding the protein of the present invention as mentioned above. Therefore, it is allowable that even differences among molecular weight, etc. are present.

Examples of the substantially equivalent amino acid sequence to the amino acid sequence represented by SEQ ID NO:12 are an amino acid sequence having an identity of not less than about 40%, preferably not less than about 60%, more preferably not less than about 70%, furthermore preferably about 80%, still more preferably not less than about 90%, most preferably not

less than about 95% to the amino acid sequence represented by SEQ ID NO:12, and so on.

The precursor proteins comprising the substantially equivalent amino acid sequence to the amino acid sequence represented by SEQ ID NO:12 include any proteins having a substantially equivalent amino acid sequence to the amino acid sequence represented by SEQ ID NO:12 and capable of yielding the protein of the present invention as mentioned above. Therefore, it is allowable that even differences among molecular weight, etc. are present.

Examples of the substantially equivalent amino acid sequence to the amino acid sequence represented by SEQ ID NO:13 are an amino acid sequence having an identity of not less than about 40%, preferably not less than about 60%, more preferably not less than about 70%, furthermore preferably about 80%, still more preferably not less than about 90%, most preferably not less than about 95% to the amino acid sequence represented by SEQ ID NO:13, and so on.

The precursor proteins comprising the substantially equivalent amino acid sequence to the amino acid sequence represented by SEQ ID NO:13 include any proteins having a substantially equivalent amino acid sequence to the amino acid sequence represented by SEQ ID NO:13 and capable of yielding the protein of the present invention as mentioned above. Therefore, it is allowable that even differences among molecular weight, etc. are present.

And, the precursor proteins of the present invention may include a protein comprising (i) an amino acid sequence wherein one or more amino acid residues (e.g. about 1 to 20, preferably about 1 to 9, more preferably a few (e.g. 1 to 5) amino acid residues) are deleted from the amino acid sequence represented by any one of SEQ ID NO:10 to SEQ ID NO:13, (ii) an amino acid

sequence wherein one or more amino acid residues (e.g. about 1 to 20, preferably about 1 to 9, more preferably a few (e.g. 1 to 5) amino acid residues) are added to the amino acid sequence represented by any one of SEQ ID NO:10 to SEQ ID NO:13, (iii) an amino acid sequence wherein one or more amino acid residues (e.g. about 1 to 20, preferably about 1 to 9, more preferably a few (e.g. 1 to 5) amino acid residues) in the amino acid sequence represented by any one of SEQ ID NO:10 to SEQ ID NO:13 are substituted with one or more amino acid residues, or (iv) a combination thereof, and so on.

The precursor proteins of the present invention is usually in the carboxyl (-COOH) or carboxylate (-COO<sup>-</sup>) form at C-terminus, but may instead be in the amide (-CONH<sub>2</sub>) or ester (-COOR) form in the same manner as the protein of the present invention as mentioned above.

Furthermore, the precursor protein of the present invention includes (1) a protein in which the N-terminal amino acid residue (e.g. Met) is protected with a protective group, (2) a protein in which the N-terminal side Glu is cleaved in vivo to form pyroglutamic acid, (3) a protein in which the side chain of any relevant constituent amino acid has been protected by any protective group, (4) a peptide in which the carboxyl group of the side chain of any relevant constituent amino acid is amidated (-CONH<sub>2</sub>) or esterified (-COOR), and (5) a complex protein such as glycoproteins available upon attachment of sugar chains in the same manner as the protein of the present invention as mentioned above.

The specific examples of the precursor proteins are (i) a protein in which the signal peptide of the present invention having an amino acid sequence represented by SEQ ID NO:14 as mentioned below binds to the N-terminus of the protein having the amino acid

sequence represented by SEQ ID NO:1 of the present invention (that is, a protein having the amino acid sequence represented by SEQ ID NO:11), (ii) a protein in which the signal peptide of the present invention  
5 having an amino acid sequence represented by SEQ ID NO:15 as mentioned below is deleted from the N-terminus of the precursor protein having the amino acid sequence represented by SEQ ID NO:11 of the present invention (that is, a protein having the amino acid sequence  
10 represented by SEQ ID NO:10), (iii) a protein in which the signal peptide of the present invention having an amino acid sequence represented by SEQ ID NO:16 as mentioned below binds to the N-terminus of the protein having the amino acid sequence represented by SEQ ID  
15 NO:2 of the present invention (that is, a protein having the amino acid sequence represented by SEQ ID NO:12), (iv) a protein in which the signal peptide of the present invention having an amino acid sequence represented by SEQ ID NO:17 as mentioned below binds to  
20 the N-terminus of the protein having the amino acid sequence represented by SEQ ID NO:3 of the present invention (that is, a protein having the amino acid sequence represented by SEQ ID NO:13), and so on.

As the precursor proteins of the present invention  
25 have the signal peptide, it can secrete the protein of the present invention out side of cells. And, the precursor proteins are useful as intermediates for producing the protein of the present invention.

The precursor proteins of the present invention  
30 have the same functions as the protein of the present invention as mentioned below, for example, physiological activities such as a nerve-extending activity and a neuro-regenerative activity in the central nervous system, etc., a gliocyte stimulating  
35 activity, an activity of forming memories in brain, and have a utility in the same way as the protein of the



present invention.

Examples of the signal peptide of the present invention includes a signal peptide having (i) an amino acid sequence represented by SEQ ID NO:14 (a 1st to 37th amino acid sequence of SEQ ID NO: 11 or Fig.1), (ii) an amino acid sequence represented by SEQ ID NO:15 (a 1st to 24th amino acid sequence of SEQ ID NO:11 or Fig.1), (iii) an amino acid sequence represented by SEQ ID NO:16 (a 1st to 34th amino acid sequence of SEQ ID NO:12 or Fig.2) or (iv) an amino acid sequence represented by SEQ ID NO:17 (a 1st to 34th amino acid sequence of SEQ ID NO:13 or Fig.3) or (v) a substantial equivalent thereto, and so on.

The signal peptide of the present invention may be a peptide derived from the above-mentioned cells of mammals or all tissues in which such cells are present, or may be a peptide derived from fishes such as goldfish, zebrafish, salmon, trout, herring and carp, or may be a synthetic signal peptide.

Examples of the substantially equivalent amino acid sequence to the amino acid sequence represented by SEQ ID NO:14 are an amino acid sequence having an identity of not less than about 60%, preferably not less than about 70%, more preferably about 80%, furthermore preferably not less than about 90%, most preferably not less than about 95% to the amino acid sequence represented by SEQ ID NO:14, and so on.

Examples of the substantially equivalent amino acid sequence to the amino acid sequence represented by SEQ ID NO:15 are an amino acid sequence having an identity of not less than about 60%, preferably not less than about 70%, more preferably about 80%, furthermore preferably not less than about 90%, most preferably not less than about 95% to the amino acid sequence represented by SEQ ID NO:15, and so on.

Examples of the substantially equivalent amino acid sequence to the amino acid sequence represented by SEQ ID NO:16 are an amino acid sequence having an identity of not less than about 60%, preferably not less than about 70%, more preferably about 80%, furthermore preferably not less than about 90%, most preferably not less than about 95% to the amino acid sequence represented by SEQ ID NO:16, and so on.

Examples of the substantially equivalent amino acid sequence to the amino acid sequence represented by SEQ ID NO:17 are an amino acid sequence having an identity of not less than about 60%, preferably not less than about 70%, more preferably about 80%, furthermore preferably not less than about 90%, most preferably not less than about 95% to the amino acid sequence represented by SEQ ID NO:17, and so on.

The signal peptides of the present invention include any peptides having the substantially equivalent amino acid sequence to the amino acid sequence represented by SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16 or SEQ ID NO:17, and capable of showing a function as a signal peptide. Therefore, it is allowable that even differences among molecular weight, etc. are present.

And, the signal peptides of the present invention may include a peptide comprising (i) an amino acid sequence wherein one or more amino acid residues (e.g. about 1 to 6, preferably a few (e.g. 1 to 4) amino acid residues) are deleted from the amino acid sequence as mentioned above, (ii) an amino acid sequence wherein one or more amino acid residues (e.g. about 1 to 6, preferably a few (e.g. 1 to 4) amino acid residues) are added to the amino acid sequence as mentioned above, (iii) an amino acid sequence wherein one or more amino acid residues (e.g. about 1 to 6, preferably a few (e.g. 1 to 4) amino acid residues) in the amino acid

sequence as mentioned above, or (iv) a combination thereof, and so on, as long as the signal peptide shows a function as a signal peptide.

5 The signal peptides of the present invention is usually in the carboxyl ( $-\text{COOH}$ ) or carboxylate ( $-\text{COO}^-$ ) form at C-terminus, but may instead be in the amide ( $-\text{CONH}_2$ ) or ester ( $-\text{COOR}$ ) form in the same manner as the protein of the present invention as mentioned above.

10 The specific examples of the signal peptides of the present invention are (1) a peptide having an amino acid sequence represented by SEQ ID NO:14, (2) a peptide having an amino acid sequence represented by SEQ ID NO:15, (3) a peptide having an amino acid  
15 sequence represented by SEQ ID NO:16, (4) a peptide having an amino acid sequence wherein Gly is deleted from the C-terminus of the amino acid sequence represented by SEQ ID NO:16, (5) a peptide having an amino acid sequence represented by SEQ ID NO:17, (6) a  
20 peptide having an amino acid sequence wherein 7 amino acid residues are deleted from the C-terminus of the amino acid sequence represented by SEQ ID NO:17 and so on.

25 The signal peptides of the present invention can secrete various endocellular secretory protein (or peptide) such as the protein of the present invention effectively.

30 The salts of the protein, the partial peptide, the precursor protein or the signal peptide of the present invention include salts with physiologically acceptable bases (e.g. alkali metals) or acids such as organic or inorganic acids, and are preferably physiologically acceptable acid addition salts. Examples of such salts are salts thereof with inorganic acids (e.g.  
35 hydrochloric acid, phosphoric acid, hydrobromic acid or sulfuric acid, etc.) and salts thereof with organic

acids (e.g. acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, maleic acid, oxalic acid, benzoic acid, methanesulfonic acid or benzenesulfonic acid, etc..)

The protein, its partial peptide, the precursor protein, the signal peptide or a salt thereof of the present invention (hereinafter referred to as the protein of the present invention, in the description on the method for producing them) can be produced from the tissues or cells of mammals by per se known technology for purification of proteins or peptides or, as described hereinafter, by culturing a transformant carrying a DNA encoding the protein. It can also be produced in accordance with the procedures for peptide synthesis which are described hereinafter.

When the protein of the present invention is produced from the tissues or cells of mammals, the tissues or cells of mammals are homogenized and the protein of the present invention is extracted by an acid, etc.. The protein can be purified and isolated from the extract by a combination of chromatography such as reverse phase chromatography, ion exchange chromatography and so on.

For the synthesis of the protein of the present invention or their amide form, any of commercial resins available for protein synthesis can be employed. Such resins include chloromethyl resin, hydroxymethyl resin, benzhydrylamino resin, aminomethyl resin, 4-benzyloxybenzyl alcohol resin, 4-methylbenzhydrylamino resin, PAM resin, 4-hydroxymethylmethylphenylacetamidomethyl resin, polyacrylamide resin, 4-(2',4'-dimethoxyphenyl-hydroxymethyl)phenoxy resin, and 4-(2',4'-dimethoxyphenyl-Fmoc-aminoethyl)phenoxy resin. Using such a resin, amino acids which may be beforehand

protected at side-chain functional groups in a suitable manner can be serially condensed with the  $\alpha$ -amino group in the order corresponding to the amino acid sequence of the objective protein or peptide by various  
5      condensation techniques which are per se known. After completion of the final condensation reaction, the protein or peptide is separated from the resin and the protective groups are removed. Then, in highly diluted solution, the intramolecular disulfide-forming reaction  
10     is carried out to provide the objective proteins or amides thereof.

Referring to the above condensation of protected amino acids, various activating agents known to be useful for protein synthesis can be utilized, and  
15     carbodiimide reagents are especially preferred. The carbodiimide reagents include DCC, N,N'-diisopropylcarbodiimide, and N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide and so on. For activation by these reagents, the protected amino acid  
20     and a racemization inhibitor (e.g. HOBt, HOObt, etc.) can be directly added to the resin, or the protected amino acid can be activated beforehand in the form of symmetric acid anhydride, HOBt ester or HOObt ester and, then, added to the resin.

25     The solvent used for the above-mentioned activation of protected amino acids or a conjugation thereof to the resin can be optionally selected from among the solvents known to be useful for protein condensation reactions. Examples of the solvent are  
30     acid amides (e.g. N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone, etc.), halogenated hydrocarbons (e.g. methylene chloride, chloroform, etc.), alcohols (e.g. trifluoroethanol, etc.), sulfoxides (e.g. dimethyl sulfoxide, etc.),  
35     ethers (e.g. pyridine, dioxane, tetrahydrofuran, etc.), nitriles (e.g. acetonitrile, propionitrile, etc.),

esters (e.g. methyl acetate, ethyl acetate, etc.), and suitable mixtures of these solvents. The reaction temperature can be selected from the range known to be useful for protein-forming reactions, usually the range of about -20°C to about 50°C. The activated amino acid derivative is generally used in a 1.5 to 4-fold excess. When the condensation is found insufficient by ninhydrin assay, the reaction can be repeated to make the sufficient condensation thoroughly. When sufficient condensation can not be achieved by the repeated reaction, an unreacted amino acid can be acetylated by using acetic anhydride or acetylimidazole so as not to effect a subsequent reaction.

The protective groups for protecting the amino group of the starting compound include Z, Boc, t-pentyloxycarbonyl, isobornyloxycarbonyl, 4-methoxybenzyloxycarbonyl, Cl-Z, Br-Z, adamantyloxycarbonyl, trifluoroacetyl, phthaloyl, formyl, 2-nitrophenylsulfenyl, diphenylphosphinothioyl, Fmoc, and so on.

The carboxyl group can be protected in the form of, for example, an alkyl ester (e.g. straight-chain, branched, or cyclic alkyl esters such as methyl, ethyl, propyl, butyl, t-butyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 2-adamantyl, and so on), an aralkyl ester (e.g. benzyl, 4-nitrobenzyl, 4-methoxybenzyl, 4-chlorobenzyl, benzhydryl, and so on), phenacyl ester, benzyloxycarbonylhydrazide, t-butoxycarbonylhydrazide or tritylhydrazide.

The hydroxyl group of serine can be protected in the form of an ester or an ether. The group suitable for esterification includes carboxylic acid-derived acyl groups such as a lower(C<sub>1-6</sub>) alkanoyl group (e.g. acetyl, etc.), an aroyl group (e.g. benzoyl, etc.), a benzyloxycarbonyl, an ethoxycarbonyl group and so on. The group suitable for etherification includes a benzyl

group, a tetrahydropyranyl group, a t-butyl group and so on.

The protective group used for protecting the phenolic hydroxyl group of tyrosine includes Bzl, Cl<sub>2</sub>-Bzl, 2-nitrobenzyl, Br-Z, t-butyl and so on.

The protective group for the imidazole group of histidine includes Tos, 4-methoxy-2,3,6-trimethylbenzenesulfonyl, DNP, benzyloxymethyl, Bum, Boc, Trt, Fmoc and so on.

The starting compound with activated carboxyl groups includes the corresponding acid anhydride, azide, and active ester (e.g. esters with alcohols such as pentachlorophenol, 2,4,5-trichlorophenol, 2,4-dinitrophenol, cyanomethyl alcohol, p-nitrophenol, HONB, N-hydroxysuccinimide, N-hydroxyphthalimide, HOBT, etc.). The starting compound with activated amino groups includes the corresponding phosphorylamide.

The method for removal of such protective groups includes catalytic reduction in a hydrogen stream in the presence of a catalyst (e.g. Pd black or Pd-on-carbon), acid treatment with anhydrous hydrogen fluoride, methanesulfonic acid, trifluoromethanesulfonic acid, trifluoroacetic acid or a mixture thereof, treatment with a base such as diisopropylethylamine, triethylamine, piperidine, piperazine or the like, and reduction with sodium metal in liquid ammonia. The above deprotection by treatment with acid is generally conducted at a temperature of about -20°C to 40°C. This acid treatment can be carried out advantageously in the presence of a cation acceptor such as anisole, phenol, thioanisole, m-cresol, p-cresol, dimethyl sulfide, 1,4-butanedithiol, 1,2-ethanedithiol, or the like. The 2,4-dinitrophenyl group used for protecting the imidazole group of histidine can be removed by treatment with thiophenol, and the formyl group used for protecting the indole

group of tryptophan can be removed not only by said acid treatment in the presence of 1,2-ethanedithiol, 1,4-butanedithiol or the like as described hereinbefore, but also by alkali treatment with diluted sodium hydroxide solution, diluted liquid ammonia, or the like.

The method for protecting any functional group that should not take part in the contemplated reaction, the protective group to be used for such protection, the method for eliminating the protective group, and the method for activating the functional group to be involved in the contemplated reaction can all be optionally selected from among the known methods and groups.

An alternative method for providing the protein in amide form typically comprises protecting the  $\alpha$ -carboxyl group of the C-terminal amino acid in the form of an amide, extending the peptide (protein) chain to a desired length towards the N-terminus, deprotecting the N-terminal  $\alpha$ -amino acid of the resulting peptide chain selectively to provide an N-terminal-deprotected fragment, preparing a peptide (protein) fragment with its C-terminal carboxyl group selectively deprotected, and condensing the two fragments in a solvent such as the mixed solvent as mentioned above. The condensation reaction can be carried out in the same manner as described hereinbefore. After purification of the protected protein thus obtained by condensation, all the protective groups are eliminated by the procedures described hereinbefore to provide the contemplated protein in crude form. This crude protein is purified by suitable known purification techniques and lyophilized to provide the desired protein amide.

A method for providing the protein in an ester form comprises condensing the  $\alpha$ -carboxyl group of the C-terminal amino acid with a suitable alcohol to



prepare the corresponding ester and subjecting this ester to the same procedure as described for purification of the protein amide to provide the objective ester of the protein.

5           The partial peptide of the present invention or a salt thereof can be produced by per se known procedures for peptide synthesis or by cleaving the protein with a suitable peptidase. The process for peptide synthesis may be a solid-phase synthesis and/or a liquid-phase  
10           synthesis. Namely, the objective peptide can be produced by condensing a partial peptide or amino acid capable of constituting the partial peptide of the present invention with the residual part thereof and, when the product has a protective group, the protective  
15           group is removed whereupon a desired peptide can be manufactured. The known technology for condensation and deprotection includes the procedures described in the following literature (1)-(5).

(1) M. Bodanszky and M. A. Ondetti, Peptide Synthesis, Interscience Publishers, New York, 1966  
20           (2) Schroeder and Luebke, The Peptide, Academic Press, New York, 1965

(3) Nobuo Izumiya et al., Fundamentals and Experiments in Peptide Synthesis, Maruzen, 1975

(4) Haruaki Yajima and Shumpei Sakakibara, Biochemical Experiment Series 1, Protein Chemistry IV, 205, 1977  
25           (5) Haruaki Yajima (ed.), Development of Drugs-Continued, 14, Peptide Synthesis, Hirokawa Shoten

After the reaction, the partial peptide of the  
30           present invention can be purified and isolated by a combination of conventional purification techniques such as solvent extraction, distillation, column chromatography, liquid chromatography, and recrystallization. When the partial peptide isolated  
35           as above is in a free form, it can be converted to a suitable salt by known methods or a method analogous

thereto. On the other hand, when it is isolated as a salt, it can be converted to a free form or to any other salt thereof by known methods or a method analogous thereto.

5

The DNA coding for the protein of the present invention may be any DNAs comprising a nucleotide sequence encoding the protein of the present invention as mentioned above. It may also be any one of genomic DNA, genomic DNA library, cDNA derived from the tissues or cells as mentioned above, cDNA library derived from the tissues or cells as mentioned above, and synthetic DNA.

The vector for constructing a library may include bacteriophage, plasmid, cosmid, and phagemid. Furthermore, using a total RNA fraction or a mRNA fraction prepared from the tissues or cells, a direct amplification can be carried out by Reverse Transcriptase Polymerase Chain Reaction (hereinafter, referred to as RT-PCR method) technique.

Examples of DNA coding for the protein comprising the amino acid sequence represented by SEQ ID NO:1 or a substantially equivalent thereto of the present invention are (1) a DNA comprising a nucleotide sequence represented by SEQ ID NO:18, or (2) a DNA which comprises a nucleotide sequence hybridizing to the nucleotide sequence represented by SEQ ID NO:18 under a high stringent condition and codes for a protein having a substantially and qualitatively equivalent activity (e.g. nerve-extending activity or neuro-regenerative activity in the central nervous system, etc., gliocyte stimulating activity, activity of forming memories in brain) to the protein comprising the amino acid sequence represented by ID No:1.

Examples of the nucleotide sequence hybridizing to the nucleotide sequence represented by SEQ ID NO:18 are

a nucleotide sequence which has not less than about 60%, preferably not less than about 70%, more preferably not less than about 80%, still more preferably not less than about 90%, most preferably not less than about 95% identity to the nucleotide sequence represented by SEQ ID NO:18.

Examples of DNA coding for the protein comprising the amino acid sequence represented by SEQ ID NO:2 or a substantially equivalent thereto of the present invention are (1) a DNA comprising a nucleotide sequence represented by SEQ ID NO:19, or (2) a DNA which comprises a nucleotide sequence hybridizing to the nucleotide sequence represented by SEQ ID NO:19 under a high stringent condition and codes for a protein having a substantially and qualitatively equivalent activity (e.g. nerve-extending activity or neuro-regenerative activity in the central nervous system, etc., gliocyte stimulating activity, activity of forming memories in brain) to the protein comprising the amino acid sequence represented by ID No:2, and so on.

Examples of the nucleotide sequence hybridizing to the nucleotide sequence represented by SEQ ID NO:19 are a nucleotide sequence which has not less than about 60%, preferably not less than about 70%, more preferably not less than about 80%, still more preferably not less than about 90%, most preferably not less than about 95% identity to the nucleotide sequence represented by SEQ ID NO:19.

Examples of DNA coding for the protein having the amino acid sequence represented by SEQ ID NO:3 or a substantially equivalent thereto of the present invention are (1) a DNA comprising a nucleotide sequence represented by SEQ ID NO:20, or (2) a DNA which comprises a nucleotide sequence hybridizing to the nucleotide sequence represented by SEQ ID NO:20

under a high stringent condition and codes for a protein having a substantially and qualitatively equivalent activity (e.g. nerve-extending activity or neuro-regenerative activity in the central nervous system, etc., gliocyte stimulating activity, activity of forming memories in brain) to the protein comprising the amino acid sequence represented by ID No:3, and so on.

Examples of the nucleotide sequence hybridizing to the nucleotide sequence represented by SEQ ID NO:20 are a nucleotide sequence which has not less than about 60%, preferably not less than about 70%, more preferably not less than about 80%, still more preferably not less than about 90%, most preferably not less than about 95% identity to the nucleotide sequence represented by SEQ ID NO:20.

The hybridization can be carried out by per se known methods such as the method described in Molecular Cloning, 2nd (J. Sambrook et al., Cold Spring Harbor Lab. Press, 1989) and so on. When a commercially available library is used, the hybridization can be carried out in accordance with the instructions given in the accompanying manual, and particularly, be carried out under a high stringent condition.

Under the high stringent condition,  $\text{Na}^+$  concentration is at about 19 to 40mM, preferably about 19 to 20 mM and a temperature is at about 50 to 70°C, preferably about 60 to 65°C. Particularly, the condition at about 19 mM of  $\text{Na}^+$  and about 65°C is preferred.

Preferable examples of the DNA coding for the protein comprising the amino acid sequence represented by SEQ ID NO:1 are a DNA comprising the nucleotide sequence represented by SEQ ID NO:18.

Preferable examples of the DNA coding for the protein comprising the amino acid sequence represented

by SEQ ID NO:2 are a DNA comprising the nucleotide sequence represented by SEQ ID NO:19.

5       Preferable examples of the DNA coding for the protein comprising the amino acid sequence wherein Gly is added to the N-terminus of the amino acid sequence represented by SEQ ID NO:2 are a DNA comprising the nucleotide sequence wherein GGC are added to the 5'-terminus of the nucleotide sequence represented by SEQ ID NO:19.

10       Preferable example of the DNA coding for the protein comprising the amino acid sequence represented by SEQ ID NO:3 are a DNA comprising the nucleotide sequence represented by SEQ ID NO:20.

15       Preferable examples of the DNA coding for the protein comprising the amino acid sequence wherein 7 amino acid residues of the C-terminus of the amino acid sequence represented by SEQ ID NO:17 are added to the N-terminus of the amino acid sequence represented by SEQ ID NO:3 are a DNA comprising the nucleotide  
20       sequence wherein 21 bases of the 3'-terminus of the nucleotide sequence represented by SEQ ID NO:34 are added to the 5'-terminus of the nucleotide sequence represented by SEQ ID NO:20.

25       And, examples of the DNA coding for the protein comprising at least one amino acid sequence represented by SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 or SEQ ID NO:7 are a DNA comprising a nucleotide sequence represented by SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23 or SEQ ID NO:24, and so on.

30       Furthermore, examples of the DNA coding for the protein comprising at least one amino acid sequence represented by SEQ ID NO:4, SEQ ID NO:8, SEQ ID NO:9 or SEQ ID NO:7 are a DNA comprising a nucleotide sequence represented by SEQ ID NO:21, SEQ ID NO:25, SEQ ID NO:26  
35       or SEQ ID NO:24, and so on.

The DNA coding for the partial peptide of the present invention may be any DNAs comprising a nucleotide sequence encoding the partial peptide of the present invention as mentioned above. It may also be  
5 any one of genomic DNA, genomic DNA library, cDNA derived from the tissues or cells as mentioned above, cDNA library derived from the tissues or cells as mentioned above, and synthetic DNA.

The vector for constructing a library may include  
10 bacteriophage, plasmid, cosmid, and phagemid. Furthermore, using a total RNA fraction or a mRNA fraction prepared from the tissues or cells, a direct amplification can be carried out by RT-PCR method.

Examples of DNA coding for the partial peptide of the present invention are (i) a DNA comprising a partial nucleotide sequence of DNA which comprises a nucleotide sequence represented by SEQ ID NO: 18, SEQ ID NO:19 or SEQ ID NO:20, or (ii) a DNA comprising a partial nucleotide sequence of DNA which comprises a  
20 nucleotide sequence hybridizing under a high stringent condition to the nucleotide sequence represented by SEQ ID NO:18, SEQ ID NO:19 or SEQ ID NO:20 and codes for a protein having a substantially and qualitatively equivalent activity (e.g. nerve-extending activity or neuro-regenerative activity in the central nervous  
25 sytem, etc., gliocyte stimulating activity, activity of forming memories in brain) to the protein of the present invention.

Examples of the nucleotide sequence hybridizing to the nucleotide sequence represented by SEQ ID NO:18, SEQ ID NO:19 or SEQ ID NO:20 are a nucleotide sequence which has not less than about 60%, preferably not less than about 70%, more preferably not less than about 80%, furthermore preferably not less than about 90%,  
35 most preferably not less than about 95% identity to the nucleotide sequence represented by SEQ ID NO:18, SEQ ID

NO:19 or SEQ ID NO:20, and so on.

More specifically, examples of the DNA coding for the partial peptide comprising the amino acid sequence represented by SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 or  
5 SEQ ID NO:7 are (i) a DNA having the nucleotide sequence represented by SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23 or SEQ ID NO:24, (ii) a DNA which has a nucleotide sequence hybridizing under a high stringent condition to the nucleotide sequence represented by SEQ  
10 ID NO:21, SEQ ID NO:22, SEQ ID NO:23 or SEQ ID NO:24, and so on.

Examples of the the nucleotide sequence hybridizing to the nucleotide sequence represented by SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23 or SEQ ID  
15 NO:24 are a nucleotide sequence of not less than about 60%, preferably not less than about 70%, more preferably not less than about 80%, furthermore preferably not less than about 90%, most preferably not less than about 95% identity to the nucleotide sequence represented by SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23  
20 or SEQ ID NO:24, and so on.

Specific examples of the DNA coding for the partial peptide having an amino acid sequence represented by SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 or  
25 SEQ ID NO:7 are a DNA having a nucleotide sequence represented by SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23 or SEQ ID NO:24, and so on.

Examples of the DNA coding for the partial peptide having the amino acid sequence represented by SEQ ID  
30 NO:4, SEQ ID NO:8, SEQ ID NO:9 or SEQ ID NO:7 are (i) a DNA having the nucleotide sequence represented by SEQ ID NO:21, SEQ ID NO:25, SEQ ID NO:26 or SEQ ID NO:24, (ii) a DNA which has the nucleotide sequence hybridizing under a high stringent condition to the  
35 nucleotide sequence represented by SEQ ID NO:21, SEQ ID NO:25, SEQ ID NO:26 or SEQ ID NO:24, and so on.

Examples of the the nucleotide sequence hybridizing to the nucleotide sequence represented by SEQ ID NO:21, SEQ ID NO:25, SEQ ID NO:26 or SEQ ID NO:24 are a nucleotide sequence of not less than about 5 60%, preferably not less than about 70%, more preferably not less than about 80%, furthermore preferably not less than about 90%, most preferably not less than about 95% identity to the nucleotide sequence represented by SEQ ID NO:21, SEQ ID NO:25, SEQ ID NO:26 10 or SEQ ID NO:24, and so on.

Specific examples of the DNA coding for the partial peptide having an amino acid sequence represented by SEQ ID NO:4, SEQ ID NO:8, SEQ ID NO:9 or SEQ ID NO:7 are a DNA having a nucleotide sequence 15 represented by SEQ ID NO:21, SEQ ID NO:25, SEQ ID NO:26 or SEQ ID NO:24, and so on.

And, examples of the DNA coding for the partial peptide comprising a 41st to 106th, 121st to 179th or 187th to 211st amino acid sequence of the amino acid 20 sequence represented by any one of SEQ ID NO:11 to SEQ ID NO:13 or Fig.4 are (i) a 121st to 318th, 360th to 537th or 559th to 633rd nucleotide sequence of the nucleotide sequence represented by any one of SEQ ID NO:28 to SEQ ID NO:30 or (ii) a nucleotide sequence 25 hybridizing under a high stringent condition to the 121st to 318th, 360th to 537th or 559th to 633rd nucleotide sequence of the nucleotide sequence represented by any one of SEQ ID NO:28 to SEQ ID NO:30.

Examples of the nucleotide sequence hybridizing 30 under a high stringent condition to the 121st to 318th, 360th to 537th or 559th to 633rd nucleotide sequence of the nucleotide sequence represented by any one of SEQ ID NO:28 to SEQ ID NO:30 are a nucleotide sequence of not less than about 60%, preferably not less than about 35 70%, more preferably not less than about 80%, furthermore preferably not less than about 90%, most



preferably not less than about 95% identity to the  
121st to 318th, 360th to 537th or 559th to 633rd  
nucleotide sequence of the nucleotide sequence  
represented by any one of SEQ ID NO:28 to SEQ ID NO:30.

5       The method of hybridization and the high stringent  
condition are the same as mentioned above.

More specifically, preferable examples of the DNA  
coding for the partial peptide comprising a 41st to  
106th, 121st to 179th or 187th to 211st amino acid  
10       sequence of the amino acid sequence represented by any  
one of SEQ ID NO:11 to SEQ ID NO:13 or Fig.4 are a  
121st to 318th, 360th to 537th or 559th to 633rd  
nucleotide sequence of the nucleotide sequence  
represented by any one of SEQ ID NO:28 to SEQ ID NO:30

15

The DNA coding for the precursor protein of the  
present invention may be any DNAs comprising a  
nucleotide sequence encoding the precursor protein of  
the present invention as mentioned above. It may also  
20       be any one of genomic DNA, genomic DNA library, cDNA  
derived from the tissues or cells as mentioned above,  
cDNA library derived from the tissues or cells as  
mentioned above, and synthetic DNA.

The vector for constructing a library may include  
25       bacteriophage, plasmid, cosmid and phagemid.  
Furthermore, using a total RNA fraction or a mRNA  
fraction prepared from the tissues or cells, a direct  
amplification can be carried out by RT-PCR method.

Examples of the DNA coding for the precursor  
30       proteins comprising the amino acid sequence represented  
by SEQ ID NO:10 or a substantial equivalent thereto are  
(i) a DNA comprising a nucleotide sequence represented  
by SEQ ID NO:27 or (ii) a DNA comprising a nucleotide  
sequence which hybridizes under a high stringent  
35       condition to the nucleotide sequence represented by SEQ  
ID NO:27 and codes for the protein capable of yielding

the protein of the present invention as mentioned above.

5 Examples of the nucleotide sequence hybridizing under a high stringent condition to the nucleotide sequence represented by SEQ ID NO:27 are a nucleotide sequence which has not less than about 60%, preferably not less than about 70%, more preferably not less than about 80%, furthermore preferably not less than about 90%, most preferably not less than about 95% identity to the the nucleotide sequence represented by SEQ ID  
10 NO:27, and so on.

Specific examples of the DNA coding for the precursor protein comprising an amino acid sequence represented by SEQ ID NO:10 are a DNA having a  
15 nucleotide sequence represented by SEQ ID NO:27.

Examples of the DNA coding for the precursor proteins comprising the amino acid sequence represented by SEQ ID NO:11 or a substantially equivalent thereto are (i) a DNA comprising a nucleotide sequence  
20 represented by SEQ ID NO:28 or (ii) a DNA comprising a nucleotide sequence which hybridizes under a high stringent condition to the nucleotide sequence represented by SEQ ID NO:28 and codes for the protein capable of yielding the protein of the present  
25 invention as mentioned above.

Examples of the nucleotide sequence hybridizing under a high stringent condition to the nucleotide sequence represented by SEQ ID NO:28 are a nucleotide sequence which has not less than about 60%, preferably not less than about 70%, more preferably not less than about 80%, furthermore preferably not less than about 90%, most preferably not less than about 95% identity to the the nucleotide sequence represented by SEQ ID  
30 NO:28, and so on.

35 Specific examples of the DNA coding for the precursor protein comprising an amino acid sequence

represented by SEQ ID NO:11 are a DNA having a nucleotide sequence represented by SEQ ID NO:28.

5 Examples of the DNA coding for the precursor proteins comprising the amino acid sequence represented by SEQ ID NO:12 or a substantially equivalent thereto are (i) a DNA comprising a nucleotide sequence represented by SEQ ID NO:29 or (ii) a DNA comprising a nucleotide sequence which hybridizes under a high stringent condition to the nucleotide sequence  
10 represented by SEQ ID NO:29 and codes for the protein capable of yielding the protein of the present invention as mentioned above.

15 Examples of the nucleotide sequence hybridizing under a high stringent condition to the nucleotide sequence represented by SEQ ID NO:29 are a nucleotide sequence which has not less than about 60%, preferably not less than about 70%, more preferably not less than about 80%, furthermore preferably not less than about 90%, most preferably not less than about 95% identity  
20 to the the nucleotide sequence represented by SEQ ID NO:29, and so on.

Specific examples of the DNA coding for the precursor protein comprising an amino acid sequence represented by SEQ ID NO:12 are a DNA having a  
25 nucleotide sequence represented by SEQ ID NO:29.

Examples of the DNA coding for the precursor proteins comprising the amino acid sequence represented by SEQ ID NO:13 or a substantial equivalent thereto are (i) a DNA comprising a nucleotide sequence represented  
30 by SEQ ID NO:30 or (ii) a DNA comprising a nucleotide sequence which hybridizes under a high stringent condition to the nucleotide sequence represented by SEQ ID NO:30 and codes for the protein capable of yielding the protein of the present invention as mentioned  
35 above.

Examples of the nucleotide sequence hybridizing

under a high stringent condition to the nucleotide sequence represented by SEQ ID NO:30 are a nucleotide sequence which has not less than about 60%, preferably not less than about 70%, more preferably not less than about 80%, furthermore preferably not less than about 90%, most preferably not less than about 95% identity to the the nucleotide sequence represented by SEQ ID NO:30, and so on.

Specific examples of the DNA coding for the precursor protein comprising an amino acid sequence represented by SEQ ID NO:13 are a DNA having a nucleotide sequence represented by SEQ ID NO:30.

The method of hybridization and the high stringent condition are the same as mentioned above.

The DNA coding for the signal peptide of the present invention may be any DNAs comprising a nucleotide sequence encoding the signal peptide of the present invention as mentioned above. It may also be any one of genomic DNA, genomic DNA library, cDNA derived from the tissues or cells as mentioned above, cDNA library derived from the tissues or cells as mentioned above, and synthetic DNA.

The vector for constructing a library may include bacteriophage, plasmid, cosmid and phagemid. Furthermore, using a total RNA fraction or a mRNA fraction prepared from the tissues or cells, a direct amplification can be carried out by RT-PCR method.

Examples of the DNA coding for the signal peptide having the amino acid sequence represented by SEQ ID NO:14 or a substantially equivalent thereto are (i) a DNA comprising a nucleotide sequence represented by SEQ ID NO:31 or (ii) a DNA comprising a nucleotide sequence which hybridizes under a high stringent condition to the nucleotide sequence represented by SEQ ID NO:31 and codes for the peptide capable of showing a function as

a signal peptide.

Examples of the nucleotide sequence hybridizing under a high stringent condition to the nucleotide sequence represented by SEQ ID NO:31 are a nucleotide  
5 sequence which has not less than about 60%, preferably not less than about 70%, more preferably not less than about 80%, furthermore preferably not less than about 90%, more preferably not less than about 95% identity to the the nucleotide sequence represented by SEQ ID  
10 NO:31, and so on.

Specific examples of the DNA coding for the signal peptide having an amino acid sequence represented by SEQ ID NO:14 are a DNA having a nucleotide sequence represented by SEQ ID NO:31.

15 Examples of the DNA coding for the signal peptide having the amino acid sequence represented by SEQ ID NO:15 or a substantial equivalent thereto are (i) a nucleotide sequence represented by SEQ ID NO:32 or (ii) a nucleotide sequence which hybridizes under a high  
20 stringent condition to the nucleotide sequence represented by SEQ ID NO:32 and codes for the peptide capable of showing a function as a signal peptide.

Examples of the nucleotide sequence hybridizing under a high stringent condition to the nucleotide  
25 sequence represented by SEQ ID NO:32 are a nucleotide sequence which has not less than about 60%, preferably not less than about 70%, more preferably not less than about 80%, furthermore preferably not less than about 90%, most preferably not less than about 95% identity  
30 to the the nucleotide sequence represented by SEQ ID NO:32, and so on.

Specific examples of the DNA coding for the signal peptide having an amino acid sequence represented by SEQ ID NO:15 are a DNA having a nucleotide sequence  
35 represented by SEQ ID NO:32.

Examples of the DNA coding for the signal peptide

having the amino acid sequence represented by SEQ ID NO:16 or a substantial equivalent thereto are (i) a DNA comprising a nucleotide sequence represented by SEQ ID NO:33 or (ii) a DNA comprising a nucleotide sequence which hybridizes under a high stringent condition to the nucleotide sequence represented by SEQ ID NO:33 and codes for the peptide capable of showing a function as a signal peptide.

Examples of the nucleotide sequence hybridizing under a high stringent condition to the nucleotide sequence represented by SEQ ID NO:33 are a nucleotide sequence which has not less than about 60%, preferably not less than about 70%, more preferably not less than about 80%, furthermore preferably not less than about 90%, most preferably not less than about 95% identity to the the nucleotide sequence represented by SEQ ID NO:33, and so on.

Specific examples of the DNA coding for the signal peptide having an amino acid sequence represented by SEQ ID NO:16 are a DNA having a nucleotide sequence represented by SEQ ID NO:33.

Specific examples of the DNA coding for the signal peptide having an amino acid sequence wherein Gly is deleted from the C-terminus of the amino acid sequence represented by SEQ ID NO:16 are a DNA having a nucleotide sequence wherein GGC are deleted from the 3'-terminus of the nucleotide sequence represented by SEQ ID NO:33.

Examples of the DNA coding for the signal peptide having the amino acid sequence represented by SEQ ID NO:17 or a substantial equivalent thereto are (i) a DNA comprising a nucleotide sequence represented by SEQ ID NO:34 or (ii) a DNA comprising a nucleotide sequence which hybridizes under a high stringent condition to the nucleotide sequence represented by SEQ ID NO:34 and codes for the peptide capable of showing a function as

a signal peptide.

Examples of the nucleotide sequence hybridizing under a high stringent condition to the nucleotide sequence represented by SEQ ID NO:34 are a nucleotide  
5 sequence which has not less than about 60%, preferably not less than about 70%, more preferably not less than about 80%, furthermore preferably not less than about 90%, most preferably not less than about 95% identity to the the nucleotide sequence represented by SEQ ID  
10 NO:34, and so on.

Specific examples of the DNA coding for the signal peptide having an amino acid sequence represented by SEQ ID NO:17 are a DNA having a nucleotide sequence represented by SEQ ID NO:34.

15 Specific examples of the DNA coding for the signal peptide having an amino acid sequence wherein 7 amino acid residues are deleted from the C-terminus of the amino acid sequence represented by SEQ ID NO:17 are a DNA having a nucleotide sequence wherein 21 bases are  
20 deleted from the 3'-terminus of the nucleotide sequence represented by SEQ ID NO:34.

The method of hybridization and the high stringent condition are the same as mentioned above.

25 The DNA encoding the protein, the partial peptide or the precursor protein of the present invention (hereinafter referred to as the protein of the present invention) can be cloned either by PCR amplification by using synthetic DNA primers having a partial nucleotide  
30 sequence of the DNA coding for the protein or by hybridization using the DNA inserted in a suitable vector and labeled DNA fragment or synthetic DNA coding for a part or full region of the protein of the present invention. The hybridization can be carried out by the  
35 method described in Molecular Cloning, 2nd (J. Sambrook et al., Cold Spring Harbor Lab. Press, 1989). When a

commercially available DNA library is used, the instructions given in the accompanying manual can be followed.

5 The DNA coding for the partial peptide or the signal peptide of the present invention can be prepared according to the per se known method for producing oligonucleotides.

10 The substitution of the nucleotide sequence of the DNA can be carried out by the per se known method such as Gapped duplex method, Kunkel method and so on by using known kits such as Mutan<sup>TM</sup>-G (Takara), Mutan<sup>TM</sup>-K (Takara) and so on.

15 The cloned DNA coding for the protein of the present invention can be used directly or after digestion with a restriction enzyme or after addition of a linker depending on purposes. This DNA may have ATG as the translation initiation codon at the 5' end and TAA, TGA, or TAG as the termination codon at the 3' end. The translation initiation and termination codons  
20 can be added by means of suitable DNA adapters.

An expression vector for the protein of the present invention can be constructed by, for example, (a) cutting out an objective DNA fragment from the DNA for the protein of the present invention and (b)  
25 ligating the objective DNA fragment with the downstream side of a promoter in a suitable expression vector.

The vector may include plasmids derived from Escherichia coli, e.g., pBR322, pBR325, pUC12, pUC13, etc.; plasmids derived from Bacillus subtilis, e.g.,  
30 pUB110, pTP5, pC194, etc.; plasmids derived from yeasts e.g., pSH19, pSH15, etc.; bacteriophages such as  $\lambda$  - phage; animal virus such as retrovirus, vaccinia virus, etc.; insect virus; and other vectors such as pAl-11, pXT1, pRc/CMV, pRc/RSV, pcDNAI/Neo and so on.

35 According to the present invention, any promoter can be used as long as it is appropriate for the host



cell which is used for expressing a gene. When the host is an animal cell, the promoter includes CAG promoter, SR $\alpha$  promoter, SV40 promoter, LTR promoter, CMV (cytomegalovirus) promoter, HSV-TK promoter, etc., and CAG promoter and SR $\alpha$  promoter are preferably used. When the host for the transformation is Escherichia coli, the promoter includes preferably trp promoter, lac promoter, recA promoter,  $\lambda$ P<sub>1</sub> promoter, lpp promoter, T7 promoter, etc.. When the host for the transformation is Bacillus, the promoter includes preferably SPO1 promoter, SPO2 promoter, penP promoter, etc.. When the host is a yeast, the promoter includes preferably PHO5 promoter, PGK promoter, GAP promoter, ADH1 promoter, etc.. When the host is an insect cell, the promoter includes polyhedrin promoter, P10 promoter, etc..

The expression vectors may, if necessary, further comprise enhancers, splicing signals, polyadenylation signals, selective markers, SV40 duplicate origin (hereinafter referred to as SV40 ori). Examples of selective markers are dihydrofolic acid reductase (hereinafter referred to as dhfr gene), ampicillin resistant gene (hereinafter referred to as Amp<sup>r</sup>), neomycin-resistant gene (hereinafter referred to as Neo) and so on. The dhfr gene gives methotrexate (MTX) resistance and Neo gives G418 resistance. Particularly, when the dhfr gene is used as a selective marker against dhfr gene-deficient chinese hamster cell lines, cells transfected with the objective gene can be selected in a thymidine-free medium.

Furthermore, an appropriate signal sequence for a host can be added to the N-terminal side of the protein. When the host is Escherichia coli, the utilizable signal sequences may include PhoA signal sequence, OmpA signal sequence, etc.. When the host is Bacillus, they may include  $\alpha$ -amylase signal sequence,

subtilisin signal sequence, etc.. When the host is a yeast, they may include MF $\alpha$  signal sequence, SUC2 signal sequence, etc.. When the host is an animal cell, they may include insulin signal sequence,  $\alpha$ -interferon signal sequence, antibody molecule signal sequence, etc..

A transformant or transfectant is produced by using the vector thus constructed, which carries the DNA coding for the protein of the present invention.

The host may be, for example, Escherichia species, Bacillus species, yeast cells, insect cells, insects, animal cells, etc..

Examples of Escherichia species include Escherichia coli K12·DH1 (Proc. Natl. Acad. Sci. USA, 60, 160 (1968)), JM103 (Nucleic Acids Research, 9, 309 (1981)), JA221 (J. Mol. Biol. 120, 517 (1978)), HB101 (J. Mol. Biol., 41, 459 (1969)), C600 (Genetics, 39, 440 (1954)), etc..

Examples of Bacillus species are, for example, Bacillus subtilis MI114 (Gene, 24, 255 (1983)), 207-21 (J. Biochem., 95, 87 (1984)), etc..

Examples of yeast cells are, for example, Saccharomyces cerevisiae AH22, AH22R<sup>-</sup>, NA87-11A, DKD-5D or 20B-12, Schizosachcaromyces pombe NCYC1913 or NCYC2036, or Pichia pastoris KM71, etc..

Examples of insect cells are, for example, Spodoptera frugiperda cell (Sf cell), MG1 cell derived from center intestine of Trichoplusia ni, High Five<sup>TM</sup> cell derived from eggs of Trichoplusia ni, Mamestra brassicae-derived cell, Estigmena acrea-derived cell and so on when virus is AcNPV; and Bombyx mori N cell (BmN cell) and so on when virus is BmNPV. Examples of the Sf cell are, for example, Sf9 cell (ATCC CRL 1711), Sf21 cell (both, Vaughn J.L. et al., In Vivo, 13, 213-217(1977)) and so on.

Examples of insects include a larva of silkworm

(Bombyx mori larva) (Maeda et al., Nature, 315, 592(1985)).

Examples of animal cells are, for example, monkey-derived COS-7 cell line, Vero cell line, Chinese  
5 hamster ovary cell line (hereinafter referred to as CHO cell), dhfr gene-deficient Chinese hamster cell line (hereinafter referred to as CHO(dhfr<sup>-</sup>) cell), L cell, myeloma cell, human FL cell, 293 cell, C127 cell, BALB/3T3 cell, Sp-2/O cell, etc.. Among them, CHO  
10 cell, CHO(dhfr<sup>-</sup>) cell, 293 cell, etc. are preferred.

Depending on host cells used, transformation is done using standard techniques appropriate to such cells.

Transformation of Escherichia species can be  
15 carried out in accordance with methods as disclosed in, for example, Proceedings of the National Academy of Sciences of the United State of America, Vol. 69, 2110 (1972), and Gene, Vol. 17, 107 (1982), etc..

Transformation of Bacillus species can be carried  
20 out in accordance with methods as disclosed in, for example, Molecular & General Genetics, Vol. 168, 111 (1979), etc..

Transformation of yeast cells can be carried out in accordance with methods as disclosed in, for  
25 example, Methods in Enzymology, Vol. 194, 182-187(1991), Proceedings of the National Academy of Sciences of the United State of America, vol. 75, 1929 (1978), etc..

Transformation of insect cells or insects can be  
30 carried out in accordance with methods as disclosed in, for example, Bio/Technology, Vol. 6, 47-55, (1988).

Transformation of animal cells can be carried out by methods as disclosed in, for example, Cell  
Engineering, separate Vol. 8, New Cell Engineering  
35 Experiment Protocol, 263-267(1995) (Shujun Company), Virology, Vol. 52, 456 (1973), etc..

In introducing the expression vector into cells, known methods such as a calcium phosphate method (Graham, F. L. and van der Eb, A. J., Virology, 52, 456-467(1973)), an electroporation (Neumann, E. et al., EMBO J., 1,841-845(1982)), etc. may be used.

The transformants or transfectants wherein the expression vector carrying the DNA coding for the protein of the present invention can be obtained according to the aforementioned techniques.

Examples of methods for expressing the protein of the present invention stably using animal cells are a method for selecting the cells wherein the above-mentioned expression vector is incorporated in the chromosome by means of clone selection. Briefly, the transformant is first selected using the above-mentioned selective marker as an index for selection. Then the animal cell produced as such by using the selective marker is repeatedly subjected to a clone selection to give an animal cell strain which stably exhibits a high ability of expressing the protein of the present invention. When a dhfr gene is used as a selective marker, the drug-resistant cells are selected by a culture with sequentially increasing the MTX concentration to amplify the DNA coding for the protein of the present invention with dhfr gene in the cells whereby an animal cell strain exhibiting far higher expression can be obtained.

The protein of the present invention or a salt thereof can be also manufactured by culturing the transformant under a condition where the DNA coding for the protein of the present invention can be expressed to express and accumulate the protein of the present invention.

Culture of the transformants (or transfectants) of Escherichia or Bacillus species can be carried out preferably in a liquid culture medium. The culture

medium may contains carbon sources, nitrogen sources, minerals, etc. which are necessary for growing the transformants. The carbon sources may include glucose, dextrin, soluble starch, sucrose, etc.. The nitrogen sources may include organic or inorganic substances such as ammonium salts, nitrates, corn steep liquor, peptone, casein, meat extracts, bean-cakes, potato extracts, etc.. Examples of minerals include calcium chloride, sodium dihydrogen phosphate, magnesium chloride, etc.. It is further allowable to add yeast extracts, vitamins, growth factors, etc.. It is suitable that the pH of culture medium is at about 5 to 8.

The culture medium for Escherichia species is, for example, preferably M9 medium which contains glucose and casamino acid (Miller, Journal of Experiments in Molecular Genetics, 431-433, Cold Spring Harbor Laboratory, New York, (1972)). If necessary, drugs such as 3 $\beta$ -indolyl acrylic acid can be added to the medium to improve the efficiency of the promoter. In the case of Escherichia organisms as a host, the culture is carried out usually at about 15 to 43°C for about 3 to 24 hours. As required, aeration and stirring may be applied. In the case of Bacillus organisms as a host, the culture is carried out usually at about 30 to 40°C for about 6 to 24 hours. As required, aeration and stirring may also be applied.

In the case of yeast transformants, the culture medium used includes, for example, Burkholder minimum medium (Bostian, K.L. et al., Proc. Natl. Acad. Sci. USA, 77, 4505 (1980)), SD medium containing 0.5% casamino acid (Bitter, G.A. et al., Proc. Natl. Acad. Sci. USA, 81, 5330 (1984)), etc.. It is preferable that the pH of the culture medium is adjusted to be from about 5 to 8. The culture is carried out usually at about 20 to 35°C for about 24 to 72 hours. As

required, aeration and stirring may be applied.

In the case of the transformants (or transfectants) of insect cells or insects, the culture medium used includes the Grace's insect medium supplemented with additives such as inactivated 10% bovine serum (Grace, T.C.C., Nature, 195, 788 (1962)). It is preferable that the pH of the culture medium is adjusted to be about 6.2 to 6.4. The culture is usually carried out at about 27°C for about 3 to 5 days. As desired, aeration and stirring may be applied.

In the case of the transformants (or transfectants) of animal cells, the culture medium used includes MEM medium (Science, 122, 501 (1952)), DMEM medium (Virology, 8, 396 (1959)), RPMI 1640 medium (J. Amer. Med. Ass. 199, 519 (1967)), 199 medium (Proc. Sci. Biol. Med. 73, 1 (1950)), etc. which contain, for example, about 5 to 20% of fetal calf serum. It is preferable that the pH is from about 6 to 8. The culture is usually carried out at about 30 to 40°C for about 15 to 72 hours. As required, medium exchange, aeration and stirring may be applied. Especially when CHO (dhfr<sup>-</sup>) cells and dhfr selective marker gene are used, it is preferred to use a DMEM medium containing a dialyzed fetal bovine serum which rarely contains thymidine.

Separation and purification of the protein from the above-mentioned cultures can be carried out according to methods described herein below.

To extract the protein from the cultured microorganisms or cells, the microorganisms or cells are collected by known methods after the culture, suspended in a suitable buffer solution, disrupted by ultrasonication, lysozyme and/or freezing and thawing, etc. and, then, a crude protein extract is obtained by centrifugation or filtration. Other conventional

extraction or isolation methods can be applied. The buffer solution may contain a protein-denaturing agent such as urea or guanidine hydrochloride or a surfactant such as Triton X-100™.

5 In the case that proteins are secreted into culture media, supernatants are separated from the microorganisms or cells after culture and collected by known methods. The culture supernatant containing the protein can be purified by a suitable combination of  
10 known methods for separation, isolation and purification. The known methods of separation, isolation and purification include methods which utilizes solubility, such as salting out or sedimentation with solvents, methods which utilizes  
15 primarily a difference in the molecular size or weight, such as dialysis, ultrafiltration, gel filtration and SDS-polyacrylamide gel electrophoresis, methods utilizing a difference in the electric charge, such as ion-exchange chromatography, methods utilizing specific  
20 affinity such as affinity chromatography, methods utilizing a difference in the hydrophobic property, such as reversed-phase high-performance liquid chromatography, and methods utilizing a difference in the isoelectric point such as isoelectric  
25 electrophoresis, etc..

In case that the protein thus obtained is in a free form, it can be converted to a salt thereof by known methods or a method analogous thereto. In case that the protein thus obtained is in a salt form vice  
30 versa, it can be converted to a free form or to any other salt thereof by known methods or a method analogous thereto.

The protein produced by the transformant can be arbitrarily modified or a part of polypeptide can be  
35 removed therefrom, by a suitable protein-modifying enzyme before or after the purification. The protein-

modifying enzyme includes trypsin, chymotrypsin, arginyl endopeptidase, protein kinase, glycosidase, etc.. The existence of the protein of the present invention thus obtained can be detected or determined  
5 by binding assay with a labeled ligand or by enzyme immunoassays (enzyme linked immunoassays) using specific antibodies, respectively.

The antibodies against the protein of the present  
10 invention, its partial peptide, the precursor protein or a salt thereof (hereinafter referred to as the protein, etc. of the present invention) are any antibodies such as polyclonal antibodies and monoclonal antibodies which can recognize the protein, etc. of the  
15 present invention. The antibody against the protein, etc. of the present invention may have an activity to neutralize an activity of the protein, etc. of the present invention.

The antibodies against the protein, etc. of the  
20 present invention may be manufactured by methods per se known to those of skill in the art or methods similar thereto, using the protein, etc. of the present invention as an antigen.

#### 25 Preparation of a Monoclonal Antibody:

##### (a) Preparation of Monoclonal Antibody-Producing Cells

The protein of the present invention is administered to mammals either solely or together with carriers or diluents to the site favorable for antibody  
30 production. In order to potentiate the antibody productivity upon the administration, complete Freund's adjuvants or incomplete Freund's adjuvants may be administered. The administration is usually carried out once every 2 to 6 weeks and 2 to 10 times in total.  
35 Examples of the applicable mammals are monkeys, rabbits, dogs, guinea pigs, mice, rats, sheep and



goats. The use of mice and rats is preferred.

In establishing cells which produce monoclonal antibodies, an animal with the detectable antibody titer is selected from animals (e.g. mice) immunized with antigens, then spleen or lymph node is collected after 2 to 5 days from the final immunization and antibody-producing cells contained therein are fused with myeloma cells derived from homogeneous or heterogeneous animals to obtain monoclonal antibody-producing hybridomas. Measurement of the antibody titer in antisera may, for example, be carried out by reacting a labeled protein, which will be mentioned later, with the antiserum followed by determining the binding activity of the labeling agent combined with the antibody. The cell fusion may be carried out, for example, by a method of Koehler and Milstein (Nature, 256, 495 (1975)). Examples of the fusion accelerator are polyethylene glycol (PEG), Sendai virus, etc. and the use of PEG is preferred.

Examples of the myeloma cells are those derived from warm-blooded animals such as NS-1, P3U1, SP2/0, AP-1, etc. and the use of P3U1 is preferred. The preferred fusion ratio of the numbers of antibody-producing cells used (spleen cells) to the numbers of myeloma cells is within a range of about 1:1 to 20:1. When PEG (preferably, PEG 1000 to PEG 6000) is added in a concentration of about 10 to 80% followed by incubating at 20 to 40°C, preferably, at 30 to 37°C, for 1 to 10 minutes, an efficient cell fusion can be carried out.

Various methods may be applied for screening a hybridoma which produces a monoclonal antibody. For example, a supernatant of hybridoma culture is added to a solid phase (e.g. microplate) to which the protein antigen is adsorbed either directly or with a carrier, then anti-immunoglobulin antibody (anti-mouse

immunoglobulin antibody is used when the cells used for the cell fusion are those of mouse) which is labeled with a radioactive substance, an enzyme or the like, or protein A is added thereto and then monoclonal  
5 antibodies bound on the solid phase are detected; or a supernatant of the hybridoma culture is added to the solid phase to which anti-immunoglobulin or protein A is adsorbed, then the protein, etc. labeled with a radioactive substance or an enzyme is added and  
10 monoclonal antibodies bound with the solid phase is detected.

Selection and cloning of the monoclonal antibody-producing hybridoma may be carried out by methods per se known to those of skill in the art or methods  
15 similar thereto. Usually, it is carried out in a medium for animal cells, containing HAT (hypoxanthine, aminopterin and thymidine). With respect to a medium for the selection, for the cloning and for the growth, any medium may be used so far as hybridoma is able to  
20 grow therein. Examples of the medium are an RPMI 1640 medium (Dainippon Pharmaceutical Co., Ltd., Japan) containing 1 to 20% (preferably 10 to 20%) of fetal calf serum (FCS), GIT medium (Wako Pure Chemical, Japan) containing 1 to 20% of fetal calf serum and a  
25 suitable serum-free medium for hybridoma (SFM-101; Nissui Seiyaku, Japan). The culture temperature is usually 20 to 40°C and, preferably, about 37°C. The culture period is usually from 5 days to 3 weeks and, preferably, 1 to 2 weeks. The culture is usually  
30 carried out in 5% carbon dioxide gas. The antibody titer of the supernatant of the hybridoma culture may be measured by the same manner as in the above-mentioned measurement of the antibody titer in the antiserum.

35 (b) Purification of the Monoclonal Antibody

The separation and purification of the monoclonal

antibody may be carried out by methods for separating/purifying immunoglobulin such as salting-out, precipitation with alcohol, isoelectric precipitation, electrophoresis, adsorption/deadsorption using ion exchangers such as DEAE, ultracentrifugation, gel filtration, specific purifying methods in which only an antibody is collected by treatment with an active adsorbent such as an antigen-binding solid phase, protein A or protein G and the bond is dissociated whereupon the antibody is obtained.

#### Preparation of a Polyclonal Antibody:

The polyclonal antibody of the present invention can be produced by per se known methods or methods analogous thereto. The method comprises preparing an immunogen (protein antigen) per se or a conjugate of an immunogen with a carrier protein, immunizing a warm-blooded animal in the same manner as described for the production of the monoclonal antibody, harvesting a fraction containing the antibody against the protein, etc. of the present invention from the immunized animal, and purifying the harvested antibody.

Referring to the immunogen-carrier protein conjugate for use in the immunization of mammals, the kind of carrier protein and the ratio of the carrier and hapten are not particularly restricted only if the production of the antibody against the hapten conjugated with the particular carrier protein and used for immunization proceeds efficiently. Thus, for example, bovine serum albumin, bovine thyroglobulin, hemocyanine, or the like is coupled in the weight ratio of about 0.1 to 20, preferably about 1 to about 5, to unity of the hapten.

A variety of condensing agents can be used for this coupling between the hapten and the carrier. Thus, for example, a glutaraldehyde, carbodiimide,

maleimide, or a thiol or dithiopyridyl group-containing active ester reagent can be employed.

5 The condensation reaction product is administered to a warm-blooded animal at a site favorable for antibody production, either as it is alone or together with a carrier or a diluent. Enhancing antibody production, complete Freund's adjuvant or incomplete Freund's adjuvant may be administered. Administration is carried out generally once in about 2 to 6 weeks for 10 a total of about 3 to 10 times.

The polyclonal antibody can be harvested from the blood, ascites fluid, or other body fluid, preferably from the blood, of the host mammals.

15 The polyclonal antibody titer in the antiserum can be determined in the same manner as the determination of a monoclonal antibody described hereinbefore. The separation and purification of the polyclonal antibody can be carried out by the same method as the separation and purification of a monoclonal antibody.

20 The oligonucleotides or their derivatives having a nucleotide sequence complementary or substantially complementary to the DNA or mRNA coding for the protein, the partial peptide or the precursor protein of the present invention (hereinafter referred to as 25 the DNA or mRNA of the present invention) can be any oligonucleotides or their derivatives which have a nucleotide sequence complementary or substantially complementary to that of the DNA or mRNA of the present invention and capable of promoting expression of the 30 protein, etc. of the present invention.

The nucleotide sequence substantially complementary to the DNA or mRNA of the present invention may, for example, be a nucleotide sequence 35 having an identity of not less than about 60%, preferably not less than about 70%, more preferably not

less than about 80%, still more preferably not less than about 90%, more preferably not less than about 95% to the total nucleotide sequence or partial nucleotide sequence of the nucleotide sequence complementary to that the DNA or mRNA of the present invention. Particularly preferred is an oligonucleotide or a derivative thereof which has an identity of not less than about 60%, preferably not less than about 70%, and more preferably not less than about 80%, and still more preferably, not less than about 90%, more preferably not less than about 95% to the nucleotide sequence of the domain, of the complete nucleotide sequence complementary to that of the DNA or mRNA of the present invention, which encodes the N-terminal region of the protein of the present invention (e.g. the nucleotide sequence of the domain around the initiation codon). The oligonucleotides or their derivatives can be synthesized using a known DNA synthesis hardware.

The protein, its partial peptide or a salt thereof of the present invention has physiological activities such as a nerve-extending activity or neuro-regenerative activity in the central nervous system, etc., a gliocyte stimulating activity, an activity of formulating memories in brain. Therefore, the protein, its partial peptide or a salt thereof of the present invention can be used in various applications.

Typical applications of the protein, its partial peptide or a salt thereof of the present invention (hereinafter referred to collectively as the protein, etc. of the present invention), the DNA coding for the protein, etc. of the present invention (hereinafter briefly referred to as the DNA of the present invention), the antibody against the protein, etc. of the present invention (hereinafter briefly referred to as the antibody of the present invention) and the

oligonucleotide or a derivative thereof are shown below.

(1) Pharmaceutical composition

5       The protein, etc. of the present invention and the DNA of the present invention are useful as drugs such as therapeutic or prophylactic agent for a defect the gene coding for the protein of the present invention and associated diseases therewith, a dysfunction of the protein of the present invention and associated diseases therewith and so on. Specifically, the protein, etc. of the present invention or the DNA of the present invention are useful as drugs such as a therapeutic or prophylactic agent for Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, dementia or cerebellar degeneration.

For example, when there is a patient in whom the protein, etc. of the present invention in the body cannot function sufficiently or normally because of its decrease or defect, the protein, etc. of the present invention of the patient can be expected to function sufficiently or normally by:

- (a) administering the DNA coding for the protein, etc. of the present invention to the patient to express it;
- (b) inserting the DNA coding for the protein, etc. of the present invention into cells to express it and transplanting the cells to the patient, or
- (c) administering the protein, etc. of the present invention to the patient.

For example, the protein, etc. of the present invention can be used orally in the form of tablets which may be sugar coated as necessary, capsules, elixirs, microcapsules etc., or non-orally in the form of injectable preparations such as aseptic solutions and suspensions in water or other pharmaceutically

acceptable liquids. These preparations can be produced by mixing the protein, etc. of the present invention with physiologically acceptable carriers, flavoring agents, excipients, vehicles, antiseptics, stabilizers, binders etc. in unit dosage forms required for generally accepted manners of pharmaceutical preparation. Active ingredient contents in these preparations are set so that an appropriate dose within the specified range is obtained.

When the DNA of the present invention is used as the above-mentioned drug, the DNA may be used alone or after inserting it into a suitable vector such as retrovirus vector, adenovirus vector, adenovirus-associated virus vector, pox virus etc. followed by administering the product vector to a warm-blooded animal by a conventional means. The DNA can also be administered as "naked" DNA, with physiologically acceptable carriers such as adjuvants to assist in uptake, by "gene" gun or by a catheter such as a catheter with a hydrogel.

If one wishes to use the protein, etc. of the present invention, one may use it in a purified form, preferably in a purity of at least 90%, more preferably at least 95%, still more preferably at least 98% and most preferably at least 99%.

Additives which can be mixed in tablets, capsules etc. include binders such as gelatin, corn starch, tragacanth and gum arabic, excipients such as crystalline cellulose, swelling agents such as corn starch, gelatin and alginic acid, lubricants such as magnesium stearate, sweetening agents such as sucrose, lactose and saccharin, and flavoring agents such as peppermint, akamono oil and cherry. When the unit dosage form is the capsule, liquid carriers such as oils and fats may be incorporated in addition to the above-mentioned materials. Sterile compositions for

injection can be formulated by ordinary methods of pharmaceutical preparation, for example, by dissolving or suspending active ingredients, naturally occurring vegetable oils such as sesame oil and coconut oil, etc.  
5 in vehicles such as water for injection to create pharmaceutical compositions.

Aqueous liquids for injection include physiological saline and isotonic solutions containing glucose and other auxiliary agents, e.g., D-sorbitol,  
10 D-mannitol and sodium chloride, and may be used in combination with appropriate dissolution aids such as alcohols, e.g., ethanol, polyalcohols, e.g., propylene glycol and polyethylene glycol, nonionic surfactants, e.g., polysorbate 80<sup>TM</sup> and HCO-50 etc. Oily liquids  
15 include sesame oil and soybean oil, and may be used in combination with dissolution aids such as benzyl benzoate and benzyl alcohol. Furthermore the above-mentioned materials may also be formulated with buffers, e.g., phosphate buffer and sodium acetate  
20 buffer; soothing agents, e.g., benzalkonium chloride, procaine hydrochloride; stabilizers, e.g., human serum albumin, polyethylene glycol; preservatives, e.g., benzyl alcohol, phenol; antioxidants etc. An appropriate ampule is normally filled in with the thus-  
25 prepared pharmaceutical composition such as an injectable liquid.

The vector comprising the DNA of the present invention can be formulated as well as mentioned above, and usually can be used non-orally.

30 Because the thus-obtained preparation is safe and of low toxicity, it can be administered to mammals (e.g., human, rat, mouse, guinea pig, rabbit, sheep, pig, bovine, horse, cat, dog, monkey, etc.).

The dose of the protein, etc. of the present  
35 invention may vary depending on subject of disease, subject of administration, way of administration, and



so on. When the protein, etc. of the present invention is used, for example, for treating Alzheimer's disease by oral administration, the dose of the protein, etc. of the present invention is normally about 0.1 to 100mg, preferably 1.0 to 50mg, and more preferably 1.0 to 20mg per day for an adult human (weighing 60 kg). When the protein, etc. of the present invention is used, for example, for treating Alzheimer's disease by non-oral administration, it is advantageous to administer the protein, etc. of the present invention in the form of injectable preparation at a daily dose of about 0.01 to 30 mg, preferably about 0.1 to 20 mg, and more preferably about 0.1 to 10 mg per administration by an intravenous injection for an adult human (weighing 60 kg), depending on subject of administration, subject disease and so on. For other animal species, corresponding does as converted per 60 kg weight can be administered.

## (2) Gene diagnostic agent

By using the DNA of the present invention as a probe, for instance, an abnormality (gene abnormality) of the DNA or mRNA coding for the protein, etc. of the present invention in mammals (e.g. human, rat, mouse, guinea pig, rabbit, sheep, swine, bovine, horse, cat, dog, monkey, etc.) can be detected. Therefore, the DNA of the present invention is useful as a gene diagnostic agent for the damage to the DNA or mRNA, mutation thereof, or decreased expression thereof, or increased expression or overexpression of the DNA or mRNA.

The above-mentioned gene diagnosis using the DNA of the present invention can be carried out by, for example, the per se known Northern hybridization assay or PCR-SSCP assay (Genomics, 5, 874-879 (1989); Proc. Natl. Acad. Sci. USA, 86, 2766-2770 (1989)).

When a decrease in expression of the mRNA is

detected or a mutation of the DNA is detected by the PCR-SSCP assay, it may lead, with high probability, to the diagnosis of Alzheimer's disease, Parkinson's disease, Huntigton's disease, amyotrophic lateral  
5     sclerosis, dementia or cerebellar degeneration.

(3) Quantitative determination of the protein of the present invention, its partial peptide or a salt thereof

10         The antibody of the present invention is capable of specifically recognizing the protein, etc. of the present invention and, accordingly, it can be used for quantitative determination of the protein, etc. of the present invention in test liquid samples and  
15     particularly for quantitative determination by sandwich immunoassays.

Thus, the present invention provides, for example, the following methods:

(i) a quantitative determination of the protein, etc. of the present invention in a test liquid sample, which  
20     comprises

(a) competitively reacting the test liquid sample and a labeled protein, etc. of the present invention with the antibody of the present invention, and  
25     (b) measuring the ratio of the labeled protein, etc. of the present invention binding with the antibody; and  
(ii) a quantitative determination of the protein, etc. of the present invention in a test liquid sample, which comprises

30     (a) reacting the test liquid sample with an antibody immobilized on an insoluble carrier and another labeled antibody simultaneously or continuously, and

(b) measuring the activity of the labeling agent on the insoluble carrier,  
35     wherein one antibody is capable of recognizing the N-terminal region of the protein, etc. of the present

invention while another antibody is capable of recognizing the C-terminal region of the protein, etc. of the present invention.

When the monoclonal antibody of the present invention recognizing the protein, etc. of the present invention (hereinafter, sometimes referred to as "monoclonal antibody of the present invention") is used, the quantity of the protein of the present invention can be determined and, moreover, the protein, etc. of the present invention can be detected by means of a tissue staining, etc. as well. For such an object, antibody molecules per se may be used, or F(ab')<sub>2</sub>, Fab' or Fab fractions of the antibody molecule may also be used. There is no particular limitation for measuring methods using the antibody of the present invention and any measuring method may be used so far as it relates to a method in which the amount of antibody, antigen or antibody-antigen complex, depending on or corresponding to the amount of antigen, e.g. the amount of the protein, etc. of the present invention in the liquid sample to be determined, is detected by a chemical or a physical means and then calculated using a standard curve prepared by a standard solution containing the known amount of antigen. For example, nephrometry, competitive method, immunometric method and sandwich method are suitably used and, in terms of sensitivity and specificity, the sandwich method which will be described herein later is particularly preferred.

Examples of the labeling agent used in the measuring method using the labeling substance are radioisotopes, enzymes, fluorescent substances, luminescent substances, colloids, magnetic substances, etc.. Examples of the radioisotope are (<sup>125</sup>I), (<sup>131</sup>I), (<sup>3</sup>H) and (<sup>14</sup>C). Preferred examples of the enzyme are those which are stable and with much specific activity,

such as  $\beta$ -galactosidase,  $\beta$ -glucosidase, alkaline phosphatase, peroxidase and malate dehydrogenase.

Examples of the fluorescent substance are fluorescamine, fluorescein isothiocyanate, etc..

5 Examples of the luminescent substance are luminol, luminol derivatives, luciferin, lucigenin, etc.. Further, a biotin-avidin system may also be used for binding an antibody or an antigen with a labeling agent.

10 In an insolubilization (immobilization) of antigens or antibodies, a physical adsorption may be used or a chemical binding which is usually used for insolubilization or immobilization of proteins or enzymes may be used as well. Examples of the carrier  
15 are insoluble polysaccharides such as agarose, dextran and cellulose; synthetic resins such as polystyrene, polyacrylamide and silicone; glass; etc..

In a sandwich method, the test liquid is allowed to react with an insolubilized monoclonal antibody of the present invention (the first reaction), then it is  
20 allowed to react with an another labeled monoclonal antibody of the present invention (the second reaction) and the activity of the labeling agent on the insoluble carrier is measured whereupon the amount of the protein, etc. of the present invention in the test liquid can be  
25 determined. The first reaction and the second reaction may be conducted reversely or simultaneously or they may be conducted with an interval. The type of the labeling agent and the method of insolubilization may  
30 be the same as those mentioned hereinbefore. In the immunoassay by means of a sandwich method, it is not always necessary that the antibody used for the labeled antibody and the antibody for the solid phase is one type or one species but, with an object of improving  
35 the measuring sensitivity, etc., a mixture of two or more antibodies may be used as well.

In the method of measuring the protein, etc. of the present invention by the sandwich method of the present invention, the preferred monoclonal antibodies of the present invention used for the first and the  
5 second reactions are antibodies wherein their sites binding to the protein, etc. of the present invention are different from each other. Thus, antibodies used in the first and the second reactions are those wherein, when an antibody used in the second reaction  
10 recognizes the C-terminal region of the protein, etc. of the present invention, then another antibody recognizing the site other than C-terminal regions, e.g. recognizing the N-terminal region, is preferably used in the first reaction.

15 The monoclonal antibody of the present invention may be used in a measuring system other than the sandwich method such as a competitive method, an immunometric method and a nephrometry. In the competitive method, an antigen in the test liquid and a  
20 labeled antigen are allowed to react with an antibody in a competitive manner, then an unreacted labeled antigen (F) and a labeled antigen (B) binding with an antibody are separated (i.e. B/F separation) and the labeled amount of any of B and F is measured whereupon  
25 the amount of the antigen in the test liquid is determined. With respect to a method for such a reaction, there are a liquid phase method in which a soluble antibody is used as the antibody and the B/F separation is conducted by polyethylene glycol, a  
30 second antibody to the above-mentioned antibody, etc.; and a solid phase method in which an immobilized antibody is used as the first antibody or a soluble antibody is used as the first antibody while an immobilized antibody is used as the second antibody.

35 In the immunometric method, an antigen in the test solution and an immobilized antigen are subjected to a

competitive reaction with a certain amount of a labeled antibody followed by separating into solid and liquid phases or the antigen in the test liquid and an excess amount of labeled antibody are allowed to react, then  
5 an immobilized antigen is added to bind an unreacted labeled antibody with the solid phase and separated into solid and liquid phases. After that, the labeled amount of any of the phases is measured to determine the antigen amount in the test liquid.

10 In the nephrometry, the amount of insoluble sediment which is produced as a result of the antigen-antibody reaction in a gel or in a solution is measured. Even when the antigen amount in the test liquid is small and only a small amount of the sediment  
15 is obtained, a laser nephrometry wherein scattering of laser is utilized can be suitably used.

In applying each of those immunological measuring methods (immunoassays) to the measuring method of the present invention, it is not necessary to set up any  
20 special condition, operation, etc. therefor. A measuring system (assay system) for the protein, etc. of the present invention may be constructed taking the technical consideration of persons skilled in the art into consideration in the conventional conditions and  
25 operations for each of the methods. With details of those conventional technical means, a variety of reviews, reference books, etc. may be referred to.

They are, for example, Hiroshi Irie (ed):  
"Radioimmunoassay" (Kodansha, Japan, 1974); Hiroshi  
30 Irie (ed): "Radioimmunoassay; Second Series" (Kodansha, Japan, 1979); Eiji Ishikawa et al. (ed): "Enzyme Immunoassay" (Igaku Shoin, Japan, 1978); Eiji Ishikawa et al. (ed): "Enzyme Immunoassay" (Second Edition) (Igaku Shoin, Japan, 1982); Eiji Ishikawa et al. (ed):  
35 "Enzyme Immunoassay" (Third Edition) (Igaku Shoin, Japan, 1987); "Methods in Enzymology" Vol. 70

(Immunochemical Techniques (Part A)); ibid. Vol. 73  
(Immunochemical Techniques (Part B)); ibid. Vol. 74  
(Immunochemical Techniques (Part C)); ibid. Vol. 84  
(Immunochemical Techniques (Part D: Selected  
5 Immunoassays)); ibid. Vol. 92 (Immunochemical  
Techniques (Part E: Monoclonal Antibodies and General  
Immunoassay Methods)); ibid. Vol. 121 (Immunochemical  
Techniques (Part I: Hybridoma Technology and Monoclonal  
Antibodies)) (Academic Press); etc.

10 By using the antibody of the present invention in  
the above manner, the protein, etc. of the present  
invention can be assayed with high sensitivity.

In addition, by quantitative determination of the  
protein, etc. of the present invention using the  
15 antibody of the present invention, various diseases  
associated with the protein, etc. of the present  
invention can be diagnosed.

When a decrease in concentration of the protein,  
etc. of the present invention is detected by  
20 determining the concentration of the protein, etc. of  
the present invention by using the antibody of the  
present invention, it may lead, with high probability,  
to the diagnosis of various diseases such as  
Alzheimer's disease, Parkinson's disease, Huntington's  
25 disease, amyotrophic lateral sclerosis, dementia or  
cellular degeneration.

Thus, the antibody of the present invention is  
useful as a diagnostic agent for the above-mentioned  
diseases.

30 Furthermore, the antibody of the present invention  
can be used for the purpose of detecting the protein,  
etc. of the present invention which may be present in  
test samples such as body fluids or tissues. The  
antibody can also be used for the construction of an  
35 antibody column for purification of the protein, etc.  
of the present invention, detection of the protein,

etc. of the present invention in the fractions in the course of purification, and analysis of the behavior of the protein, etc. of the present invention in the test cell.

5

(4) Screening for candidate medicinal compounds against various diseases

10 A compound, or a salt thereof, which promotes the function of the protein, etc. of the present invention, for example, physiological activities such as a nerve-extending or neuro-regenerative activity, a gliocyte stimulating activity and an activity of forming memories in brain, can be used as a therapeutic or prophylactic agent for various diseases such as, for  
15 example, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), dementia and cerebellar degeneration. Therefore, the protein, etc. of the present invention is useful as a screening reagent for compounds or salts thereof capable of promoting the function of the  
20 protein, etc. of the present invention.

The present invention, therefore, further provides a method of screening for a compound capable of promoting the function of the protein, etc. of the  
25 present invention (hereinafter sometimes referred to briefly as a promoter of the function of the protein, etc. of the present invention) which comprises using the protein, etc. of the present invention. To be specific, the present invention provides  
30 (a) a method for screening for a promoter of the function of the protein, etc. of the present invention which comprises comparing the result in cases that (i) the protein, etc. of the present invention is contacted with a nerve cell or a nerve tissue and (ii) the  
35 protein, etc. of the present invention and a test compound are contacted with a nerve cell or a nerve



tissue, and

(b) a method for screening for a promoter of the function of the protein, etc. of the present invention which comprises comparing the result in cases that (i) the protein, etc. of the present invention is administered to a vertebrate and (ii) the protein, etc. of the present invention and a test compound are administered to a vertebrate.

More specifically, the above screening method (a) comprises assaying the physiological activity, such as a nerve-extending activity or neuroregenerative activity, a gliocyte stimulating activity of the protein, its partial peptide or a salt thereof of the present invention in the above-mentioned cases (i) and (ii) and comparing the results. In the above screening method (b), the activity of forming memories in brain, etc. of the protein, its partial peptide or a salt thereof of the present invention are assayed in the cases (i) and (ii) and the results are compared.

Examples of the nerve cells are neuroblastoma cells, glioma cells, and the corresponding hybrid cells (e.g. N18TG-2, IMR-32, GOTO (e.g. GOTO-P3), NB1, C6BU-1, U251, KNS42, KNS81, NG108-15 cells, and PC-12 cells capable of differentiating into nerves).

Examples of the nerve tissues are mouse neuroepithelial cells, rat hippocampal primary culture cells, mouse embryonic culture Purkinje cells, and mouse dorsal root ganglia, among other cells.

The test compound includes but is not limited to peptides, proteins, non-peptide compounds, synthetic compounds, fermentation products, cell extracts, plant extracts, animal tissue extracts, and blood plasma. The compound may be a novel compound or a known compound.

To carry the screening method (a) into practice, a protein sample is first prepared by dissolving or

suspending the protein, its partial peptide or a salt thereof of the present invention (hereinafter sometimes referred to as the protein, etc. of the invention) in a screening buffer. The screening buffer may be any  
5 buffer that does not affect the contact of the protein, etc. of the present invention with the nerve cells or nerve tissues (for example, phosphate buffer and Tris-HCl buffer within the pH range of about 4-10 (preferably pH about 6-8). The contact time is  
10 generally about 1-10 days and preferably about 7-10 days. The contacting temperature is generally about 37°C.

The nerve-extending or neuro-regenerative activity in the central nerve system or gliocyte stimulating  
15 activity of the protein, etc. of the present invention can be assayed by the conventional technique, for example by measuring the elongation of the optic nerve axon or determining the change in intracellular  $\text{Ca}^{2+}$  concentration.

20 Thus, the test compound which promotes physiological activities, such as a nerve-extending or neuro-regenerative activity or a gliocyte stimulating activity, by not less than about 20%, preferably not less than about 30%, more preferably not less than  
25 about 50%, and most preferably not less than about 70% in case (ii) as compared with case (i) can be selected as a candidate compound which promotes the function of the protein, etc. of the present invention.

To carry the screening method (b) of the present  
30 invention into practice, the protein, etc. of the present invention and the test compound are administered to a vertebrate by the intravenous, subcutaneous, intramuscular or oral route. The dosage of the protein, etc. of the present invention for oral  
35 administration to human or chimpanzee (body weight 60 kg) is about 0.1 to 100 mg, preferably about 1.0 to 50

mg, and for still better results, about 1.0 to 20 mg per day. The unit dose for parenteral administration is dependent on the subject and method of administration but in the case of an injectable dosage form, it can be administered to human or chimpanzee (body weight 60 kg) with advantage by the intravenous route in a daily dose of about 0.01 to 30 mg, preferably about 0.1 to 20 mg, and more preferably about 0.1 to 10 mg. For animals, the equivalent of the above-mentioned dose per 60 kg body weight can be administered.

The vertebrate includes not only fish (e.g. carp, salmon, herring, trout, goldfish, etc.) but also mammals such as human, mouse, rat, rabbit, sheep, swine, bovine, horse, cat, dog, monkey, chimpanzee, etc..

The activity of forming memories in brain of the protein, etc. of the present invention can be assayed by known methods, for example in accordance with the water maze experiment protocol of Morris (Morris, R. G. M., Journal of Neuroscientific Methods, 11, 47-60 (1984)).

Thus, the test compound which promotes the activity of forming memories in brain by not less than about 20%, preferably not less than 50%, or more preferably not less than 70%, for instance, in case (ii) as compared with case (i) can be selected as a candidate compound which promotes the function of the protein, etc. of the present invention.

The screening kit of the present invention comprises the protein, its partial peptide or a salt thereof of the present invention. The following is an exemplary screening kit of the invention.

Screening Reagents:

(1) Assay buffer

Hank's solution

(2) Protein sample

The protein or a salt thereof of the present invention

5 (3) Nerve cells or nerve tissue

The nerve cells or nerve tissues as mentioned above which are cultured in a 24-well plate using Eagle's MEM, Hank's solution, etc. at a seeding density of  $10^4$  cells/well under 5% carbon dioxide at 37°C.

10 (4) Detection

Observation under the inverted microscope.

Assay Protocol:

The cells with extended neurites per unit field of view in the wells to which the test compound is added  
15 are counted and a significance test is made with respect to the number of cells with extended neurites per unit field of view in the control wells to which the test compound is not added.

The compounds and salts thereof obtained by using  
20 the above screening method or screening kit of the present invention are compounds selected from the above-mentioned test compounds such as peptides, proteins, non-peptide compounds, synthetic compounds, fermentation products, cell extracts, plant extracts,  
25 animal tissue extracts, and blood plasma. The such compounds can promote the function of the protein, etc. of the present invention.

The compound which promotes the function of the protein, etc. of the present invention may by itself  
30 promote the function of the protein, etc. of the present invention by showing physiological activities such as a nerve-extending or neuro-regenerative activity or a gliocyte stimulating activity, either additively or synergistically, or even if it does not  
35 show the physiological activities by itself, may promote the function of the protein, etc. of the

present invention.

The salts of the compound identified by the screening method as mentioned above includes salts with physiologically acceptable bases (e.g. alkali metals) or acids such as organic or inorganic acids, and is preferably a physiologically acceptable acid addition salt. Examples of such salts are salts thereof with inorganic acids (e.g. hydrochloric acid, phosphoric acid, hydrobromic acid or sulfonic acid, etc.) and salts thereof with organic acids (e.g. acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, maleic acid, oxalic acid, benzoic acid, methanesulfonic acid or benzenesulfonic acid, etc..)

The compound which promotes the function of the protein, etc. of the present invention or a salt thereof is useful as a safe therapeutic or prophylactic agent of low toxicity for a variety of diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), dementia, and cerebellar degeneration.

When the compound obtained by using the screening method or the screening kit of the present invention is used as the therapeutic or prophylactic agent, it can be used in accordance with the conventional method.

For example, the compound can be used orally in the form of tablets which may be sugar coated as necessary, capsules, elixirs, microcapsules etc., or non-orally in the form of injectable preparations such as aseptic solutions and suspensions in water or other pharmaceutically acceptable liquids. These preparations can be produced by the mixing compound or a salt thereof with physiologically acceptable carriers, flavoring agents, excipients, vehicles, antiseptics, stabilizers, binders etc. in unit dosage forms required for generally accepted manners of

pharmaceutical preparation. Active ingredient contents in these preparations are set so that an appropriate dose within the specified range is obtained. These tablets, capsules, elixirs, microcapsules and  
5 injectable preparations may be the same as the therapeutic or prophylactic agent comprising the protein, etc. of the present invention as mentioned above.

Because the thus-obtained preparation is safe and  
10 of low toxicity, it can be administered to mammals (e.g., human, mouse, rat, rabbit, sheep, pig, bovine, horse, cat, dog, monkey, chimpanzee, etc.).

The dose of the compound obtained by the screening method may vary depending on subject of disease,  
15 subject of administration, way of administration, and so on.

When the compound is used, for example, for treating Alzheimer's disease by oral administration, the dose of the compound is normally about 0.1 to 100  
20 mg, preferably 1.0 to 50 mg, and more preferably 1.0 to 20 mg per day for an adult human (weighing 60 kg). When the compound is used, for example, for treating Alzheimer's disease by non-oral administration, it is advantageous to administer the compound in the form of  
25 injectable preparation at a daily dose of about 0.01 to 30 mg, preferably about 0.1 to 20 mg, and more preferably about 0.1 to 10 mg per administration by an intravenous injection for an adult human (weighing 60 kg), depending on subject of administration, subject of  
30 disease and so on. For other animal species, corresponding doses as converted per 60 kg weight can be administered.

(6) The oligonucleotide or a derivative thereof  
35 The oligonucleotide or a derivative thereof which is capable of complementary binding to the DNA or mRNA

coding for the protein, etc. of the present invention and promotes the expression of the DNA, the mRNA or the protein, etc. of the present invention is capable of promoting the function of the protein, etc. of the present invention in vivo. Therefore, the oligonucleotide or a derivative thereof is used for a prophylactic or therapeutic agent for various diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, dementia and cerebellar degeneration.

When the oligonucleotide or a derivative thereof is used for the prophylactic or therapeutic composition as mentioned above, it can be formulated in the same way as the prophylactic or therapeutic agent containing the protein or the DNA of the present invention and can be administered to mammals.

Because the thus-obtained preparation is safe and of low toxicity, it can be administered to mammals (e.g., human, mouse, rat, rabbit, sheep, pig, bovine, horse, cat, dog, monkey, chimpanzee, etc.).

The DNA may be used alone or after inserting it into a suitable vector such as retrovirus vector, adenovirus vector, adenovirus-associated virus vector, pox virus etc. followed by administering the product vector to a mammal by a conventional means. The oligonucleotide or a derivative thereof can also be administered oligonucleotide or a derivative thereof with physiologically acceptable carriers such as adjuvants to assist in uptake, by "gene" gun or by a catheter such as a catheter with a hydrogel.

In addition, the oligonucleotide or a derivative thereof can be used as a diagnostic oligonucleotide probe for investigating the presence of the DNA of the present invention or the status of its expression in various tissues and cells.

(6) Construction of a transgenic non-human animal containing the DNA coding for the protein of the present invention

5 The transgenic non-human animals which express the protein, etc. of the present invention can be prepared by using the DNA of the present invention.

The non-human animal (hereinafter referred to as animal) includes mammals such as rats, mice, rabbits, sheep, pigs, bovines, cats, dogs, monkeys and so on.

10 For transfer of the DNA of the present invention to the host animal, it is generally advantageous to use a gene construct prepared by linking the DNA at downstream of a promoter capable of being expressed in animal cells. For example, in transferring the mice-  
15 derived DNA of the present invention, it can be linked at downstream of a promoter, which is capable of causing expression of the DNA of the present invention in various animals and is derived from animals having high homology to mice, to prepare a gene construct  
20 which can then be microinjected into the fertilized egg cell of mice, whereby a DNA transferred animal showing a high production of the protein of the present invention can be provided.

25 As the promoter, promoters derived from viruses, ubiquitous expression promoters such as metallothionein, etc. can be used.

Transferring the DNA of the present invention at the fertilized egg cell stage, the DNA can be ubiquitous in all the germ cells and somatic cells of  
30 the host animal. The presence of the protein, etc. of the present invention in the germ cells of the transgenic animal following DNA transfer means that all the germ cells and somatic cells of all the progeny of the transgenic animal harbor the protein, etc. of the  
35 present invention. Thus, the offspring of animals of this line to which gene is passed down have the



protein, etc. of the present invention in their germ cells and somatic cells.

The animal to which the DNA of the present invention has been transferred can be verified by  
5 mating to retain the gene stably and then bred as an animal harboring the DNA from generation to generation under the usual breeding conditions. By acquiring homozygous animals having the transferred gene in both homologous chromosomes and mating the animals of both  
10 sexes, they can be bred serially so that all the progeny may harbor the DNA.

Since the animal to which the DNA of the present invention is transferred shows a high expression of the protein, etc. of the present invention, it is useful as  
15 an animal for screening for compounds promoting the function of the protein, etc. of the present invention.

As other potential uses for transgenic animals harboring the DNA of the present invention, the following uses can be suggested.

- 20 (a) Use as a cell source for tissue culture;
- (b) Analysis of the relationship of the protein, etc. of the present invention to proteins which are specifically expressed or activated by the protein by direct analysis of DNAs or RNAs in the tissues of the  
25 transgenic animal harboring the DNA of the present invention or analysis of the composition of the protein expressed by the DNA;
- (c) Study of the functions of cells established from tissues such as brain or peripheral tissues which are  
30 generally difficult to culture in the standard tissue culture technique by introducing the DNA into them;
- (d) Screening of drugs capable of enhancing the cell functions by using the cells described in (c);
- (e) Isolation and purification of the muteins of the  
35 present invention from cell lines showing a high expression the protein, etc..

In the specification and drawings of the present application, the abbreviations used for bases (nucleotides), amino acids and so forth are those recommended by the IUPAC-IUB Commission on Biochemical Nomenclature or those conventionally used in the art. Examples thereof are given below. Amino acids for which optical isomerism is possible are, unless otherwise specified, in the L form.

DNA : Deoxyribonucleic acid  
10 cDNA : Complementary deoxyribonucleic acid  
A : Adenine  
T : Thymine  
G : Guanine  
C : Cytosine  
15 RNA : Ribonucleic acid  
mRNA : Messenger ribonucleic acid  
dATP : Deoxyadenosine triphosphate  
dTTP : Deoxythymidine triphosphate  
dGTP : Deoxyguanosine triphosphate  
20 dCTP : Deoxycytidine triphosphate  
ATP : Adenosine triphosphate  
EDTA : Ethylenediaminetetracetic acid  
SDS : Sodium dodecyl sulfate  
Gly : Glycine  
25 Ala : Alanine  
Val : Valine  
Leu : Leucine  
Ile : Isoleucine  
Ser : Serine  
30 Thr : Threonine  
Cys : Cysteine  
Met : Methionine  
Glu : Glutamic acid  
Asp : Aspartic acid  
35 Lys : Lysine  
Arg : Arginine

His : Histidine  
Phe : Phenylalanine  
Tyr : Tyrosine  
Trp : Tryptophan  
5 Pro : Proline  
Asn : Asparagine  
Gln : Glutamine  
pGlu : Pyroglutamic acid  
Substitution groups, protecting groups and  
10 reagents used in the specification of the present  
application are represented by the symbols set forth  
below.  
Me : Methyl  
Et : Ethyl  
15 Bu : Butyl  
Ph : Phenyl  
TC : Thiazolidine-4(R)-carboxamide  
Tos : p-toluene sulfonyl  
CHO : Formyl  
20 Bzl : Benzyl  
Cl<sub>2</sub>-Bzl: 2,6-dichlorobenzyl  
Bom : Benzyloxymethyl  
Z : Benzyloxycarbonyl  
Br-Z : 2-bromobenzyloxycarbonyl  
25 Cl-Z : 2-chlorobenzyloxycarbonyl  
Boc : Tert-butoxycarbonyl  
DNP : Dinitrophenyl  
Trt : Trityl  
Bom : Tert-butoxymethyl  
30 Fmoc : N-9-fluorenylmethyloxycarbonyl  
HOBt : 1-hydroxybenzotriazole  
HOObt : 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazine  
HONB : 1-hydroxy-5-norbornene-2,3-dicarboximide  
DCC : Dicyclohexylcarbodiimide  
35 SEQ ID NOS of the SEQUENCE LIST in the  
specification show the following sequences.

SEQ ID NO:1 shows an amino acid sequence of the mature human ependymin-like protein of the present invention.

5 SEQ ID NO:2 shows an amino acid sequence of the mature rat ependymin-like protein of the present invention.

SEQ ID NO:3 shows an amino acid sequence of the mature mouse ependymin-like protein of the present invention.

10 SEQ ID NO:4 shows a common amino acid sequence between the human ependymin-like protein, rat ependymin-like protein and mouse ependymin-like protein of the present invention.

15 SEQ ID NO:5 shows a common amino acid sequence between the human ependymin-like protein, rat ependymin-like protein and mouse ependymin-like protein of the present invention.

20 SEQ ID NO:6 shows a common amino acid sequence between the human ependymin-like protein, rat ependymin-like protein and mouse ependymin-like protein of the present invention.

25 SEQ ID NO:7 shows a common amino acid sequence between the human ependymin-like protein, rat ependymin-like protein and mouse ependymin-like protein of the present invention.

SEQ ID NO:8 shows a common amino acid sequence between the human ependymin-like protein and rat ependymin-like protein of the present invention.

30 SEQ ID NO:9 shows a common amino acid sequence between the human ependymin-like protein and rat ependymin-like protein of the present invention.

SEQ ID NO:10 shows an amino acid sequence of the precursor protein of human ependymin-like protein of the present invention.

35 SEQ ID NO:11 shows an amino acid sequence of the precursor protein of human ependymin-like protein of

the present invention.

SEQ ID NO:12 shows an amino acid sequence of the precursor protein of rat ependymin-like protein of the present invention.

5        SEQ ID NO:13 shows an amino acid sequence of the precursor protein of mouse ependymin-like protein of the present invention.

10        SEQ ID NO:14 shows an amino acid sequence of the signal peptide of human ependymin-like protein of the present invention.

SEQ ID NO:15 shows an amino acid sequence of the signal peptide of human ependymin-like protein of the present invention.

15        SEQ ID NO:16 shows an amino acid sequence of the signal peptide of rat ependymin-like protein of the present invention.

SEQ ID NO:17 shows an amino acid sequence of the signal peptide of mouse ependymin-like protein of the present invention.

20        SEQ ID NO:18 shows a nucleotide sequence of the DNA coding for the human ependymin-like protein having an amino acid sequence represented by SEQ ID NO:1 of the present invention.

25        SEQ ID NO:19 shows a nucleotide sequence of the DNA coding for the rat ependymin-like protein having an amino acid sequence represented by SEQ ID NO:2 of the present invention.

30        SEQ ID NO:20 shows a nucleotide sequence of the DNA coding for the mouse ependymin-like protein having an amino acid sequence represented by SEQ ID NO:3 of the present invention.

35        SEQ ID NO:21 shows a nucleotide sequence of the DNA coding for the common amino acid sequence, which is represented by SEQ ID NO:4, between the human ependymin-like protein, rat ependymin-like protein and mouse ependymin-like protein of the present invention.

SEQ ID NO:22 shows a nucleotide sequence of the DNA coding for the common amino acid sequence, which is represented by SEQ ID NO:5, between the human  
5 mouse ependymin-like protein, rat ependymin-like protein and mouse ependymin-like protein of the present invention.

SEQ ID NO:23 shows a nucleotide sequence of the DNA coding for the common amino acid sequence, which is represented by SEQ ID NO:6, between the human  
10 mouse ependymin-like protein, rat ependymin-like protein and mouse ependymin-like protein of the present invention.

SEQ ID NO:24 shows a nucleotide sequence of the DNA coding for the common amino acid sequence, which is represented by SEQ ID NO:7, between the human  
15 mouse ependymin-like protein, rat ependymin-like protein and mouse ependymin-like protein of the present invention.

SEQ ID NO:25 shows a nucleotide sequence of the DNA coding for the common amino acid sequence, which is represented by SEQ ID NO:8, between the human  
20 ependymin-like protein and rat ependymin-like protein of the present invention.

SEQ ID NO:26 shows a nucleotide sequence of the DNA coding for the common amino acid sequence, which is represented by SEQ ID NO:9, between the human  
25 ependymin-like protein and rat ependymin-like protein of the present invention.

SEQ ID NO:27 shows a nucleotide sequence of the DNA coding for the precursor protein having an amino acid sequence represented by SEQ ID NO:10 of the human  
30 ependymin-like protein of the present invention.

SEQ ID NO:28 shows a nucleotide sequence of the DNA coding for the precursor protein having an amino acid sequence represented by SEQ ID NO:11 of the human  
ependymin-like protein of the present invention.

SEQ ID NO:29 shows a nucleotide sequence of the DNA coding for the precursor protein having an amino  
35 acid sequence represented by SEQ ID NO:12 of the rat

ependymin-like protein of the present invention.

SEQ ID NO:30 shows a nucleotide sequence of the DNA coding for the precursor protein having an amino acid sequence represented by SEQ ID NO:13 of the mouse  
5 ependymin-like protein of the present invention.

SEQ ID NO:31 shows a nucleotide sequence of the DNA coding for the signal peptide, which has an amino acid sequence represented by SEQ ID NO:14, of the human  
ependymin-like protein of the present invention.

10 SEQ ID NO:32 shows a nucleotide sequence of the DNA coding for the signal peptide, which has an amino acid sequence represented by SEQ ID NO:15, of the human ependymin-like protein of the present invention.

15 SEQ ID NO:33 shows a nucleotide sequence of the DNA coding for the signal peptide, which has an amino acid sequence represented by SEQ ID NO:16, of the rat ependymin-like protein of the present invention.

20 SEQ ID NO:34 shows a nucleotide sequence of the DNA coding for the signal peptide, which has an amino acid sequence represented by SEQ ID NO:17, of the mouse ependymin-like protein of the present invention.

25 SEQ ID NO:35 shows a nucleotide sequence of the probe used for cloning the DNA coding for the human ependymin-like protein of the present invention in Example 1.

30 The transformant strain of Escherichia coli, designated XL1-Blue/phEDN1-95, which was obtained in the Reference Example 1 mentioned hereinafter, is on deposit under the terms of the Budapest Treaty from August 28, 1996, with the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, JAPAN (NIBH) under the Accession Number of FERM BP-5640. They are also on  
35 deposit from September 2, 1996 with the IFO under the Accession Number of IFO 16011.

The transformant strain of Escherichia coli,

designated SURE/prEDN91-6, which was obtained in the Example 3 mentioned hereinafter, is on deposit under the terms of the Budapest Treaty from November 28, 1996, with the NIBH under the Accession Number of FERM BP-5759. It is also on deposit from September 2, 1996 with the IFO under the Accession Number of IFO 16053.

The transformant strain of Escherichia coli, designated SURE/pmEDN78-13, which was obtained in the Example 5 mentioned hereinafter, is on deposit under the terms of the Budapest Treaty from May 20, 1997, with the NIBH under the Accession Number of FERM BP-5949. It is also on deposit from June 4, 1997 with the IFO under the Accession Number of IFO 16090.

#### Brief Description of the Drawings

Fig. 1 shows the nucleotide sequence of the DNA coding for the human ependymin-like protein of the present invention obtained in Example 1 and the amino acid sequence encoded thereby. The arrow indicates the signal peptide cleavage site. The region surrounded by a square indicates the N-glycosylation site. The underlines indicate the ATTTA sequence associated with the lability of the mRNA and the poly(A)<sup>+</sup> addition signal, respectively.

Fig. 2 shows the nucleotide sequence of the DNA coding for the rat ependymin-like protein of the present invention obtained in Example 3 and the amino acid sequence encoded thereby. The arrow indicates the signal peptide cleavage site. The region surrounded by a square indicates the N-glycosylation site. The underline indicates the poly(A)<sup>+</sup> addition signal.

Fig. 3 shows the nucleotide sequence of the DNA coding for the mouse ependymin-like protein of the present invention obtained in Example 5 and the amino acid sequence encoded thereby. The arrow indicates the signal peptide cleavage site. The region surrounded by



a square indicates the N-glycosylation site. The underline indicates the poly(A)<sup>+</sup> addition signal.

Fig. 4 is a comparative diagram of the amino acid sequence of the human ependymin-like protein of the present invention obtained in Example 1, the amino acid sequence of the rat ependymin protein of the present invention obtained in Example 3, and the amino acid sequence of the mouse ependymin-like protein of the present invention obtained in Example 5. (1) represents the amino acid sequence of the human ependymin-like protein of the present invention, (2) represents the amino acid sequence of the rat ependymin-like protein of the present invention, and (3) represents the amino acid sequence of the mouse ependymin-like protein of the present invention. The shaded area represents the amino acid residues showing the amino acid residues homologous among the human ependymin-like protein, rat ependymin-like protein and mouse ependymin-like protein.

Fig. 5 is a comparative diagram of the amino acid sequence of the human ependymin-like protein of the present invention obtained in Example 1 and the amino acid sequence of the rat ependymin protein of the present invention obtained in Example 3. (1) represents the amino acid sequence of the human ependymin-like protein of the present invention and (2) represents the amino acid sequence of the rat ependymin-like protein of the present invention. The shaded area represents the amino acid residues homologous between the human ependymin-like protein and rat ependymin-like protein.

Fig. 6 shows the amounts of expression of the mRNA coding for the human ependymin-like protein of the present invention in various tissues as determined by the Northern hybridization method (electrophoregram), where (1) represents heart, (2) brain, (3) placenta,

(4) lung, (5) liver, (6) skeletal muscle, (7) kidney, (8) pancreas, (9) spleen, (10) thymus, (11) prostate, (12) testis, (13) ovary, (14) small intestine, (15) colon, (16) peripheral white blood cell, (17) fetal brain, (18) fetal lung, (19) fetal liver and (20) fetal kidney. The figure (kb) at left indicates the size of the RNA molecular mass marker.

Fig. 7 shows the amounts of expression of the mRNA coding for the rat ependymin-like protein of the present invention in various tissues as determined by the Northern hybridization method (electrophoregram), where (1) represents brain, (2) spinal cord, (3) heart, (4) liver, (5) pancreas, (6) stomach, (7) small intestine, (8) testis, (9) ovary and (10) placenta. The figure (kb) at left indicates the size of the RNA molecular mass marker.

Fig. 8 shows the amounts of expression of the mRNA coding for the mouse ependymin-like protein of the present invention in various tissues as determined by the Northern hybridization method (electrophoregram), where (1) represents brain, (2) spinal cord, (3) lung and (4) liver. The figure (kb) at left indicates the size of the RNA molecular mass marker.

Fig. 9 shows the amounts of expression of the mRNA coding for the human ependymin-like protein of the present invention in various parts of the human CNS as determined by the Northern hybridization method (electrophoregram), where (1) represents cerebellum, (2) cerebral cortex, (3) medulla, (4) spinal cord, (5) occipital pole, (6) frontal lobe, (7) temporal lobe, (8) putamen, (9) amygdala, (10) caudate nucleus, (11) corpus callosum, (12) hippocampus, (13) whole brain, (14) substantia nigra, (15) subthalamic nucleus and (16) thalamus. G3PDH represents the amount of expression of the mRNA coding for glyceraldehyde-3-phosphate dehydrogenase used as the internal marker.

Best Mode for Carrying Out the Present Invention

## Examples

The following examples are intended to describe the present invention in further detail and should by no means be interpreted as defining the scope of the present invention. The gene manipulation using Escherichia coli was carried out in accordance with the procedure described in Molecular Cloning 2nd (J. Sambrook et al., Cold Spring Harbor Lab. Press, 1989).

## Example 1

Cloning of the cDNA coding for human ependymin-like protein

From 5 µg of human placental poly(A)<sup>+</sup>RNA (Clontech), a first strand DNA was synthesized using an oligo(dT) primer having XhoI site at a terminus and SuperScript II MMLV RNase H<sup>-</sup> reverse transcriptase (Gibco BRL). Then, using E. coli DNA polymerase I and RNase H, a second strand was synthesized. In this manner, a double-stranded cDNA was obtained from the poly(A)<sup>+</sup>RNA. This double-stranded DNA was treated with Pfu DNA polymerase (Stratagene) to provide blunt ends and an EcoRI adapter was added. This double-stranded DNA with the EcoRI adapter added to either end was subjected to gel filtration to remove cDNAs about 1000 bp and less and using T4 polynucleotide kinase (Takara Shuzo), the EcoRI adapters were phosphorylated. This cDNA was then digested with XhoI, and after integration with λZAPII EcoRI-XhoI arm (Stratagene), in vitro packaging was carried out to construct a human placental cDNA library of about  $2.1 \times 10^7$  pfu as a whole (insertion rate ≥ 99%). The λ phage of a cDNA library of about  $3.0 \times 10^6$  pfu was used to infect E. coli XL1-Blue MRF' and about  $2.5 \times 10^4$  plaques per plate were seeded on soft agar plates and incubated at 37°C overnight. The resulting plaques were transferred onto

a nylon membrane filter (Hybond N, Amersham) and treated with denaturing solution (0.5 N sodium hydroxide, 1.5 M sodium chloride) and neutralizing solution (0.5 M Tris-HCl (pH 7.0), 1.5 M sodium chloride), and 2 x SSC (20 x SSC = 3 M sodium chloride, 0.3 M sodium citrate) in the order mentioned, air-dried, and irradiated with ultraviolet light to fix the phage DNA on the nylon membrane filter.

On the other hand, as a probe, an oligonucleotide having the nucleotide sequence of SEQ ID NO:35 was labeled using [ $\gamma$ -<sup>32</sup>P]ATP (DuPont) and T4 polynucleotide kinase (Takara Shuzo). Hybridization was carried out at 65°C in a hybridization buffer (5 x SSPE (20 x SSPE=3.6 M sodium chloride, 0.2 M sodium phosphate (pH 7.7), 20 mM EDTA), 5 x Denhardt's solution, 100 µg/ml heat-denatured salmon sperm DNA, 0.1% SDS) containing the labeled probe. The filter was finally rinsed in 0.1 x SSC-0.1% SDS solution at 50°C and an autoradiogram was prepared to detect the plaques hybridizing with the probe.

The above procedure was repeated for purification to the single clone stage and 8 phage clones, namely phage clones λhEDN 59, 64, 82, 90, 91, 95, 99-2, and 112, were infected with helper phage and excised in vivo. The plasmids with the cDNA fragment inserted in the EcoRI-XhoI site of pBluescript SK (-) were recovered in E. coli SOLR to provide phEDN1-59, -64, -82, -90, -91, -95, -99-2, and -112, respectively. After cultivation of E. coli SOLR harboring each of those plasmids, the plasmid DNA was purified using QIAGEN Plasmid Mini Kit (Qiagen) and the sequencing reaction was carried out using DNA Sequencing Kit (Perkin-Elmer). The base sequence of the inserted cDNA fragment was determined using DNA Sequencer 377 (Perkin-Elmer). phEDN1-95, among them, had a 2507 bp cDNA fragment containing the poly(A)<sup>+</sup> chain (Fig. 1),

and a novel 224-residue protein containing a signal peptide consisting of 24 or 37 amino acid residues was encoded in this cDNA fragment. In addition, this protein had two N-glycosylation sites. This protein had moderate homology with ependymin occurring in the brain of bony fish, with 23.6% homology with rainbow trout ependymin. Furthermore, all the four cysteine residues conserved in ependymins were found conserved in this protein, indicating that it was human ependymin-like protein. On the other hand, the cDNA inserted in phEDN1-99-2 among the clones sequenced above showed a silent substitution of one base from <sup>190</sup>Arg (CGG) to <sup>190</sup>Arg (CGT), suggesting the existence of polymorphism in respect of this base.

The plasmid phEDN1-95 containing the DNA coding for human ependymin-like protein according to the present invention was introduced into Escherichia coli XL1-Blue to provide a transformant, namely E. coli XL1-Blue/phEDN1-95.

## Example 2

### Northern hybridization of human tissues

A membrane filter (MTN blot, Clontech) preblotted with 2 µg of human tissue poly(A)<sup>+</sup> RNA was subjected to prehybridization in a hybridization buffer (50% formamide, 5 x SSPE (20 x SSPE = 3.6 M sodium chloride, 0.2 M sodium phosphate (pH 7.7), 20 mM EDTA), 5 x Denhardt's solution, 0.1% SDS, 100 µg/ml heat-denatured salmon sperm DNA) at 42°C.

On the other hand, the BamHI-SpeI 383 bp cDNA fragment of the cDNA coding for human ependymin-like protein as shown in Fig. 1 (the cDNA fragment having a nucleotide sequence of bases no. 643 to no. 1025 of the base sequence shown in Fig. 1), as a probe, was labeled with [ $\alpha$ -<sup>32</sup>P]dCTP (DuPont) using Random Primer Labeling Kit (Amersham). After 12 hours of prehybridization in

a hybridization buffer (50% formamide, 5 x SSPE, 5 x Denhardt's solution, 0.1% SDS, 100 µg/ml heat-denatured salmon sperm DNA) at 42°C, hybridization was carried out in a hybridization buffer (50% formamide, 5 x SSPE, 5 x Denhardt's solution, 0.1% SDS, 100 µg/ml heat-denatured salmon sperm DNA) containing the labeled probe at 42°C for 18 hours. The filter was finally rinsed with 0.1 x SSC (20 x SSC = 3 M sodium chloride, 0.3 M sodium citrate)-0.1% SDS at 55°C and an autoradiogram was prepared to detect a band hybridizing with the probe. As a result, the molecular mass of the mRNA coding for this protein was about 2.5 kb and the amount of its expression was largest in the skeletal muscle, heart, and brain and slightly less in the prostate, ovary, and testis. In the kidney, its expression was found in fetuses as well (Fig. 6).

### Example 3

#### Cloning of cDNA encoding rat ependymin-like protein

From 8-week-old male Sprague-Dawley rats, the whole brain was enucleated and the total RNA was prepared by the guanidine-isothiocyanate method. Then, using the oligo(dT) span column (Pharmacia), a poly(A)<sup>+</sup>RNA fraction was obtained from the total RNA prepared above. From 5 µg of this poly(A)<sup>+</sup>RNA, a first strand DNA was synthesized using NotI site-terminated an oligo(dT) primer having NotI site at a terminus and SuperScript II MMLV RNase H<sup>-</sup> reverse transcriptase (Gibco BRL). Then, using *E. coli* DNA polymerase I, *E. coli* DNA ligase, and RNase H, a second strand DNA was synthesized to provide a double-stranded cDNA from the poly(A)<sup>+</sup>RNA. This double-stranded DNA was treated with T4 DNA polymerase (Gibco BRL) to prepare blunt ends and an SalI adapter was added. This double-stranded DNA with the SalI adapter added to either end was cut with NotI and subjected to gel filtration to remove cDNAs of

about 1000 bp and less. After integration with  $\lambda$ gt22A SalI-NotI arm (Gibco BRL), in vitro packaging was carried out to construct a rat brain cDNA library of about  $3.4 \times 10^6$  pfu as a whole (insertion rate  $\geq 99\%$ ).

5 The  $\lambda$  phage of a cDNA library of about  $2.2 \times 10^6$  pfu was used to infect E. coli Y1090r<sup>-</sup> and about  $2.2 \times 10^6$  plaques per plate were seeded on soft agar plates and incubated at 37°C overnight. The resulting plaques were transferred onto a nylon membrane filter (Hybond  
10 N, Amersham) and treated serially with denaturing solution (0.5 N sodium hydroxide, 1.5 M sodium chloride), neutralizing solution (0.5 M Tris-HCl (pH 7.0), 1.5 M sodium chloride), and 2 x SSC (20 x SSC = 3M sodium chloride, 0.3 M sodium citrate). The filter  
15 was air-dried and irradiated with ultraviolet light to fix the phage DNA on the nylon membrane filter.

On the other hand, as a probe, the BamHI-SpeI 383 bp cDNA fragment of the cDNA coding for human  
20 ependymin-like protein as shown in Fig. 1 (the cDNA fragment having a nucleotide sequence of bases no. 643 to no. 1025 of the nucleotide sequence shown in Fig. 1) was labeled with [ $\alpha$ -<sup>32</sup>P]dCTP (DuPont) using Random  
Primer Labeling Kit (Amersham). Hybridization was carried out in a hybridization buffer (5 x SSPE, 5 x  
25 Denhardt's solution, 100  $\mu$ g/ml heat-denatured salmon sperm DNA, 0.1% SDS) containing the labeled probe at 65°C. The filter was finally rinsed with 2 x SSC-0.1% SDS solution at 60°C and an autoradiogram was prepared to detect plaques hybridizing with the probe.

30 The above procedure was repeated for purification to the single clone stage and the phage DNA was extracted from each of 5 clones, namely phage clones  $\lambda$ rEDN 8, 56, 88, 91, and 100. After cleavage with restriction enzymes SalI and NotI, the cDNA fragment  
35 was inserted into the SalI-NotI site of pGEM11zf(-) to provide prEDN 8, 56, 88, 91-6, and 100, respectively.

The E. coli DH10B harboring each of those plasmids was cultured and using QIAGEN Plasmid Mini Kit (Qiagen), the plasmid DNA was purified. The sequencing reaction was carried out using DNA Sequencing Kit (Perkin-Elmer) and the base sequence of the inserted cDNA fragment was determined using DNA Sequencer 377 (Perkin-Elmer).

Among the above plasmids, prEDN91-6 had a 2202 bp cDNA fragment containing the poly(A)<sup>+</sup> chain (Fig. 2). Encoded in this cDNA fragment was a 224-residue rat endodymin-like protein containing a signal peptide consisting of 33 or 34 amino acids, with three N-glycosylation sites. The amino acid sequence of the rat endodymin-like protein had 74.6% homology with human endodymin-like protein, and all the cysteine residue sites in the mature region were conserved.

The plasmid prEDN91-6 containing the DNA coding for rat endodymin-like protein according to the present invention was introduced into Escherichia coli SURE to provide a transformant, namely E. coli SURE/prEDN91-6.

#### Example 4

##### Northern hybridization of rat tissues

From 8-week-old Sprague-Dawley rats (Charles River Japan), various tissues (brain, spine, heart, liver, spleen, stomach, small intestine, testis, ovary, placenta) were isolated and the total RNA was prepared by the guanidine-thiocyanate method. This total RNA was subjected to an oligo(dT) span column (Pharmacia) to prepare a poly(A)<sup>+</sup>RNA. This poly(A)<sup>+</sup>RNA, 2.5 µg, was subjected to 1.2% formalin-modified agarose gel electrophoresis and blotted on a nylon membrane filter (Biodyne B, Nippon Pall) by capillary blotting for 16 hours. This nylon membrane filter was treated with ultraviolet light to fix the blotted RNA and prehybridization was carried out in a hybridization buffer (50% formamide, 5 x SSPE (20 x SSPE = 3.6 M



sodium chloride, 0.2 M sodium phosphate (pH 7.7), 20 mM EDTA), 5 x Denhardt's solution, 0.1% SDS, 100 µg/ml heat-denatured salmon sperm DNA) at 42°C.

On the other hand, as a probe, an Eco47III-PstI  
5 1025 bp cDNA fragment of the cDNA coding for rat ependymin-like protein as shown in Fig. 2 (the cDNA fragment having a nucleotide sequence of bases no. 111 to no. 1135 of the nucleotide sequence shown in Fig. 2) was labeled with [ $\alpha$ -<sup>32</sup>P]dCTP using Random Primer  
10 Labeling Kit (Amersham). Hybridization was carried out in hybridization buffer (50% formamide, 5 x SSPE, 5 x Denhardt's solution, 0.5% SDS, 100 µg/ml heat-denatured salmon sperm DNA) containing the labeled probe at 42°C for 16 hours. The filter was finally rinsed with 0.1 x  
15 SSC-0.1% SDS solution at 50°C and an autoradiogram was prepared to detect the band hybridizing with the probe (Fig. 7). As a result, an mRNA with a mass of about 2.4 kb was found to have been expressed abundantly in the brain, spinal cord, and heart and moderately in the  
20 ovary and in the placenta at 17.5 days after conception as well.

#### Example 5

Cloning of cDNA encoding mouse ependymin-like protein  
25 Eight-week-old male C57 BL/6N mice (Charles River Japan) were sacrificed by decapitation. The spinal cord was isolated and the total RNA was prepared by the acid-phenol guanidine chloroform method. From this total RNA, a poly(A)<sup>+</sup>RNA fraction was prepared using an  
30 oligo(dT) cellulose column (Pharmacia). From 5 µg of this poly(A)<sup>+</sup>RNA, a first strand DNA was synthesized by using an oligo (dt) primer having XhoI site at a terminus and SuperScript II MMLV RNase H<sup>-</sup> reverse transcriptase (Gibco BRL) and, then, a second strand  
35 DNA was synthesized by using E. coli DNA polymerase I and RNase H to construct a double-stranded cDNA from

the poly(A)<sup>+</sup>RNA. This double-stranded DNA was treated with pfu DNA polymerase (Stratagene) to provide blunt ends and an EcoRI adapter was added. Then, the EcoRI adapter at either end of this double-stranded DNA was phosphorylated by using T4 polynucleotide kinase (Takara Shuzo). This cDNA was digested with XhoI, subjected to gel filtration to remove cDNA of about 400 bp and less, and integrated with  $\lambda$ ZAPII EcoRI-XhoI arm (Stratagene). This recombinant phage DNA was subjected to in vitro packaging to construct a mouse spinal cord cDNA library of about  $2.9 \times 10^6$  pfu as a whole (insertion rate  $\geq 99\%$ ). The  $\lambda$  phage of this cDNA library was used to infect E. coli XL 1-Blue MRF' and about  $2.7 \times 10^4$  plaques per plate were seed on soft agar plates and incubated at 37°C overnight for plaque formation. The resulting plaques were transferred onto a nylon membrane filter (Hybond N<sup>+</sup>, Amersham) and treated serially with denaturing solution (0.5 N sodium hydroxide, 1.5 M sodium chloride), neutralizing solution (0.5 M Tris-HCl (pH 7.0), 1.5 M sodium chloride), and 2 x SSC (20 x SSC = 3 M sodium chloride, 0.3 M sodium citrate). After air-drying, the filter was irradiated with ultraviolet light to fix the phage DNA on the nylon membrane filter.

On the other hand, as a probe, the Eco47III-PstI 1025 bp cDNA fragment of the cDNA coding for rat ependymin-like protein as shown in Fig. 2 (the cDNA fragment having a nucleotide sequence of bases no. 111 to no. 1135 of the nucleotide sequence shown in Fig. 2) was labeled using [ $\alpha$ -<sup>32</sup>P]dCTP (DuPont) and Random Primer Labeling Kit (Amersham). Hybridization was carried out in a hybridization buffer (5 x SSPE, 5 x Denhardt's solution, 100  $\mu$ g/ml heat-denatured salmon sperm DNA, 0.5% SDS) containing the labeled probe at 65°C. The filter was finally rinsed with 0.2 x SSC-0.1% SDS solution at 50°C and an autoradiogram was

prepared to detect plaques hybridizing with the probe.

The above procedure was repeated for purification to the single clone stage and the resultant 15 phage clones  $\lambda$ EDN 4, 8, 30, 32, 47, 51, 59, 66, 68, 77, 78, 81, 85, 98, and 99 were respectively infected with the helper phage and subjected to in vivo excision, whereby the plasmids carrying the cDNA fragment inserted in the EcoRI-XhoI site of pBluescript SK(-), namely pmEDN4-1, 8-1, 30-3, 32-5, 47-3, 51-5, 59-7, 66-7, 68-9, 77-11, 78-13, 81-15, 85-9, 98-17, and 99-19, were recovered in Escherichia coli XL0LR. The E. coli XL0LR strains harboring pmEDN4-1, 8-1, 32-5, 47-3, 59-7, 66-7, 68-9, 77-11, 78-13, 81-15, and 99-19, respectively, among the above plasmids, were cultured and using QIAGEN Plasmid Mini Kit (QIAGEN), plasmid DNAs were purified. The sequencing reaction was carried out using Perkin-Elmer DNA Sequencing Kit (Perkin-Elmer) and the base sequence of the inserted cDNA fragment was determined by using DNA Sequencer 377 (Perkin-Elmer). Among the above plasmids, pmEDN78-13 had a 2403 bp cDNA fragment (SEQ ID NO: Fig. 3) containing a poly(A)<sup>+</sup> chain, and a 224-residue mouse ependymin-like protein containing a signal peptide consisting of 30 or 37 amino acids had been encoded in this cDNA fragment.

On the other hand, among the clones determined for base sequence, pmEDN32-5, 47-3, 77-11, 78-13, 81-15, and 99-19 had the poly(A)<sup>+</sup> chain added in the same position as pmEDN78-13 but pmEDN4-1, 8-1, 59-7, 66-7, and 68-9 had a cDNA fragment retrenched in the 3' nontranslation region by 113 bp by recognizing the poly(A)<sup>+</sup> addition signal upstream of that in the case of pmEDN78-13.

The amino acid sequence of mouse ependymin-like protein was 91.1% homologous with the amino acid sequence of rat ependymin-like protein and 74.4% homologous with that of human ependymin-like protein,

and the cysteine residue sites in the mature region and two N-glycosylation sites were all conserved.

The plasmid pmEDN78-13 containing the DNA coding for mouse ependymin-like protein according to the present invention was introduced into Escherichia coli SURE to provide a transformant, namely E. coli SURE/pmEDN78-13.

#### Example 6

##### 10 Northern hybridization of mouse tissues

From 8-week-old C57 BL/6N mice (Charles River Japan), various tissues (brain, spinal cord, lung, and liver) were isolated and the total RNA was prepared by the acid-phenolguanidine chloroform method. From this total RNA, poly(A)<sup>+</sup>RNA was prepared by means of an oligo(dT) spin column (Pharmacia). This poly(A)<sup>+</sup>RNA, 2.5 µg, was subjected to 1.2% formalin-modified agarose gel electrophoresis and blotted on a nylon membrane filter (Nippon Pall, Biodyne B) by capillary blotting for 19 hours. This nylon membrane filter was treated with ultraviolet light to fix the RNA blot and prehybridization was carried out in hybridization buffer (50% formamide, 5 x SSPE (20 x SSPE = 3.6 M sodium chloride, 0.2 M sodium phosphate (pH 7.7), 20 mM EDTA), 5 x Denhardt's solution, 0.5% SDS, 100 µg/ml heat-denatured salmon sperm DNA) at 42°C. On the other hand, for use as a probe, the SpeI 799 bp cDNA fragment of the cDNA coding for mouse ependymin-like protein (the cDNA fragment having a nucleotide sequence of bases no. 198 to no. 996 of the base sequence shown in Fig. 3) was labeled with [ $\alpha$ -<sup>32</sup>P]dCTP and Random Primer Labeling Kit (Amersham). Hybridization was carried out in a hybridization buffer (50% formamide, 5 x SSPE, 5 x Denhardt's solution, 0.5% SDS, 100 µg/ml heat-denatured salmon sperm DNA) containing the labeled probe at 42°C for 18 hours. The filter was finally rinsed with 0.1 x

SSC-0.1% SDS solution at 50°C and an autoradiogram was prepared to detect the band hybridizing with the probe. As a result, the mRNA with a mass of about 2.4 kb was most abundant in the spinal cord, followed by the brain, and weakly expressed in the lung as well (Fig. 8).

#### Example 7

Northern hybridization of various parts of the human central nervous system

Using membrane filters (MTN blot, Clonetek) preblotted with 2 µg of the poly(A)<sup>+</sup>RNA from various segments of the human brain, prehybridization was carried out in hybridization buffer (50% formamide, 5 x SSPE (20 x SSPE = 3.6 M sodium chloride, 0.2 M sodium phosphate (pH 7.7), 20 mM EDTA), 5 x Denhardt's solution, 0.5% SDS, 100 µg/ml heat-denatured salmon sperm DNA) at 42°C.

On the other hand, as a probe, the BamHI-SpeI 383 bp cDNA fragment of the cDNA coding for human ependymin-like protein (the cDNA fragment having a nucleotide sequence of bases no. 643 to no. 1025 of the nucleotide sequence shown in Fig. 1) was labeled by using [ $\alpha$ -<sup>32</sup>P]dCTP (DuPont) and Random Primer Labeling Kit (Amersham). Prehybridization was carried out in a hybridization buffer (50% formamide, 5 x SSPE, 5 x Denhardt's solution, 0.1% SDS, 100 µg/ml heat-denatured salmon sperm DNA) at 42°C for 12 hours. Then, hybridization was carried out in a hybridization buffer (50% formamide, 5 x SSPE, 5 x Denhardt's solution, 0.1% SDS, 100 µg/ml heat-denatured salmon sperm DNA) containing the labeled probe at 42°C for 18 hours. The filter was finally rinsed with 0.1 x SSC (20 x SSC = 3 M sodium chloride, 0.3 M sodium citrate)-0.1% SDS solution at 55°C and an autoradiogram was prepared to detect the band hybridizing with the probe (Fig. 9).

As a result, it was found that this mRNA had been expressed in most parts of the central nervous system, indicating its important role in nerve tissues.

## 5 Industrial Applicability

The protein, its partial peptide or a salt thereof of the present invention has physiological activities such as a nerve-extending or nerve-regenerating activity, a gliocyte stimulating activity, and so on. The protein, etc. or the DNA coding for the protein, etc. of the present invention is useful as a therapeutic or prophylactic agent for Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), dementia or cerebellar degeneration. The antibody against the protein, etc. can be used in the assay of the protein, etc. in a test sample. Furthermore, the protein, etc. is useful as a screening reagent for compounds or their salts capable of promoting the function of the protein.

## 20 SEQUENCE LISTING

### INFORMATION FOR SEQ ID NO:1

#### (i) SEQUENCE CHARACTERISTICS

25 (A) LENGTH:187

(B) TYPE: Amino acid

(C) TOPOLOGY: Linear

(ii) MOLECULE TYPE: Protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1

30

Ala Pro Arg Pro Cys Gln Ala Pro Gln Gln Trp Glu Gly Arg Gln Val

1 5 10 15

Met Tyr Gln Gln Ser Ser Gly Arg Asn Ser Arg Ala Leu Leu Ser Tyr

20 25 30

35 Asp Gly Leu Asn Gln Arg Val Arg Val Leu Asp Glu Arg Lys Ala Leu

35 40 45

105

Ile Pro Cys Lys Arg Leu Phe Glu Tyr Il Leu Leu Tyr Lys Asp Gly  
 50 55 60  
 Val Met Phe Gln Ile Asp Gln Ala Thr Lys Gln Cys Ser Lys Met Thr  
 65 70 75 80  
 5 Leu Thr Gln Pro Trp Asp Pro Leu Asp Ile Pro Gln Asn Ser Thr Phe  
 85 90 95  
 Glu Asp Gln Tyr Ser Ile Gly Gly Pro Gln Glu Gln Ile Thr Val Gln  
 100 105 110  
 Glu Trp Ser Asp Arg Lys Ser Ala Arg Ser Tyr Glu Thr Trp Ile Gly  
 10 115 120 125  
 Ile Tyr Thr Val Lys Asp Cys Tyr Pro Val Gln Glu Thr Phe Thr Ile  
 130 135 140  
 Asn Tyr Ser Val Ile Leu Ser Thr Arg Phe Phe Asp Ile Gln Leu Gly  
 145 150 155 160  
 15 Ile Lys Asp Pro Ser Val Phe Thr Pro Pro Ser Thr Cys Gln Met Ala  
 165 170 175  
 Gln Leu Glu Lys Met Ser Glu Asp Cys Ser Trp  
 180 185

## 20 INFORMATION FOR SEQ ID NO:2

## (i) SEQUENCE CHARACTERISTICS

(A) LENGTH:190

(B) TYPE: Amino acid

(C) TOPOLOGY: Linear

## 25 (ii) MOLECULE TYPE: Protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2

Ser Pro Gly Thr Pro Gln Pro Cys Gln Ala Pro Gln Gln Trp Glu Gly  
 1 5 10 15  
 30 Arg Gln Val Leu Tyr Gln Gln Ser Ser Gly His Asn Ser Arg Ala Leu  
 20 25 30  
 Val Ser Tyr Asp Gly Leu Asn Gln Arg Val Arg Val Leu Asp Glu Arg  
 35 40 45  
 Lys Ala Leu Ile Pro Cys Lys Arg Leu Phe Glu Tyr Ile Leu Leu Tyr  
 35 50 55 60  
 Lys Asp Gly Val Met Phe Gln Ile Glu Gln Ala Thr Lys Leu Cys Ala

106

```

      65              70              75              80
Lys Ile Pro Leu Ala Glu Pro Trp Asp Pro Leu Asp Ile Pro Gln Asn
      85              90              95
Ser Thr Phe Glu Asp Gln Tyr Ser Ile Gly Gly Pro Gln Glu Gln Ile
5      100              105              110
Met Val Gln Glu Trp Ser Asp Arg Arg Thr Ala Arg Ser Tyr Glu Thr
      115              120              125
Trp Ile Gly Val Tyr Thr Ala Lys Asp Cys Tyr Pro Val Gln Glu Thr
      130              135              140
10 Phe Ile Arg Asn Tyr Thr Val Val Leu Ser Thr Arg Phe Phe Asp Val
      145              150              155              160
Gln Leu Gly Ile Lys Asp Pro Ser Val Phe Thr Pro Pro Ser Thr Cys
      165              170              175
Gln Thr Ala Gln Pro Glu Lys Met Lys Glu Asn Cys Ser Leu
15      180              185              190

```

## INFORMATION FOR SEQ ID NO:3

## (i) SEQUENCE CHARACTERISTICS

(A) LENGTH:187

20 (B) TYPE: Amino acid

(C) TOPOLOGY: Linear

(ii) MOLECULE TYPE: Protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3

```

25 Thr Pro Gln Pro Cys Gln Ala Pro Gln Gln Trp Glu Gly Arg Gln Val
   1              5              10              15
Leu Tyr Gln Gln Ser Ser Gly His Asn Asn Arg Ala Leu Val Ser Tyr
      20              25              30
Asp Gly Leu Asn Gln Arg Val Arg Val Leu Asp Glu Arg Lys Ala Leu
30      35              40              45
Ile Pro Cys Lys Arg Leu Phe Glu Tyr Ile Leu Leu Tyr Lys Glu Gly
      50              55              60
Val Met Phe Gln Ile Glu Gln Ala Thr Lys Gln Cys Ala Lys Ile Pro
      65              70              75              80
35 Leu Val Glu Ser Trp Asp Pro Leu Asp Ile Pro Gln Asn Ser Thr Phe
      85              90              95

```



107

Glu Asp Gln Tyr Ser Ile Gly Gly Pro Gln Glu Gln Ile Leu Val Gln  
                     100                    105                    110  
 Glu Trp Ser Asp Arg Arg Thr Ala Arg Ser Tyr Glu Thr Trp Ile Gly  
                     115                    120                    125  
 5 Val Tyr Thr Ala Lys Asp Cys Tyr Pro Val Gln Glu Thr Phe Ile Arg  
                     130                    135                    140  
 Asn Tyr Thr Val Val Met Ser Thr Arg Phe Phe Asp Val Gln Leu Gly  
                     145                    150                    155                    160  
 Ile Lys Asp Pro Ser Val Phe Thr Pro Pro Ser Thr Cys Gln Ala Ala  
 10                    165                    170                    175  
 Gln Pro Glu Lys Met Ser Asp Gly Cys Ser Leu  
                     180

## INFORMATION FOR SEQ ID NO:4

- 15 (i) SEQUENCE CHARACTERISTICS
- (A) LENGTH:13
  - (B) TYPE: Amino acid
  - (C) TOPOLOGY: Linear
- (ii) MOLECULE TYPE: Peptide
- 20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4

Pro Cys Gln Ala Pro Gln Gln Trp Glu Gly Arg Gln Val  
   1                    5                    10

- 25 INFORMATION FOR SEQ ID NO:5
- (i) SEQUENCE CHARACTERISTICS
- (A) LENGTH:32
  - (B) TYPE: Amino acid
  - (C) TOPOLOGY: Linear
- 30 (ii) MOLECULE TYPE: Peptide
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5

Gln Ile Asp Gln Ala Thr Lys Gln Cys Ser Lys Met Thr Leu Thr Gln  
   1                    5                    10                    15  
 35 Pro Trp Asp Pro Leu Asp Ile Pro Gln Asn Ser Thr Phe Glu Asp Gln  
                     20                    25                    30

## INFORMATION FOR SEQ ID NO:6

## (i) SEQUENCE CHARACTERISTICS

(A) LENGTH:25

(B) TYPE: Amino acid

5 (C) TOPOLOGY: Linear

(ii) MOLECULE TYPE: Peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6

Ser Tyr Glu Thr Trp Ile Gly Ile Tyr Thr Val Lys Asp Cys Tyr Pro  
10 1 5 10 15  
Val Gln Glu Thr Phe Thr Ile Asn Tyr  
20

## INFORMATION FOR SEQ ID NO:7

15 (i) SEQUENCE CHARACTERISTICS

(A) LENGTH:17

(B) TYPE: Amino acid

(C) TOPOLOGY: Linear

(ii) MOLECULE TYPE: Peptide

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7

Gln Leu Gly Ile Lys Asp Pro Ser Val Phe Thr Pro Pro Ser Thr Cys  
1 5 10 15  
Gln

25

## INFORMATION FOR SEQ ID NO:8

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH:39

(B) TYPE: Amino acid

30 (C) TOPOLOGY: Linear

(ii) MOLECULE TYPE: Peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8

Ser Tyr Asp Gly Leu Asn Gln Arg Val Arg Val Leu Asp Glu Arg Lys  
35 1 5 10 15  
Ala Leu Ile Pro Cys Lys Arg Leu Phe Glu Tyr Ile Leu Leu Tyr Lys

109

20 25 30  
 Asp Gly Val Met Phe Gln Ile  
 35

- 5 INFORMATION FOR SEQ ID NO:9  
 (i) SEQUENCE CHARACTERISTICS  
 (A) LENGTH:26  
 (B) TYPE: Amino acid  
 (C) TOPOLOGY: Linear  
 10 (ii) MOLECULE TYPE: Peptide  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9

Pro Trp Asp Pro Leu Asp Ile Pro Gln Asn Ser Thr Phe Glu Asp Gln  
 1 5 10 15  
 15 Tyr Ser Ile Gly Gly Pro Gln Glu Gln Ile  
 20 25

- INFORMATION FOR SEQ ID NO:10  
 (i) SEQUENCE CHARACTERISTICS  
 20 (A) LENGTH:200  
 (B) TYPE: Amino acid  
 (C) TOPOLOGY: Linear  
 (ii) MOLECULE TYPE: Protein  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10

25  
 Trp Thr Leu Cys Gly Leu Cys Ser Leu Gly Ala Val Gly Ala Pro Arg  
 1 5 10 15  
 Pro Cys Gln Ala Pro Gln Gln Trp Glu Gly Arg Gln Val Met Tyr Gln  
 20 25 30  
 30 Gln Ser Ser Gly Arg Asn Ser Arg Ala Leu Leu Ser Tyr Asp Gly Leu  
 35 40 45  
 Asn Gln Arg Val Arg Val Leu Asp Glu Arg Lys Ala Leu Ile Pro Cys  
 50 55 60  
 Lys Arg Leu Phe Glu Tyr Ile Leu Leu Tyr Lys Asp Gly Val Met Phe  
 35 65 70 75 80  
 Gln Ile Asp Gln Ala Thr Lys Gln Cys Ser Lys Met Thr Leu Thr Gln

110

```

      85              90              95
Pro Trp Asp Pro Leu Asp Ile Pro Gln Asn Ser Thr Phe Glu Asp Gln
      100              105              110
Tyr Ser Ile Gly Gly Pro Gln Glu Gln Ile Thr Val Gln Glu Trp Ser
5      115              120              125
Asp Arg Lys Ser Ala Arg Ser Tyr Glu Thr Trp Ile Gly Ile Tyr Thr
      130              135              140
Val Lys Asp Cys Tyr Pro Val Gln Glu Thr Phe Thr Ile Asn Tyr Ser
      145              150              155              160
10 Val Ile Leu Ser Thr Arg Phe Phe Asp Ile Gln Leu Gly Ile Lys Asp
      165              170              175
Pro Ser Val Phe Thr Pro Pro Ser Thr Cys Gln Met Ala Gln Leu Glu
      180              185              190
Lys Met Ser Glu Asp Cys Ser Trp
15      195              200

```

## INFORMATION FOR SEQ ID NO:11

## (i) SEQUENCE CHARACTERISTICS

(A) LENGTH:224

20 (B) TYPE: Amino acid

(C) TOPOLOGY: Linear

(ii) MOLECULE TYPE: Protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11

```

25 Met Pro Gly Arg Ala Pro Leu Arg Thr Val Pro Gly Ala Leu Gly Ala
   1              5              10              15
Trp Leu Leu Gly Gly Leu Trp Ala Trp Thr Leu Cys Gly Leu Cys Ser
      20              25              30
Leu Gly Ala Val Gly Ala Pro Arg Pro Cys Gln Ala Pro Gln Gln Trp
30      35              40              45
Glu Gly Arg Gln Val Met Tyr Gln Gln Ser Ser Gly Arg Asn Ser Arg
      50              55              60
Ala Leu Leu Ser Tyr Asp Gly Leu Asn Gln Arg Val Arg Val Leu Asp
      65              70              75              80
35 Glu Arg Lys Ala Leu Ile Pro Cys Lys Arg Leu Phe Glu Tyr Ile Leu
      85              90              95

```

111

```

Leu Tyr Lys Asp Gly Val Met Phe Gln Ile Asp Gln Ala Thr Lys Gln
      100                      105                      110
Cys Ser Lys Met Thr Leu Thr Gln Pro Trp Asp Pro Leu Asp Ile Pro
      115                      120                      125
5  Gln Asn Ser Thr Phe Glu Asp Gln Tyr Ser Ile Gly Gly Pro Gln Glu
      130                      135                      140
Gln Ile Thr Val Gln Glu Trp Ser Asp Arg Lys Ser Ala Arg Ser Tyr
145                      150                      155                      160
Glu Thr Trp Ile Gly Ile Tyr Thr Val Lys Asp Cys Tyr Pro Val Gln
10                      165                      170                      175
Glu Thr Phe Thr Ile Asn Tyr Ser Val Ile Leu Ser Thr Arg Phe Phe
      180                      185                      190
Asp Ile Gln Leu Gly Ile Lys Asp Pro Ser Val Phe Thr Pro Pro Ser
      195                      200                      205
15 Thr Cys Gln Met Ala Gln Leu Glu Lys Met Ser Glu Asp Cys Ser Trp
      210                      215                      220

```

## INFORMATION FOR SEQ ID NO:12

## (i) SEQUENCE CHARACTERISTICS

20 (A) LENGTH:224

(B) TYPE: Amino acid

(C) TOPOLOGY: Linear

## (ii) MOLECULE TYPE: Protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12

25

```

Met Leu Thr Arg Ala Pro Arg Arg Leu Val Gln Gly Pro Arg Glu Thr
 1              5              10              15
Trp Leu Leu Gly Gly Leu Trp Val Trp Ile Leu Cys Gly Leu Gly Met
      20              25              30
30 Ala Gly Ser Pro Gly Thr Pro Gln Pro Cys Gln Ala Pro Gln Gln Trp
      35              40              45
Glu Gly Arg Gln Val Leu Tyr Gln Gln Ser Ser Gly His Asn Ser Arg
      50              55              60
Ala Leu Val Ser Tyr Asp Gly Leu Asn Gln Arg Val Arg Val Leu Asp
35  65              70              75              80
Glu Arg Lys Ala Leu Ile Pro Cys Lys Arg Leu Phe Glu Tyr Ile Leu

```

112

```

      85              90              95
Leu Tyr Lys Asp Gly Val Met Phe Gln Ile Glu Gln Ala Thr Lys Leu
      100              105              110
Cys Ala Lys Ile Pro Leu Ala Glu Pro Trp Asp Pro Leu Asp Ile Pro
5      115              120              125
Gln Asn Ser Thr Phe Glu Asp Gln Tyr Ser Ile Gly Gly Pro Gln Glu
      130              135              140
Gln Ile Met Val Gln Glu Trp Ser Asp Arg Arg Thr Ala Arg Ser Tyr
      145              150              155              160
10 Glu Thr Trp Ile Gly Val Tyr Thr Ala Lys Asp Cys Tyr Pro Val Gln
      165              170              175
Glu Thr Phe Ile Arg Asn Tyr Thr Val Val Leu Ser Thr Arg Phe Phe
      180              185              190
Asp Val Gln Leu Gly Ile Lys Asp Pro Ser Val Phe Thr Pro Pro Ser
15      195              200              205
Thr Cys Gln Thr Ala Gln Pro Glu Lys Met Lys Glu Asn Cys Ser Leu
      210              215              220

```

## INFORMATION FOR SEQ ID NO:13

- 20 (i) SEQUENCE CHARACTERISTICS
- (A) LENGTH:224
  - (B) TYPE: Amino acid
  - (C) TOPOLOGY: Linear
- (ii) MOLECULE TYPE: Protein
- 25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13

```

Met Pro Ala Arg Ala Pro Arg Arg Leu Val Gln Gly Pro Arg Gly Thr
  1              5              10              15
Trp Leu Leu Gly Ser Leu Trp Val Trp Val Leu Cys Gly Leu Gly Met
30      20              25              30
Ala Gly Ser Leu Gly Thr Pro Gln Pro Cys Gln Ala Pro Gln Gln Trp
      35              40              45
Glu Gly Arg Gln Val Leu Tyr Gln Gln Ser Ser Gly His Asn Asn Arg
      50              55              60
35 Ala Leu Val Ser Tyr Asp Gly Leu Asn Gln Arg Val Arg Val Leu Asp
      65              70              75              80

```

113

Glu Arg Lys Ala Leu Ile Pro Cys Lys Arg Leu Phe Glu Tyr Ile Leu  
                             85                            90                            95  
 Leu Tyr Lys Glu Gly Val Met Phe Gln Ile Glu Gln Ala Thr Lys Gln  
                             100                            105                            110  
 5 Cys Ala Lys Ile Pro Leu Val Glu Ser Trp Asp Pro Leu Asp Ile Pro  
                             115                            120                            125  
 Gln Asn Ser Thr Phe Glu Asp Gln Tyr Ser Ile Gly Gly Pro Gln Glu  
                             130                            135                            140  
 Gln Ile Leu Val Gln Glu Trp Ser Asp Arg Arg Thr Ala Arg Ser Tyr  
 10 145                            150                            155                            160  
 Glu Thr Trp Ile Gly Val Tyr Thr Ala Lys Asp Cys Tyr Pro Val Gln  
                             165                            170                            175  
 Glu Thr Phe Ile Arg Asn Tyr Thr Val Val Met Ser Thr Arg Phe Phe  
                             180                            185                            190  
 15 Asp Val Gln Leu Gly Ile Lys Asp Pro Ser Val Phe Thr Pro Pro Ser  
                             195                            200                            205  
 Thr Cys Gln Ala Ala Gln Pro Glu Lys Met Ser Asp Gly Cys Ser Leu  
                             210                            215                            220

## 20 INFORMATION FOR SEQ ID NO:14

## (i) SEQUENCE CHARACTERISTICS

(A) LENGTH:37

(B) TYPE: Amino acid

(C) TOPOLOGY: Linear

## 25 (ii) MOLECULE TYPE: Peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14

Met Pro Gly Arg Ala Pro Leu Arg Thr Val Pro Gly Ala Leu Gly Ala  
           1                            5                            10                            15  
 30 Trp Leu Leu Gly Gly Leu Trp Ala Trp Thr Leu Cys Gly Leu Cys Ser  
                             20                            25                            30  
 Leu Gly Ala Val Gly  
                             35

## 35 INFORMATION FOR SEQ ID NO:15

## (i) SEQUENCE CHARACTERISTICS

114

- (A) LENGTH:24  
 (B) TYPE: Amino acid  
 (C) TOPOLOGY: Linear  
 (ii) MOLECULE TYPE: Peptide  
 5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15

Met Pro Gly Arg Ala Pro Leu Arg Thr Val Pro Gly Ala Leu Gly Ala  
 1 5 10 15  
 Trp Leu Leu Gly Gly Leu Trp Ala  
 10 20

## INFORMATION FOR SEQ ID NO:16

- (i) SEQUENCE CHARACTERISTICS  
 (A) LENGTH:34  
 15 (B) TYPE: Amino acid  
 (C) TOPOLOGY: Linear  
 (ii) MOLECULE TYPE: Peptide  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16

20 Met Leu Thr Arg Ala Pro Arg Arg Leu Val Gln Gly Pro Arg Glu Thr  
 1 5 10 15  
 Trp Leu Leu Gly Gly Leu Trp Val Trp Ile Leu Cys Gly Leu Gly Met  
 20 25 30  
 Ala Gly

25

## INFORMATION FOR SEQ ID NO:17

- (i) SEQUENCE CHARACTERISTICS  
 (A) LENGTH:37  
 (B) TYPE: Amino acid  
 30 (C) TOPOLOGY: Linear  
 (ii) MOLECULE TYPE: Peptide  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17

Met Pro Ala Arg Ala Pro Arg Arg Leu Val Gln Gly Pro Arg Gly Thr  
 35 1 5 10 15  
 Trp Leu Leu Gly Ser Leu Trp Val Trp Val Leu Cys Gly Leu Gly Met



115

20 25 30  
 Ala Gly Ser Leu Gly  
 35

## 5 INFORMATION FOR SEQ ID NO:18

## (i) SEQUENCE CHARACTERISTICS

(A) LENGTH:561

(B) TYPE: Nucleic acid

(C) STRANDESS: Double

10 (D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18

G C C C C G C G C C C G T G C C A G G C G C C G C A G C A G T G G G A G G G G C G C C A G G T T A T G T A C C A G C A A 60  
 15 A G T A G C G G G C G C A A C A G C C G C G C C T G C T C T C T A C G A C G G G C T C A A C C A G C G C T G C G G 120  
 G T G C T G G A C G A G A G G A G G C G C T G A T C C C C T G C A A G A G A T T A T T T G A A T A T A T T T G C T G 180  
 T A T A A G G A T G G A G T G A T G T T T C A G A T T G A C C A A G C C A C C A A G C A G T G C T C A A G A T G A C C 240  
 C T G A C A C A G C C C T G G G A T C C T C T T G A C A T T C C T C A A A A C T C C A C C T T T G A A G A C C A G T A C 300  
 T C C A T C G G G G G G C C T C A G G A G C A G A T C A C C G T C C A G G A G T G G T C G G A C A G A A A G T C A G C T 360  
 20 A G A T C C T A T G A A A C C T G G A T T G G C A T C T A T A C A G T C A A G G A T T G C T A T C C T G T C C A G G A A 420  
 A C C T T T A C C A T A A A C T A C A G T G T G A T A T T G T C T A C G C G G T T T T T G A C A T C C A G C T G G G T 480  
 A T T A A G A C C C C T C G G T G T T A C C C C T C C A A G C A C G T G C C A G A T G G C C C A A C T G G A G A A G 540  
 A T G A G C G A A G A C T G C T C C T G G 561

## 25 INFORMATION FOR SEQ ID NO:19

## (i) SEQUENCE CHARACTERISTICS

(A) LENGTH:570

(B) TYPE: Nucleic acid

(C) STRANDESS: Double

30 (D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19

T C C C C G G G A A C C C G C A G C C A T G C C A G G C G C C C A G C A G T G G G A G G G A C G T C A G G T T C T G 60  
 35 T A C C A G C A G A G C A G C G G G C A C A A C A G C C G C G C C T G G T G T C C T A C G A T G G T C T C A A C C A G 120  
 C G C G T G C G G G T G C T G G A C G A A A G G A A G G C G C T G A T C C C C T G C A A G A G A T T A T T T G A A T A C 180

```

      ATTTTACTCT ATAAGGATGG AGTGATGTTT CAGATTGAAC AAGCCACCAA ACTGTGTGCA   240
      AAGATACCCT TGGCAGAACC CTGGGATCCT CTCGACATTC CCCAGAATTC TACCTTTGAA   300
      GATCAGTACT CTATCGGAGG GCCTCAGGAG CAGATCATGG TCCAGGAATG GTCTGACAGG   360
      AGGACAGCCA GATCCTATGA AACCTGGATT GGCCTTTATA CAGCCAAGGA TTGCTACCCG   420
5     GTCCAGGAGA CCTTCATTAG GAACTACACT GTGGTCCTGT CCACTCGGTT CTTTGATGTG   480
      CAGTTGGGCA TTAAAGACCC CTCTGTGTTC ACCCCACCAA GCACGTGCCA GACAGCACAG   540
      CCAGAGAAGA TGAAAGAGAA CTGCTCCCTG                                     570

```

## INFORMATION FOR SEQ ID NO:20

## 10 (i) SEQUENCE CHARACTERISTICS

- (A) LENGTH:561
- (B) TYPE: Nucleic acid
- (C) STRANDENESS: Double
- (D) TOPOLOGY: Linear

## 15 (ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20

```

      ACCCCACAGC CATGCCAGGC ACCCCAGCAG TGGGAGGGAC GCCAGGTTCT GTACCAGCAG   60
      AGCAGCGGGC ACAACAACCG CGCCCTGGTG TCCTACGATG GTCTCAACCA GCGCGTGCGG   120
20    GTGCTGGACG AGAGGAAAGC GCTGATCCCC TGCAAGAGAT TATTTGAATA CATTTTACTC   180
      TATAAGGAGG GAGTGATGTT TCAGATTGAA CAAGCCACCA AACAGTGTGC AAAGATCCCC   240
      TTGGTGGAAT CCTGGGATCC TCTGGACATT CCCCAGAATT CTACCTTTGA AGATCAGTAC   300
      TCCATCGGAG GGCCTCAGGA GCAGATCCTG GTCCAGGAGT GGTCTGACAG AAGAACAGCA   360
      AGATCCTATG AAACCTGGAT CGGCGTTTAT ACAGCCAAGG ATTGTTATCC GGTCCAGGAG   420
25    ACCTTCATCA GGAACACAC TGTGGTCATG TCCACGCGGT TCTTTGATGT GCAGCTAGGC   480
      ATTAAGGACC CCTCTGTGTT CACCCACCA AGCACATGCC AGGCAGCGCA GCCAGAGAAG   540
      ATGAGTGACG GCTGCTCCTT G                                             561

```

## INFORMATION FOR SEQ ID NO:21

## 30 (i) SEQUENCE CHARACTERISTICS

- (A) LENGTH:39
- (B) TYPE: Nucleic acid
- (C) STRANDENESS: Double
- (D) TOPOLOGY: Linear

## 35 (ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21

CCGTGCCAGG CGCCGCAGCA GTGGGAGGGG CGCCAGGTT 39

INFORMATION FOR SEQ ID NO:22

(i) SEQUENCE CHARACTERISTICS

5 (A) LENGTH:96

(B) TYPE: Nucleic acid

(C) STRANDENESS: Double

(D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: cDNA

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22

CAGATTGACC AAGCCACCAA GCAGTGCTCA AAGATGACCC TGACACAGCC CTGGGATCCT 60  
CTTGACATTC CTCAAAAC TC CACCTTTGAA GACCAG 96

15 INFORMATION FOR SEQ ID NO:23

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH:75

(B) TYPE: Nucleic acid

(C) STRANDENESS: Double

20 (D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23

TCCTATGAAA CCTGGATTGG CATCTATACA GTCAAGGATT GCTATCCTGT CCAGGAAACC 60  
25 TTTACCATAA ACTAC 75

INFORMATION FOR SEQ ID NO:24

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH:51

30 (B) TYPE: Nucleic acid

(C) STRANDENESS: Double

(D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24

35

CAGCTGGGTA TTAAAGACCC CTCGGTGTTT ACCCCTCCAA GCACGTGCCA G 51

118

## INFORMATION FOR SEQ ID NO:25

## (i) SEQUENCE CHARACTERISTICS

(A) LENGTH:117

(B) TYPE: Nucleic acid

5 (C) STRANDENESS: Double

(D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25

10 TCCTACGACG GGCTCAACCA GCGCGTGCGG GTGCTGGACG AGAGGAAGGC GCTGATCCCC 60  
TGCAAGAGAT TATTGAATA TATTTTGCTG TATAAGGATG GAGTGATGTT TCAGATT 117

## INFORMATION FOR SEQ ID NO:26

## 15 (i) SEQUENCE CHARACTERISTICS

(A) LENGTH:78

(B) TYPE: Nucleic acid

(C) STRANDENESS: Double

(D) TOPOLOGY: Linear

20 (ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26

CCCTGGGATC CTCTTGACAT TCCTCAAAAC TCCACCTTTG AAGACCAGTA CTCCATCGGG 60  
GGGCCTCAGG AGCAGATC 78

25

## INFORMATION FOR SEQ ID NO:27

## (i) SEQUENCE CHARACTERISTICS

(A) LENGTH:600

(B) TYPE: Nucleic acid

30 (C) STRANDENESS: Double

(D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27

35 TGGACCCTGT GCGGCCTGTG CAGCCTGGGG GCGGTGGGAG CCCC GCGCCC GTGCCAGGCG 60  
CCGCAGCAGT GGGAGGGGCG CCAGGTTATG TACCAGCAAA GTAGCGGGCG CAACAGCCGC 120

```

GCCCTGCTCT CCTACGACGG GCTCAACCAG CGCGTGCGGG TGCTGGACGA GAGGAAGGCG 180
CTGATCCCCT GCAAGAGATT ATTTGAATAT ATTTTGCTGT ATAAGGATGG AGTGATGTTT 240
CAGATTGACC AAGCCACCAA GCAGTGCTCA AAGATGACCC TGACACAGCC CTGGGATCCT 300
CTTGACATTC CTCAAAACCT CACCTTTGAA GACCAGTACT CCATCGGGGG GCCTCAGGAG 360
5 CAGATCACCG TCCAGGAGTG GTCGGACAGA AAGTCAGCTA GATCCTATGA AACCTGGATT 420
GGCATCTATA CAGTCAAGGA TTGCTATCCT GTCCAGGAAA CCTTTACCAT AAACCTACAGT 480
GTGATATTGT CTACGCGGTT TTTTGACATC CAGCTGGGTA TTAAAGACCC CTCGGTGTTT 540
ACCCCTCCAA GCACGTGCCA GATGGCCCAA CTGGAGAAGA TGAGCGAAGA CTGCTCCTGG 600

```

## 10 INFORMATION FOR SEQ ID NO:28

## (i) SEQUENCE CHARACTERISTICS

(A) LENGTH:672

(B) TYPE: Nucleic acid

(C) STRANDESS: Double

## 15 (D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28

```

ATGCCAGGAC GCGCTCCCCT CCGCACCGTC CCGGGCGCCC TGGGTGCCTG GCTGCTGGGC 60
20 GGCCTCTGGG CCTGGACCCT GTGCGGCCTG TGCAGCCTGG GGGCGGTGGG AGCCCCGCGC 120
CGGTGCCAGG CGCCGCAGCA GTGGGAGGGG CGCCAGGTTA TGTACCAGCA AAGTAGCGGG 180
CGCAACAGCC GCGCCCTGCT CTCCTACGAC GGGCTCAACC AGCGCGTGCG GGTGCTGGAC 240
GAGAGGAAGG CGCTGATCCC CTGCAAGAGA TTATTTGAAT ATATTTTGCT GTATAAGGAT 300
GGAGTGATGT TTCAGATTGA CCAAGCCACC AAGCAGTGCT CAAAGATGAC CCTGACACAG 360
25 CCCTGGGATC CTCTTGACAT TCCTCAAAAC TCCACCTTTG AAGACCAGTA CTCCATCGGG 420
GGGCCTCAGG AGCAGATCAC CGTCCAGGAG TGGTCGGACA GAAAGTCAGC TAGATCCTAT 480
GAAACCTGGA TTGGCATCTA TACAGTCAAG GATTGCTATC CTGTCCAGGA AACCTTTACC 540
ATAAACTACA GTGTGATATT GTCTACGCGG TTTTTTGACA TCCAGCTGGG TATTAAAGAC 600
CCCTCGGTGT TTACCCCTCC AAGCACGTGC CAGATGGCCC AACTGGAGAA GATGAGCGAA 660
30 GACTGCTCCT GG 672

```

## INFORMATION FOR SEQ ID NO:29

## (i) SEQUENCE CHARACTERISTICS

(A) LENGTH:672

## 35 (B) TYPE: Nucleic acid

(C) STRANDESS: Double

(D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29

```

5  ATGCTCACAC GCGCTCCCCG CCGCCTGGTC CAGGGGCCCC GGGAGACCTG GCTGCTTGGC   60
   GGCCTCTGGG TCTGGATATT GTGCGGCCTG GGGATGGCGG GCTCCCCGGG AACCCCGCAG   120
   CCATGCCAGG CGCCCCAGCA GTGGGAGGGA CGTCAGGTTC TGTACCAGCA GAGCAGCGGG   180
   CACAACAGCC GCGCCCTGGT GTCCTACGAT GGTCTCAACC AGCGCGTGCG GGTGCTGGAC   240
   GAAAGGAAGG CGCTGATCCC CTGCAAGAGA TTATTTGAAT ACATTTTACT CTATAAGGAT   300
10  GGAGTGATGT TTCAGATTGA ACAAGCCACC AAAGTGTGTG CAAAGATACC CTTGGCAGAA   360
   CCCTGGGATC CTCTCGACAT TCCCCAGAAT TCTACCTTTG AAGATCAGTA CTCTATCGGA   420
   GGGCCTCAGG AGCAGATCAT GGTCCAGGAA TGCTCTGACA GGAGGACAGC CAGATCCTAT   480
   GAAACCTGGA TTGGCGTTTA TACAGCCAAG GATTGCTACC CGGTCCAGGA GACCTTCATT   540
   AGGAACTACA CTGTGGTCCT GTCCACTCGG TTCTTTGATG TGCAGTTGGG CATTAAAGAC   600
15  CCCTCTGTGT TCACCCACC AAGCACGTGC CAGACAGCAC AGCCAGAGAA GATGAAAGAG   660
   AACTGCTCCC TG                                     672

```

INFORMATION FOR SEQ ID NO:30

(i) SEQUENCE CHARACTERISTICS

20 (A) LENGTH:672

(B) TYPE: Nucleic acid

(C) STRANEDNESS: Double

(D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: cDNA

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30

```

ATGCCCCGCGC GCGCTCCCCG CCGCCTGGTC CAGGGGCCCTC GGGGGACCTG GCTGCTGGGA   60
AGCCTCTGGG TCTGGGTGCT GTGCGGCCTG GGGATGGCGG GCTCCCTGGG AACCCACAG   120
CCATGCCAGG CACCCAGCA GTGGGAGGGA CGCCAGGTTC TGTACCAGCA GAGCAGCGGG   180
30  CACAACAACC GCGCCCTGGT GTCCTACGAT GGTCTCAACC AGCGCGTGCG GGTGCTGGAC   240
   GAGAGGAAAG CGCTGATCCC CTGCAAGAGA TTATTTGAAT ACATTTTACT CTATAAGGAG   300
   GGAGTGATGT TTCAGATTGA ACAAGCCACC AAACAGTGTG CAAAGATCCC CTTGGTGGAA   360
   TCCTGGGATC CTCTGGACAT TCCCCAGAAT TCTACCTTTG AAGATCAGTA CTCCATCGGA   420
   GGGCCTCAGG AGCAGATCCT GGTCCAGGAG TGCTCTGACA GAAGAACAGC AAGATCCTAT   480
35  GAAACTTGGA TCGGCGTTTA TACAGCCAAG GATTGTTATC CGGTCCAGGA GACCTTCATC   540
   AGGAACTACA CTGTGGTCAT GTCCACGCGG TTCTTTGATG TGCAGCTAGG CATTAAAGAC   600

```

121

CCCTCTGTGT TCACCCACC AAGCACATGC CAGGCAGCGC AGCCAGAGAA GATGAGTGAC 660  
GGCTGCTCCT TG 672

## INFORMATION FOR SEQ ID NO:31

- 5 (i) SEQUENCE CHARACTERISTICS  
    (A) LENGTH:111  
    (B) TYPE: Nucleic acid  
    (C) STRANDESS: Double  
    (D) TOPOLOGY: Linear  
10 (ii) MOLECULE TYPE: cDNA  
    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31

ATGCCAGGAC GCGCTCCCCT CCGCACCGTC CCGGGCGCCC TGGGTGCCTG GCTGCTGGGC 60  
GGCCTCTGGG CCTGGACCCT GTGCGGCTG TGCAGCCTGG GGGCGGTGGG A 111

15

## INFORMATION FOR SEQ ID NO:32

- (i) SEQUENCE CHARACTERISTICS  
    (A) LENGTH:72  
    (B) TYPE: Nucleic acid  
20 (C) STRANDESS: Double  
    (D) TOPOLOGY: Linear  
    (ii) MOLECULE TYPE: cDNA  
    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31

25 ATGCCAGGAC GCGCTCCCCT CCGCACCGTC CCGGGCGCCC TGGGTGCCTG GCTGCTGGGC 60  
GGCCTCTGGG CC 72

## INFORMATION FOR SEQ ID NO:33

- (i) SEQUENCE CHARACTERISTICS  
30 (A) LENGTH:102  
    (B) TYPE: Nucleic acid  
    (C) STRANDESS: Double  
    (D) TOPOLOGY: Linear  
    (ii) MOLECULE TYPE: cDNA  
35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33

ATGCTCACAC GCGCTCCCG CCGCCTGGTC CAGGGGCCCC GGGAGACCTG GCTGCTTGGC 60  
GGCCTCTGGG TCTGGATATT GTGCGGCCTG GGGATGGCGG GC 102

## INFORMATION FOR SEQ ID NO:34

- 5 (i) SEQUENCE CHARACTERISTICS  
    (A) LENGTH:111  
    (B) TYPE: Nucleic acid  
    (C) STRANDENESS: Double  
    (D) TOPOLOGY: Linear  
10 (ii) MOLECULE TYPE: cDNA  
    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34

ATGCCCCGCG CCGCTCCCG CCGCCTGGTC CAGGGGCCTC GGGGGACCTG GCTGCTGGGA 60  
AGCCTCTGGG TCTGGGTGCT GTGCGGCCTG GGGATGGCGG GCTCCCTGGG A 111  
15

## INFORMATION FOR SEQ ID NO:35

- (i) SEQUENCE CHARACTERISTICS  
    (A) LENGTH:21  
    (B) TYPE: Nucleic acid  
20 (C) STRANDENESS: Single  
    (D) TOPOLOGY: Linear  
    (ii) MOLECULE TYPE: Synthetic DNA  
    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35

25 AGGTGGAGTT TTGAGGAATG T 21



## CLAIMS

1. An ependymin-like protein derived from a mammal, or a salt thereof.
2. A protein comprising an amino acid sequence represented by SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3, or a substantially equivalent thereto, or a salt thereof.
3. The protein according to claim 2, wherein the substantially equivalent amino acid sequence to the amino acid sequence represented by SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3 is an amino acid sequence comprising an amino acid sequence represented by SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 or SEQ ID NO:7.
4. The protein according to claim 2, wherein the substantially equivalent amino acid sequence to the amino acid sequence represented by SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3 is an amino acid sequence having an identity of not less than about 95% to the amino acid sequence represented by SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3.
5. The protein according to claim 2, wherein the substantially equivalent amino acid sequence to the amino acid sequence represented by SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3 is (i) an amino acid sequence wherein one or more amino acid residues are deleted from the amino acid sequence represented by SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3, (ii) an amino acid sequence wherein one or more amino acid residues are added to the amino acid sequence represented by SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3, (iii) an amino acid sequence wherein one or more amino acid residues in the amino acid sequence represented by SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3 are substituted with one or more amino acid residues, or (iv) a combination thereof.
6. The protein according to claim 2, which has a

nerve-extending activity.

7. A partial peptide of the protein according to claim 1 or 2, or a salt thereof.

8. The partial peptide according to claim 7, which has an amino acid sequence represented by any one of SEQ ID NO:4 to SEQ ID NO:9.

9. A precursor protein of the protein according to claim 2 or a salt thereof, which comprising an amino acid sequence represented by SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12 or SEQ ID NO:13, or a substantially equivalent thereto.

10. A signal peptide comprising an amino acid sequence represented by SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16 or SEQ ID NO:17, or a substantially equivalent thereto.

11. A DNA which comprises a DNA having a nucleotide sequence coding for the protein according to claim 1 or 2.

12. The DNA according to claim 11, which comprises a nucleotide sequence represented by SEQ ID NO:18, SEQ ID NO:19 or SEQ ID NO:20.

13. A DNA which comprises a DNA having a nucleotide sequence coding for the precursor protein according to claim 9.

14. The DNA according to claim 13, which comprises a nucleotide sequence represented by SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29 or SEQ ID NO:30.

15. A DNA which comprises a DNA having a nucleotide sequence coding for the signal peptide according to claim 10.

16. The DNA according to claim 15, which comprises a nucleotide sequence represented by SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33 or SEQ ID NO:34.

17. A recombinant vector comprising the DNA according to claim 11.

18. A transformant which is transformed with the recombinant vector according to claim 17.

19. A method for producing the protein according to claim 1 or 2 or a salt thereof, which comprises cultivating the transformant according to claim 18 under conditions suitable to express and accumulate the protein according to claim 1 or 2 or a salt thereof, and collecting the same.

20. A pharmaceutical composition which comprises the protein according to claim 1 or 2, the partial peptide according to claim 7, or a salt thereof.

21. The pharmaceutical composition according to claim 20, which is a therapeutic or prophylactic agent for Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, dementia or cerebellar degeneration.

22. A pharmaceutical composition which comprises the DNA according to claim 11.

23. The pharmaceutical composition according to claim 22, which is a therapeutic or prophylactic agent for Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, dementia or cerebellar degeneration.

24. An antibody against the protein according to claim 1 or 2, the partial peptide according to claim 7, the precursor protein according to claim 9, or a salt thereof.

25. A method for quantitative determination of the protein according to claim 1 or 2, the partial peptide according to claim 7, the precursor protein according to claim 9, or a salt thereof, which comprises contacting the antibody according to claim 24 with the protein according to claim 1 or 2, the partial peptide according to claim 7, the precursor protein according to claim 9, or a salt thereof.

26. A method for quantitative determination of the protein according to claim 1 or 2, the partial peptide according to claim 7, the precursor protein according

to claim 9, or a salt thereof in a test liquid sample, which comprises

(a) competitively reacting the test liquid sample and a labeled protein according to claim 1 or 2, the partial peptide according to claim 7, the precursor protein according to claim 9, or a salt thereof with the antibody according to claim 24, and

(b) measuring the ratio of the labeled protein according to claim 1 or 2, the partial peptide according to claim 7, the precursor protein according to claim 9, or a salt thereof which binds to the antibody.

27. A method for quantitative determination of the protein according to claim 1 or 2, the partial peptide according to claim 7, the precursor protein according to claim 9, or a salt thereof in a test liquid sample, which comprises

(a) reacting the test liquid sample with the antibody according to claim 24 immobilized on an insoluble carrier and another labeled antibody according to claim 24 simultaneously or continuously, and

(b) measuring the activity of labeling agent on the insoluble carrier.

28. A method for screening for a compound which promotes a function of the protein according to claim 1 or 2, the partial protein according to claim 7, or a salt thereof, which comprises measuring and comparing the function of the protein according to claim 1 or 2, the partial protein according to claim 7 or a salt thereof, in cases that (i) the protein according to claim 1 or 2, the partial protein according to claim 7 or a salt thereof is contacted with a nerve cell or a nerve tissue and (ii) the protein according to claim 1 or 2, the partial protein according to claim 7 or a salt thereof and a test compound are contacted with a nerve cell or a nerve tissue.

29. The method according to claim 28, wherein the function is (i) a nerve-extending activity in the central nerve system or a gliocyte stimulating activity or (ii) an activity of forming memories in brain.

30. The method according to claim 28, wherein the function is a nerve-extending activity.

31. A kit for screening for a compound which promotes a function of the protein according to claim 1 or 2, the partial protein according to claim 7 or a salt thereof, which comprises the protein according to claim 1 or 2, the partial peptide according to claim 7 or a salt thereof.

32. A compound, or a salt thereof, which promotes a function of the protein according to claim 1 or 2, the partial peptide according to claim 7 or a salt thereof, and which is obtained by the method for screening according to claim 28 or the kit for screening according to claim 31.

33. A pharmaceutical composition which comprises the compound, or a salt thereof, which promotes a function of the protein according to claim 1 or 2, the partial peptide according to claim 7 or a salt thereof, and which is obtained by the method for screening according to claim 28 or the kit for screening according to claim 31.

34. The pharmaceutical composition according to claim 33, which is a therapeutic or prophylactic agent for Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, dementia or cerebellar degeneration.

35. A method for treating or preventing Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, dementia or cerebellar degeneration in a mammal which comprises administering an effective amount of the protein according to claim 1 or 2, the partial peptide according to claim 7 or a

salt thereof to said mammal.

36. A method for treating or preventing Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, dementia or cerebellar degeneration in a mammal which comprises administering an effective amount of the DNA according to claim 11 or a salt thereof to said mammal.

37. Use of the protein according to claim 1 or 2, the partial peptide according to claim 7 or a salt thereof for production of a therapeutic or prophylactic agent for Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, dementia or cerebellar degeneration.

38. Use of the DNA according to claim 11 for production of a therapeutic or prophylactic agent for Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, dementia or cerebellar degeneration.

1/17

# Fig. 1 (A)

CAGTGGCAGCAGGCAGTGGCAGCAGGCAGTGGCCCA	36
GGCAGAAATAGCTCCCGCGCGATTCACTGGAGCCTT	72
CCCCGGGCCCCTGGTCCCGGCTACCGGGACTCGCGCG	108
TCCGGATCTCAAAAGCGGCAGAGGCCACCGAAGGGA	144
CAGGAAGCACTTTGGTCCAGACCACACTCCCGGCAC	180
AGTGCGGAAAGAGCCGGCGGGAGCCACTCTGATCCC	216
GGACGCCTCAGCGCCCCCTTGGGCTTGGGCTTGCCC	252
TCGGGCGGGGAAGGCTGACCGCGATGCCAGGACGC	288
MetProGlyArg	4
GCTCCCCTCCGCACCGTCCCGGGCGCCCTGGGTGCC	324
AlaProLeuArgThrValProGlyAlaLeuGlyAla	16
TGGCTGCTGGGCGGCCTCTGGGCCTGGACCCTGTGC	360
TrpLeuLeuGlyGlyLeuTrpAlaTrpThrLeuCys	28
GGCCTGTGCAGCCTGGGGGCGGTGGGAGCCCCGCGC	396
GlyLeuCysSerLeuGlyAlaValGlyAlaProArg	40
CCGTGCCAGGCGCCGCAGCAGTGGGAGGGGCGCCAG	432
ProCysGlnAlaProGlnGlnTrpGluGlyArgGln	52
GTTATGTACCAGCAAAGTAGCGGGCGCAACAGCCGC	468
ValMetTyrGlnGlnSerSerGlyArgAsnSerArg	64
GCCCTGCTCTCCTACGACGGGCTCAACCAGCGCGTG	504
AlaLeuLeuSerTyrAspGlyLeuAsnGlnArgVal	76
CGGGTGCTGGACGAGAGGAAGGCGCTGATCCCCTGC	540
ArgValLeuAspGluArgLysAlaLeuIleProCys	88
AAGAGATTATTTGAATATATTTTGCTGTATAAGGAT	576
LysArgLeuPheGluTyrIleLeuLeuTyrLysAsp	100

2/17

# Fig. 1 (B)

GGAGTGATGTTTCAGATTGACCAAGCCACCAAGCAG	612
GlyValMetPheGlnIleAspGlnAlaThrLysGln	112
TGCTCAAAGATGACCCTGACACAGCCCTGGGATCCT	648
CysSerLysMetThrLeuThrGlnProTrpAspPro	124
CTTGACATTCCTCAAAACTCCACCTTTGAAGACCAG	684
LeuAspIleProGlnAsnSerThrPheGluAspGln	136
TACTCCATCGGGGGGCCTCAGGAGCAGATCACCGTC	720
TyrSerIleGlyGlyProGlnGluGlnIleThrVal	148
CAGGAGTGGTCGGACAGAAAGTCAGCTAGATCCTAT	756
GlnGluTrpSerAspArgLysSerAlaArgSerTyr	160
GAAACCTGGATTGGCATCTATACAGTCAAGGATTGC	792
GluThrTrpIleGlyIleTyrThrValLysAspCys	172
TATCCTGTCCAGGAAACCTTTACCATAAACTACAGT	828
TyrProValGlnGluThrPheThrIleAsnTyrSer	184
GTGATATTGTCTACGCGGTTTTTTTGACATCCAGCTG	864
ValIleLeuSerThrArgPhePheAspIleGlnLeu	196
GGTATTAAAGACCCCTCGGTGTTTACCCCTCCAAGC	900
GlyIleLysAspProSerValPheThrProProSer	208
ACGTGCCAGATGGCCCAACTGGAGAAGATGAGCGAA	936
ThrCysGlnMetAlaGlnLeuGluLysMetSerGlu	220
GACTGCTCCTGGTGAGCCTGTGCATAGGGAAGCGGC	972
AspCysSerTrp***	224
AGCATCGGATGTCAGCCCCCTGCGGCCCCCAGCTGGA	1008
GATGGATATGAGACTAGTCAAGATGTGAATGCTAAT	1044
TGGAGAGAAATATAATTTTAGGAAGATGCACATTGA	1080



3/17

# Fig. 1 (c)

TGTGGGGTTTTGATGTGTCTGATTTTGACTACTCAA 1116  
GCTCTGTTTACAGAAGAAAATTGAATGGCGAGGGTG 1152  
TGGCCATATGAACTGACTAGATGGCTAATATGGACA 1188  
CTTTGGGTATTTCTAATGCCTGTTTCAGGGCTGGTTT 1224  
TCTGCATGCACGGGTATACACATAATGCAGTGCCAT 1260  
GCACATAGGGAAGGGTCAGTAAGAGAAGTTTGCCTT 1296  
GGCAGCAAGTATTTATTGTTGACATTATTCAGAATT 1332  
AGTGATAATAAAAAGCAGAGTGATTTTGGTCAATTT 1368  
TATTATTAATTCTTAAATTCCCTGCAGAGAATGCC 1404  
CCTTTATTGCTGCACCAGGGTGGGCATTGCTCCAC 1440  
TGAGCCCTACTCCACCCTGTCCCTGCACTCCCTTGG 1476  
TTGCCAAAAAATGATAACTTAAATCCCTTCCAGAC 1512  
TTAAGAATTTTATGGCATGGCCCAATTGATATAAAC 1548  
ATTTAGAAGGAAATGAAAAGCTAAAATAGGAAGTAA 1584  
TTATTCCTCTAAAGAAACATTTTGAGCAAGGCAGTT 1620  
TAGAGAATCCTAATGTCTACACTGGCATAGCACGAG 1656  
CCATGTAAGCTTCTTTTTTTTCTATGCAAGAGTATT 1692  
GATGTATGTGCTGAATCTTCACAGACTTGTCAATAC 1728  
ACAGGCAGTATTCTAAAATAGCACTGAACAGGGAGT 1764  
CAGGAGACTATTGTCTCCTAAACCCAGGACTAGAGT 1800  
TCCCTCGTACTGTCACCTTTGGTCATTAAATGCA 1836  
CTGGGCTTGCCCGCACTTTGGCCTTCCTAGAACGCT 1872  
GCTTCATAACCTCTCTGTCTGACTTCTGCATCTCCT 1908  
TCCAGGTCAGCTCATTCACAAGAGTTGCTCCCAAGC 1944  
CTGGATGAGTTGCACCTTGCATCTTGAGCATGCATT 1980  
TCTCACAATAATTATTAAGCTGTGTGATAATTTCTG 2016  
CTTTCAGGACACTCATCCATTATCTTGGCTGTGAGC 2052  
TCCTTGGGTACGGGTACCTTGTATGTTTAATTTTAT 2088  
ATCCCTAGCACAAAGCAAGTGCCTGGCACATAGTCA 2124  
GTGCCCTAAGTATTCGTAGAGTGAAGAATGCCAGCC 2160  
TCTCTTGTCCCTGGTTTCCTTATGTGTTGAATGTGG 2196  
TTGAGTTTGTCCATTGCTAGGGAGAGACTTCCAGTA 2232  
ATAAAATTTACTATTCTAGATGCTTCTACTGTTATG 2268

4/17

# Fig. 1 (D)

TTTTATCTGCCCATTATCTTTCTTAGTTACCAGGA 2304  
GAAATGTGTGACACCTATATTATAATGAAAACAATC 2340  
TTATTACTTATAGTTTATCTATATTAAACAAATTTA 2376  
ATTGCATTTTAAAGCATTCTTTGATATTGTTGCTTT 2412  
TGCAATAAATATGGATAATCTTGGTTATAAGGGAGT 2448  
TAAAACAATGCTGTAATAAATAAAGTGTTTCATGTG 2484  
ATCAAAAAAAAAAAAAAAAAAAAAA 2507

5/17

# Fig. 2 (A)

CCAGACTCGGACCCCCAAGCCGGAAGCCTCTAAAC	36
AGAAAATTGGAAAATCGGAAAATCAGGAGAGGCCAG	72
GGCTCCTGAGCTGGTCCCAGAGCACATCTTCCACCA	108
GCGCTCAGACAACGCGCGTGACTCTCCCACGCCGGG	144
CCTCGGCTCCCTCCCAGGTTTGGCTGACCCGGAGGG	180
CCGCGAATCACGATGCTCACACGCGCTCCCCGCCGC	216
MetLeuThrArgAlaProArgArg	8
CTGGTCCAGGGGCCCCGGGAGACCTGGCTGCTTGGC	252
LeuValGlnGlyProArgGluThrTrpLeuLeuGly	20
GGCCTCTGGGTCTGGATATTGTGCGGCCTGGGGATG	288
GlyLeuTrpValTrpIleLeuCysGlyLeuGlyMet	32
GCGGGCTCCCCGGGAACCCCGCAGCCATGCCAGGCG	324
AlaGlySerProGlyThrProGlnProCysGlnAla	44
CCCCAGCAGTGGGAGGGACGTCAGGTTCTGTACCAG	360
ProGlnGlnTrpGluGlyArgGlnValLeuTyrGln	56
CAGAGCAGCGGGCACAACAGCCGCGCCCTGGTGTCC	396
GlnSerSerGlyHisAsnSerArgAlaLeuValSer	68
TACGATGGTCTCAACCAGCGCGTGCGGGTGCTGGAC	432
TyrAspGlyLeuAsnGlnArgValArgValLeuAsp	80
GAAAGGAAGGCGCTGATCCCCTGCAAGAGATTATT	468
GluArgLysAlaLeuIleProCysLysArgLeuPhe	92
GAATACATTTTACTCTATAAGGATGGAGTGATGTTT	504
GluTyrIleLeuLeuTyrLysAspGlyValMetPhe	104
CAGATTGAACAAGCCACCAAACCTGTGTGCAAAGATA	540
GlnIleGluGlnAlaThrLysLeuCysAlaLysIle	116

6/17

## Fig. 2 (B)

CCCTTGGCAGAACCCTGGGATCCTCTCGACATTCCC	576
ProLeuAlaGluProTrpAspProLeuAspIlePro	128
CAGAATTCTACCTTTGAAGATCAGTACTCTATCGGA	612
GlnAsnSerThrPheGluAspGlnTyrSerIleGly	140
GGGCCTCAGGAGCAGATCATGGTCCAGGAATGGTCT	648
GlyProGlnGluGlnIleMetValGlnGluTrpSer	152
GACAGGAGGACAGCCAGATCCTATGAAACCTGGATT	684
AspArgArgThrAlaArgSerTyrGluThrTrpIle	164
GGCGTTTATACAGCCAAGGATTGCTACCCGGTCCAG	720
GlyValTyrThrAlaLysAspCysTyrProValGln	176
GAGACCTTCATTAGGAACTACACTGTGGTCCTGTCC	756
GluThrPheIleArgAsnTyrThrValValLeuSer	188
ACTCGGTTCTTTGATGTGCAGTTGGGCATTAAAGAC	792
ThrArgPhePheAspValGlnLeuGlyIleLysAsp	200
CCCTCTGTGTTACCCCCACCAAGCACGTGCCAGACA	828
ProSerValPheThrProProSerThrCysGlnThr	212
GCACAGCCAGAGAAGATGAAAGAGAACTGCTCCCTG	864
AlaGlnProGluLysMetLysGluAsnCysSerLeu	224
TGAATTTCCATGAGCGGAAGCCACGACCTCAGCTCT	900
***	224
TAGGGACTTTGTGTGGAAATGGACTAGAGGCCAGTT	936
GGAAAGCAACTCGTCACGAGAAGCAAAGCTAGTTTT	972
AGGAAGATAAACCTATGTGGACTTGCTTGTCATCT	1008
GACTGTGGCTGCTCAGCTCTATTTTTTGGGAAGGAACC	1044
TGGGTATCCTTTCTGTGTGCAGGTGTGTAGTCAGT	1080
GCTGTAGGGTAGGACGGGGTGAAGGTGGGGTCGGCA	1116

## Fig. 2 (c)

CAAGGAGTTTGCCTCTGCAGAGTGAACCTTTTATTA 1152  
TTGCCAATAAGATTGAAAGTGATAATAAGATATAGT 1188  
ATAATTTTTTTTCAGTTCTCTCCTTACAAAGAAAGTC 1224  
CCTTGCTTGTGTGCACTAGGGTAGTGACAGTTCCCA 1260  
CTGACCCCAACACCTGCCTCTGGCTACTATGAGATGA 1296  
CCCTTTAAGATTCTTTCCAAGCTTAAATTTTGTCAC 1332  
ATGGCCCACCGGATGTAGATATTCTGCAAGGAAGTA 1368  
GAAACTTGTAATGCAAAGCAATGTTGCCTCTGAAGG 1404  
GAAAAGAAGTTTAAAGCGGGAGGCTTAGACAATCTT 1440  
AGTATCTTCATGTGAGATGAAGTCCGAGCCGTGTGT 1476  
GGTGCTTTGTGTGCAAGAGTACTGACTGCTGTGCTG 1512  
AACTATGTCTTTTCTAGCGGGCAAACAGGCTTGCA 1548  
AAACAGCACTGAATTGGGAGGCCCCCAAGTAAGGCC 1584  
TAGGATTCTCTGCTACTCTAATCCTTTAAGTAGTAA 1620  
ATGCACTAGGCTAATAGCTCTCGCCTTGCCTTTCTG 1656  
GAACTCTCTGTCTATATGACTACTGCTCACGCTTC 1692  
CAACATCAGCTCACATGTGCCCCCTGTGAGCTGCTC 1728  
CAATGCCTGAATTCATTGCACCTTACAGCTTGGCAT 1764  
GCCTTGCTCACAATACTCAGTATGCTGCGTGAGGAT 1800  
TTCCTGATTACTGGAAACTAACCTCTGTTATCCTGG 1836  
GTAAGAATCCCTTGAGTTACGGGTATCGTGTTCTGT 1872  
TTACTAATATCTCCAGCACCAAGCAAGTGCCTGGCA 1908  
CGTAGTCCGTGCCCCAACATTTGCAGAGAGGAGCT 1944  
CATCAGCTCTGTCAGTGTTTAGTTTTCTCATCTATT 1980  
AAACAGGGTTGGTTTTTCTGGTTGCTAGGGAGACTT 2016  
GTACTAATGCAACCTACTGTTCTAGATTCTTTATCA 2052  
CCGTGTTTTCAATTTGACCACGTATCACCTTTTGTTAT 2088  
CAAGAGAAATGTGTGAAGCTTGCTTTATGCTGTAGC 2124  
CATCTATATTGTAATTTATCTCTATAACAATTAAACA 2160  
AATTTATTGACACCCTAAAAAAAAAAAAAAAAAAAAA 2196  
AAAAAA 2202

8/17

# Fig. 3 (A)

GCAGAGAGCAGGAAAAACAAGCTTTGGTAAGCCTCC	36
GCCAGAGCAGAAAGAGCTGGGGCGATTTCACGCGGCT	72
TTCCCAGGCCCGGTGTCCCGGTGTCCGGAGCCCCCAA	108
GCCAGGAGCCTGTGGAACGGAAAATCGAGAGAGGCC	144
TGAACTGGGTCCCGGAGCACACCTTTCGCCAGGGCG	180
CAGAGAAGGCTCACGCGACTAGTCCAACGCAGGGCC	216
TCGGCTCTCTCTGGAGCTCGGCTGACCCTGGGGCGG	252
CAGATCACGATGCCCCGCGCGCTCCCCGCCGCCTG	288
MetProAlaArgAlaProArgArgLeu	9
GTCCAGGGGCCTCGGGGGACCTGGCTGCTGGGAAGC	324
ValGlnGlyProArgGlyThrTrpLeuLeuGlySer	21
CTCTGGGTCTGGGTGCTGTGCGGCCTGGGGATGGCG	360
LeuTrpValTrpValLeuCysGlyLeuGlyMetAla	33
GGCTCCCTGGGAACCCACAGCCATGCCAGGCACCC	396
GlySerLeuGlyThrProGlnProCysGlnAlaPro	45
CAGCAGTGGGAGGGACGCCAGGTTCTGTACCAGCAG	432
GlnGlnTrpGluGlyArgGlnValLeuTyrGlnGln	57
AGCAGCGGGCACAACAACCGCGCCCTGGTGTCCTAC	468
SerSerGlyHisAsnAsnArgAlaLeuValSerTyr	69
GATGGTCTCAACCAGCGCGTGCGGGTGCTGGACGAG	504
AspGlyLeuAsnGlnArgValArgValLeuAspGlu	81
AGGAAAGCGCTGATCCCCTGCAAGAGATTATTTGAA	540
ArgLysAlaLeuIleProCysLysArgLeuPheGlu	93
TACATTTTACTCTATAAGGAGGGAGTGATGTTTCAG	576
TyrIleLeuLeuTyrLysGluGlyValMetPheGln	105

9/17

# Fig. 3 (B)

ATTGAACAAGCCACCAAACAGTGTGCAAAGATCCCC	612
IleGluGlnAlaThrLysGlnCysAlaLysIlePro	117
TTGGTGGGAATCCTGGGATCCTCTGGACATTCCCCAG	648
LeuValGluSerTrpAspProLeuAspIleProGln	129
AATTCTACCTTTGAAGATCAGTACTCCATCGGAGGG	684
AsnSerThrPheGluAspGlnTyrSerIleGlyGly	141
CCTCAGGAGCAGATCCTGGTCCAGGAGTGGTCTGAC	720
ProGlnGluGlnIleLeuValGlnGluTrpSerAsp	153
AGAAGAACAGCAAGATCCTATGAAACTTGGATCGGC	756
ArgArgThrAlaArgSerTyrGluThrTrpIleGly	165
GTTTATACAGCCAAGGATTGTTATCCGGTCCAGGAG	792
ValTyrThrAlaLysAspCysTyrProValGlnGlu	177
ACCTTCATCAGGAACTACACTGTGGTCATGTCCACG	828
ThrPheIleArgAsnTyrThrValValMetSerThr	189
CGGTTCTTTGATGTGCAGCTAGGCATTAAGGACCCC	864
ArgPhePheAspValGlnLeuGlyIleLysAspPro	201
TCTGTGTTACCCCCACCAAGCACATGCCAGGCAGCG	900
SerValPheThrProProSerThrCysGlnAlaAla	213
CAGCCAGAGAAGATGAGTGACGGCTGCTCCTTGTGA	936
GlnProGluLysMetSerAspGlyCysSerLeu***	224
ACTCGCCGAACCTGAACCCAACCTCAGCTCTTAGTGA	972
CCTTGTATGGCAATGGATTAGAGACTAGTTTGAAAG	1008
TAACCTCTTCACTGAAAATAAAGCTAATTTTAGGAAG	1044
ATAAACCCCTATGTGGGCTTGCTTGTACATCTGACTG	1080
TGGCTGCTCAGCTCTGTTTTGAGAAGGAAAGGGGCC	1116
ATCCTTTCTGTGAGCAGGTGGGTAGTCAGTGCCATA	1152

10/17

# Fig. 3 (c)

GAGTAGGAAAGGGCGGGGGTGGGGTCAGCACAAGGA 1188  
GTTTGCCTCTGCAGGGTGAGACTTTTATTATTGCCA 1224  
ATAAGAATCGAAGGTGATAATAAGATATAGAATGCT 1260  
TTTGTTCAGTTCTCCCCCTTACAAAGAAAGTCCCTTG 1296  
CTTGTCTGCACCAGGGAAGCAAGAGCTCCCAGTGAC 1332  
ACCACCCCCTGCCTCTGGTTACTATAAGATGAGCCT 1368  
TTAAGATTCTTTCTAGACTTAAATTTTGTGCCATGG 1404  
CCCCTGGATGTAGATATTCTACAAGGAAGTAGAAA 1440  
CTTTTAATACGAAGTAATGATTCCTCTAAAGGGAAA 1476  
GGAAGTTTAAAGAGGGAGGCTTGGACAATCTTAGTA 1512  
TTTACACGTGAGATGAAATGAAGAGTCCCGTGTGCT 1548  
GCTCTGTGTGCAAGAGTACTGACCGCTCTGCTGAAC 1584  
CTTCATGTCTTTTCTAGTGGGCAACCAGGCTTCCAA 1620  
AATAGCACTGACCTGGGAGGCCCCCAAGTAAGGCCA 1656  
AGAAGTCTCTGCTACTCTAATCTTTTACGTATTAAA 1692  
TGCCTAGGCTAGTAGCCCTTGCCTTTCCTTTCCTG 1728  
AACTCTTTCAACACAACCTGTGTCTATATGACTACG 1764  
GCTCATGCTTCCAAGGTCAGCTCACATGTGACCTCT 1800  
GTGAGCTGTTCCCTCGCCTGAATTCATTGCATCTTA 1836  
CACCTTGGCATGCCTTGCTCACAATACTCATTATGC 1872  
TGTGTGGGATTTTCCTGATTACTAGAAGCTGACCTCT 1908  
GCTATCCTGGGTAAGAACGCCCTGAGTACGGGTACC 1944  
ATGCTCTGTTTACTTTAGGATCTCCAGCACCAAGCA 1980  
AGTGCCTGGCACATAGTCTGTGCCCTTAACATTTGT 2016  
AGAAAGGAGCTCACCAGCTCTGTGAGTGTTTAGTTT 2052  
CTTCATCTATTAAACAGGGTTGGTTTTTCTGGTTGC 2088  
TAGGGAGACTTATAGTAATACTTACTATTCTAG 2124  
ATTCTTCTTATCGCTGTGTTTTATTTGCCATGTATC 2160  
ATCTTTTGTATCAAGAGAAGTGTATGATGCTTGCT 2196  
TTATGCCATAGCCATCTATATTGTAATTTATCTATA 2232  
CAATTAAACAAATTTAATGAACCCTATGAATTATTC 2268  
TTTGATGTGTTTGTTTTTGTAAAGAAATATGGAGGAA 2304  
CTGAATTATAAAGAAAATAAAATCCTTCTGTAATAA 2340



11/17

# Fig. 3 (D)

TCAAATAAAGTACTTCCCATAATCAAAACCAAAAAA 2376  
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2403


# Fig. 4


(1)	1	MEGRAPLRIV	10	PGALCAWLLG	20	GLNAWTLCCGL	30	CSLGAVGAPR	40	PCQAPQOWEG	50
(2)	1	MLTRAPRRLV		QGPRETWLLG		GLWVWILCCGL		GMAGSPGTPQ		PCQAPQOWEG	50
(3)	1	MPARAPRRLV		QGPRTGTLWG		SLWVWVLCGL		GMAGSLGTPQ		PCQAPQOWEG	50
(1)	51	ROVMYQQSSG	60	RNSRALSYD	70	GLNORVRVLD	80	ERKALIPCKR	90	EEFYILLYKD	100
(2)	51	ROVLYQQSSG		HNSRALSYD		GLNORVRVLD		ERKALIPCKR		EEFYILLYKD	100
(3)	51	ROVLYQQSSG		HNNRALSYD		GLNORVRVLD		ERKALIPCKR		EEFYILLYKE	100
(1)	101	GVMFQIDQAT	110	KQCSKMTLTQ	120	PWDPLDIPON	130	STFEDQVSIG	140	GPOEQITVOE	150
(2)	101	GVMFQIEQAT		KLCAKIPLAE		PWDPLDIPON		STFEDQVSIG		GPOEQIMVOE	150
(3)	101	GVMFQIEQAT		KQCAKIPLVE		SWDPLDIPON		STFEDQVSIG		GPOEQILVOE	150
(1)	151	WSDRKSARSY	160	ETWIGIVTVK	170	DCYPVQETFT	180	INYSVILSTR	190	FEDIQLGIKD	200
(2)	151	WSDRRITARSY		ETWIGVYTAK		DCYPVQETFT		RNYTVLSTR		FEDVQLGIKD	200
(3)	151	WSDRRITARSY		ETWIGVYTAK		DCYPVQETFT		RNYTVMSTR		FEDVQEGIKD	200
(1)	201	PSVFTPPSTC	210	QMAQLEKMSD	220	DCSW*	230	.....	240	.....	250
(2)	201	PSVFTPPSTC		QTAQPEKMSD		NCSL*		.....		.....	250
(3)	201	PSVFTPPSTC		QAQPEKMSD		GCSL*		.....		.....	250

## Fig. 5

(1)	1	10	20	30	40	50
(2)	1	1	1	1	1	1
		MPGRAPLRTV	PGALGAWLLG	GLWAWTLCGL	CSLGAVCAPR	PCQAPQOWEC
		MLTRAPRRLV	OGPRETWLLG	GLWVWILCGL	GMAGSPGTPO	PCQAPQOWEC
(1)	51	60	70	80	90	100
(2)	51	1	1	1	1	1
		ROVMYQOSSG	RNSRALLSYD	GLNORVRVLD	ERKALTPCKR	EEFYALLYKD
		ROVLYQOSSG	HNSRALVSYD	GLNORVRVLD	ERKALTPCKR	EEFYALLYKD
(1)	101	110	120	130	140	150
(2)	101	1	1	1	1	1
		GVMEQIDQAT	KQCSKMTETQ	PWDPEDDIPON	STTEEDQVSTIG	GPQEQITVQF
		GVMEQIEQAT	KLGAKIPIAE	PWDPEDDIPON	STTEEDQVSTIG	GPQEQITVQF
(1)	151	160	170	180	190	200
(2)	151	1	1	1	1	1
		WSDRKSARSY	ETWIGIYIVK	DCVPVOETET	INYSVITESTR	EEEDIQEGHKB
		WSDRRRTARSY	ETWIGVYIAK	DCVPVOETET	RNYTIVVLESTR	EEEDIQEGHKB
(1)	201	210	220	230	240	250
(2)	201	1	1	1	1	1
		PSVETIPPSTIG	QMAQLEKMSH	DCSW*	.....	.....
		PSVETIPPSTIG	QTAQPEKMKH	NCSL*	.....	.....

Fig. 6



**Fig. 7**



**Fig. 8**

Fig. 9



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☒ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**